

HUMANIMAL TRUST

England & Wales · Charity number 1156927

Details

Other names	THE HUMANIMAL TRUST, VETERINARY ONE-HEALTH INITIATIVE IN CLINICAL EDUCATION, VOICE - GIVING ANIMALS A VOICE
Status	Registered
Legal form	CIO
Registered	2014-05-06
Register	View on the Charity Commission register

Contact

Address	Eashing Barns Halfway Lane Godalming GU7 2QQ
Phone	01483 791725
Email	info@humanimaltrust.org.uk
Website	https://www.humanimaltrust.org.uk/

Activities

Objects: To advance education for the public benefit in the subject of both human and animal health and, as a consequence, to relieve the suffering of animals and promote and preserve the good health of both humans and animals.

Activities: Raising awareness of the principles of One Medicine among healthcare professionals, academics and the public. Educating doctors and veterinary surgeons about the possibilities of One Medicine. Fostering collaboration in clinical research and practice.

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives, Animals
- **Who:** People With Disabilities, The General Public/mankind

Geography

- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-05-31	£925,715	£463,000	£973,787	5
2024-05-31	£522,970	£353,611	£511,072	5
2023-05-31	£206,670	£318,878	-	-
2022-05-31	£694,878	£271,490	£453,921	2
2021-05-31	£156,110	£222,838	-	-

Trustees

Name	Role	Appointed
Dr Mary Alexandra Fraser	Chair	2024-10-04
Ben Marshall		2016-07-06
DINEKE ABBING		2014-02-21
John Alan Grounds		2026-02-23
Lorna Rachel Dennard		2023-09-14
NOEL FITZPATRICK		2014-02-21
Professor Philippe Barrie Wilson		2026-02-23
Professor Roberto Marcello La Ragione		2016-08-31

HUMANIMAL TRUST

England & Wales - Charity number 1156927

Accounts



A Charity registered in
England and Wales - charity number: 1156927
Scotland - charity number: SC048960

Annual Report and Financial Statements

Period from

1st June 2024 to 31st May 2025

The trustees are pleased to present their annual report together with the financial statements of the charity for the year ended 31st May 2025.

The financial statements comply with the Charities Act 2011, the Constitution of Humanimal Trust, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102).

CHAIR'S REPORT

As each year passes, my belief in a One Medicine future becomes deeper and stronger. My third and final term as Chair has sadly come to an end, but it is with huge pride and gratitude that I look back on my time in the role. Pride, that despite plenty of challenges and obstacles we have seen the early shoots of One Medicine put down much stronger roots, spreading not only across professional and public communities in the UK, but much further afield. Gratitude, that so many have joined us in the One Medicine movement, whether as donors, supporters, professionals, volunteers or staff.

Looking back on the last twelve months, it is hard to pick out highlights as there have been so many! However, as an academic and researcher working in the field of veterinary science, the ongoing development of the Science Committee, the strength of our expert network and our announcement of both a £250,000 Cancer Development Fund and a series of Connections awards, have been inspirational. They show that the credibility of One Medicine is attracting highly respected figures in human and veterinary medicine and capturing the imagination and creativity of researchers. Looking forward to the outcomes of these and similar awards as contributions to a growing One Medicine evidence bank, is going to be one of the highlights of the next few years.

In the public domain, an ever-growing number of supporters are signing the Humanimal Trust Pledge for One Medicine and engaging with our events and activities. Many of these people have become our volunteers and supporters, the lifeblood of our charity. Without their gifts, legacies, events and sponsored fundraising efforts, as well as their belief and inspiration, our plans wouldn't leave the drawing board. Fundraising has been and will always be a challenge – we are not alone in that, but we believe that the One Medicine vision will continue to inspire more and more people to join us on the journey.

As I hand over the reins as Chair to Dr Mary Fraser, I would like to thank all those who have supported me as Chair. To staff, volunteers, patrons, supporters, committee members and experts, and especially to my fellow trustees, thank you. I plan to continue to offer my services to support Mary and the charity in any way I can. Professor Noel Fitzpatrick's dream of a world where One Medicine is the norm, continues to inspire us as we look to the challenges ahead.

Professor Roberto La Ragione, Chair of the Board of Trustees until 9 September 2025

CHIEF EXECUTIVE OFFICER'S REPORT

2024–25 has been a year of momentum and transformation for Humanimal Trust. From launching our refreshed brand identity and website to the success of our first One Medicine Month, we've grown our reach, strengthened our voice and deepened our impact. We've forged a wide range of influential new connections across science, medicine, policy and public life. These relationships are not only helping to break down silos between disciplines, but they are also laying the groundwork for future breakthroughs and meaningful collaboration - locally, nationally and globally.

Our credibility in academic and scientific fields continues to deepen. This year saw the expansion of our Science Committee, the launch of our £250,000 Cancer Discovery Fund, and the continued growth of our Connections Awards, now in their third round. We also established a One Medicine Task and Finish Group - a cross-disciplinary powerhouse of expertise providing insight and guidance as we shape the future of research, education and clinical practice.

We are especially grateful for the notification of several significant legacies this year. These gifts are not only a testament to the passion and belief of our supporters, but they will also play a vital role in funding research and long-term sustainability of the One Medicine movement.

Our One Medicine Network (formerly Humanimal Hub) is undergoing an exciting transformation thanks to the support of partners like The Salve. This revitalised platform will be a dynamic space for collaboration, knowledge-sharing and connection across human and veterinary medical fields. Its development reflects our ongoing commitment to building bridges that lead to shared progress.

We've seen a powerful uplift in sign-ups to our Humanimal Trust Pledge, surpassing 23,500 supporters - people who believe, as we do, that One Medicine is the future. This growing groundswell of public support matters. It brings energy, legitimacy and influence to our mission and signals to decision-makers that the time for action is now. Looking ahead, our focus is clear.

We will continue to fund transformative research, build a robust evidence base for One Medicine, expand our community and strengthen relationships with policymakers. Our ambition is not just to inform and inspire - but to influence real, societal change.

To everyone who has supported us - whether by donating, volunteering, fundraising, pledging, collaborating or simply sharing our message - thank you. Your commitment is helping to build a future where medical progress no longer comes at the cost of animal lives, and where humans and animals benefit equally from scientific advancement. Together, we are shaping a future defined by compassion, collaboration and shared hope.

Particular thanks to Miss Anna Radford, who has served as a trustee since October 2022. Anna stepped down from her role in December 2024 due to increasing professional commitments. Her dedication and contributions to the Trust have been invaluable, and we are deeply grateful for her service, and her continued support.

On behalf of everyone at Humanimal Trust, I want to extend our deepest thanks to Professor Roberto La Ragione, for his exceptional leadership, guidance and unwavering belief in our mission. His support has been a true anchor for the Trust, and we are incredibly fortunate that he will remain a Trustee - his wisdom and commitment continue to be an invaluable source of strength for us all. At the same time, I'm absolutely delighted to welcome from September 2025 Dr Mary Fraser as our new Chair. Her passion and experience will be a tremendous asset as we move forward together, building on the strong foundations already in place.

Joe Bailey, Chief Executive Officer

OUR IMPACT IN 2024/25

THE YEAR IN REVIEW

Our objectives for 2024-25 were driven by our three-year strategy 2023-2026. The period covered the second half of our 10th anniversary year and the first half of the following year, including our inaugural One Medicine Month (May 2025), which generated several promising outcomes and opportunities on which we can capitalise during 2025-26.

Our indicators of success are sometimes relevant to more than one workstream. Where this is the case, progress is recorded under one, rather than all the five workstreams. While this report continues to use the I-CARE structure (influence, collaboration, awareness, research, education), we plan to review the structure of our workstreams, objectives and reporting, following the end of our current three-year strategy.

Highlight achievements are listed below under each of our current workstreams.

I – Influence

Primary Three-Year Objective

Position Humanimal Trust as an influencer and global focal point for One Medicine bringing together and activating all those with a One Medicine outlook to drive awareness, understanding, law, guidance, funding and clinical practice within a clear ethical framework.

Impact in 2024/25

Parliamentary (& Regulatory) Affairs Working Group

Established in late 2024 with the support of external advisors, the Parliamentary (& Regulatory) Affairs Working Group (PAWG) is helping to shape Humanimal Trust's strategy for achieving robust regulatory support for One Medicine. With six members, the group is now focused on planning our first parliamentary reception, scheduled for early 2026 - a key step toward engaging policymakers and advancing legislative support for our mission.

Mention in UK Parliament

In April 2025, the use of dogs in scientific and regulatory procedures was debated in Parliament. Dr Danny Chambers MP - who took part in our One Medicine Task & Finish Group before being elected - spoke passionately about our mission and impact. This public endorsement of our work in Parliament underscores the growing influence of the One Medicine movement and the urgent need for ethical, cross-species collaboration in research and medicine.

C - Collaboration

Primary Three-Year Objective

Foster and demonstrate impact of greater collaboration both in research and at the clinical coalface between human and veterinary medicine, underpinned by fewer barriers and greater mutual respect.

Impact in 2024/25

One Medicine Task and Finish Group

In May 2024, we established a One Medicine Task and Finish Group, comprising leading human and animal medical professionals, to provide expert advice and guidance as we conduct our research, educational and outreach activities. Their inaugural meeting explored key questions around defining One Medicine, increasing engagement and identifying clinical trial opportunities. The discussion is available online.

One Medicine Network

Our professional online networking platform, formerly Humanimal Hub, turned five in February 2025. We consulted our community on a new name, officially relaunching as the One Medicine Network. A full platform revamp is underway, with the new-look Network launching later in 2025.

One Medicine Month – RNOH event

Launched on 1 May 2025, One Medicine Month marked a pivotal moment in Humanimal Trust's journey - our first dedicated awareness month. As part of this, clinicians, scientists and educators came together at the Royal National Orthopaedic Hospital (RNOH) in Stanmore, London to discuss bridging the divide between human and animal medicine. Members of our One Medicine Task and Finish Group and Science Committee were in attendance, along with Professor Noel Fitzpatrick. Clinicians and scientists from the RNOH and other organisations also took part, bringing fresh and valuable perspectives to the discussions.

Topics ranged from current regulatory and funding barriers for doctors and vets wanting to undertake One Medicine research, to how best to harness data to help improve veterinary research and collaboration – with the ultimate aim of ensuring more humans and animals can access the medical care that they need.

The day concluded with a 'Grand Rounds' talk by Professor Noel Fitzpatrick, attended by hospital staff. A canine patient with bone cancer - a condition shared across species - was present, powerfully illustrating the shared challenges in treatment and the promise of One Medicine. This event exemplified the heart of our mission: breaking silos, building bridges, and bringing hope through shared science.

A – Awareness

Primary Three-Year Objectives

Achieve high and consistent visibility and resonance of brand; clarity of understanding of the distinct meaning and purpose of One Medicine; public and professional propensity to support and engage. This will in turn lead to measurable increases in the credibility and influence of One Medicine and of income generation opportunities.

Establish and embed PGIE (Public and Guardian Involvement and Engagement) as a parallel approach to the established PPIE (Public, Patient Involvement and Engagement).

Impact in 2024/25

Media and social media

This year, we have continued to grow our media presence and expand our reach, ensuring our message continues to resonate across both traditional and digital platforms. Through sustained media engagement, we have maintained a consistent pipeline of coverage that highlights our work, shares expert insights and builds public awareness of our mission.

Our social media presence has grown significantly, with a strong, purposeful mix of content - from celebrating milestones and showcasing our impact, to driving fundraising campaigns and encouraging sign-ups to the Humanimal Trust Pledge for One Medicine. Our total followers have now surpassed 21.5K and we have extended our reach by joining Bluesky, connecting with new, values-aligned audiences. Engagement across platforms continues to grow, reflecting increased interest, support and participation from the public, professionals and partners alike.

We were proud to be featured in a wide range of respected media outlets, including the following: Vet Times, The Week Junior, Veterinary Practice, News Medical, Civil Society, What On Earth! Magazine, Animal Therapy Magazine, and others - amplifying our voice and reinforcing our credibility in both sector-specific and mainstream media.

10th Anniversary Symposium

On 9 October 2024, we brought together over 80 human and animal health and research professionals at the Welcome Collection - and supporters - at our 10th Anniversary Symposium, 'One Medicine: Time to Innovate, Time to Act'. Professor Noel Fitzpatrick reflected on the dramatic changes we have seen over the past 10 years, and our 11 expert speakers presented on areas including the following:

- Cancer
- Sepsis
- Antimicrobial resistance
- Bioethics
- Regenerative Medicine
- Musculoskeletal medicine

Recordings are available on our website, social media and One Medicine Network.

Public Guardian Involvement & Engagement (PGIE) group

Following our 2021 One Medicine Symposium, the need for a dedicated animal-inclusive ethical framework became clear. In response, we established a Public Guardian Involvement & Engagement (PGIE) group in late 2023 - bringing together members of the public and professionals to guide this vital work.

The group is developing a framework to support ethical, patient-focused clinical research across both human and veterinary medicine. As part of this, they will develop both a public and a professional survey to evaluate the perceptions and understanding of One Medicine and veterinary research.

Using the survey findings to develop the framework will ensure both public and professional voices are at the heart of One Medicine patient-focussed clinical research while supporting the goal to build cross-sector consensus and deliver a practical, widely adoptable Ethical Framework that strengthens collaboration and trust across disciplines.

One Medicine Month 2025

One Medicine Month (May) - our first dedicated awareness month – was designed to:

- Raise the profile of Humanimal Trust
- Promote understanding of One Medicine
- Inspire tangible action in support of our mission

The response was inspiring, and the impact was significant:

- 1.88m media reach
- 62.8k social media reach
- 8,036 social interactions
- 568 new newsletter sign-ups
- 1,857 Humanimal Trust Pledge sign-ups

This milestone campaign helped grow our community, start new conversations and build momentum for lasting change.

One Medicine Day 2025

On 6 May 2025, to mark One Medicine Day, we unveiled Humanimal Trust's new brand identity - a bold and modern reflection of our evolving journey and our unwavering commitment to caring for all species equally. In tandem with our new look, we launched our revamped website, built to better serve our community, amplify our message and create more opportunities to put One Medicine into action. Together, these efforts marked a significant step forward in strengthening our voice and expanding our impact.

Humanimal Trust's Pledge for ONE Medicine

During One Medicine Month, we also celebrated a major milestone in our mission to transform the future of medical care for humans and animals alike: more than 22,000 people had signed the Humanimal Trust Pledge. Since then, over 1,500 people have joined the One Medicine movement. That's over 23,500 voices united in support of One Medicine.

R – Research

Primary Three-Year Objective

Show evidence of the impact of Humanimal Trust-funded research-related activity on both scientific knowledge and professional practice in both human and veterinary medicine, including the following:

- a significant reduction in the use of laboratory animal models
- an increase in the development of non-animal alternatives
- at least one funder to add reciprocity into their guidance for funding

Impact in 2024/25

Cancer Discovery Fund

In October 2024, we launched a new £250,000 fund to encourage collaborative One Medicine research projects focused on improving cancer diagnosis, developing new treatments, and enhancing quality of life for all species with cancer. A diverse range of quality applications were received, with the successful project/s to be announced later in 2025.

Connections Awards

In November 2024, we awarded the second round of our unique Connections Awards - the only fund dedicated exclusively to One Medicine. This round focused on postgraduate students in human or animal health-related disciplines. The funded projects were as follows:

- a study on the levels of environmental toxins in humans and animals living in the same household
- a survey investigating One Medicine awareness among healthcare professionals in Ghana

We look forward to reporting the results in future annual reports.

On One Medicine Day (6 May 2025), we launched a third round of Connections Awards - a £10,000 fund to be split between two small-scale, multidisciplinary projects. Applications opened in July 2025.

Science Committee

We welcomed five new members to our Science Committee in 2024-25. This esteemed body of leading human and animal health professionals, academics and researchers continues to review the Trust's science strategy, grant applications and guides project funding, strengthening the global foundation of One Medicine.

E – Education

Primary Three-Year Objective

Full One Medicine Curriculum framework drafted and in wide consultation following completion of initial pilot programmes, with associated materials (downloadable and print) made available for a range of age-groups and initial CPD programmes piloted.

Impact in 2024/25

Children's books

From October 2024, our supporters had the chance to get their hands on an exclusive copy of *We Are All Animals* – the highly anticipated sequel to *Humanimal: Incredible Ways Animals are Just Like Us!*

Co-written by world history author and storyteller, Christopher Lloyd, and author Ben Hoare, and illustrated by Mark Ruffle, *We Are All Animals* takes readers on an eye-opening journey through the animal kingdom. It explores the fascinating similarities between humans and our furry, scaly, and feathered counterparts, connecting them all in weird and wonderful ways.

In November 2024, we launched our #BooksForChristmas Appeal and asked supporters to donate £20 to send a book to a children's hospital or hospice in the UK. In 2025, our team personally delivered books to children facing difficult times:

- Our Chair, Professor Roberto La Ragione, visited Noah's Ark Hospice in Barnet and gifted books
- Our Vice-Chair of Trustees, Dr Mary Fraser, went to Rachel House in Kinross, Scotland
- Our Fundraising and Partnerships Manager, Sarah Colbourne, went to St Catherine's Hospice in Crawley
- Our Patron, Dr Matt Morgan, visited Tŷ Hafan Children's Hospice in South Wales
- Our Science and Research Consultant, Iva Hauptmannova, visited the Royal National Orthopaedic Hospital in London

BCH Ltd sponsored a number of copies of *Humanimal*, donated to Birmingham Women's and Children's NHS Foundation Trust.

Conference presentations and talks

Throughout the year, our team shared the One Medicine message through talks and presentations at several institutions and events, including the following:

- Final-year Vet Nursing students at Wrexham University
- UK Centre for Animal Law (A-law) Conference at Birmingham City University
- Canine Arthritis Management Chronic Pain Symposium
- Edition Dog Live
- University of Chester's Welcome Fair

One Medicine video series

During the summer of 2024, we shared a four-part video series featuring Professor Noel Fitzpatrick, covering the following:

- The concept of One Medicine
- The future of One Medicine
- Reciprocity
- Treating naturally occurring diseases

The series was picked up by News Medical, one of the world's leading open-access medical and life sciences hubs, who published the full series on their website. The series has been viewed over 1,360 times.

Creative Awards

Now in their third year, the 2025 Creative Awards – themed around We Are All Animals – attracted 135 entries from individuals across the globe, who showcased their creative talents in artwork, poetry, photography and ceramics. The competition featured five age categories, starting from age seven, and this year saw the introduction of a new category for human and animal medical professionals and students. We also welcomed a new judge, Intensive Care Consultant, author and Patron of Humanimal Trust, Dr Matt Morgan.

Curriculum

Following a change of emphasis away from younger age-groups (with the exception of the children's books referred to above) and a decision to defer development of CPD programmes, this objective will be more thoroughly reviewed as part of our 2026-29 strategy.

Income

Primary Three-Year Objective

Achieve sustainable income and steady pipelines from diverse sources at a level that allows us the security to invest in steady growth in staff and activity so that we can achieve organisational goals and objectives.

Impact in 2024/25

100 Club

On One Medicine Day 2025, we invited businesses, organisations and individuals to join our new 100 Club. With only 100 membership places available, the Club offers a unique opportunity to actively support and shape the One Medicine movement by committing to a minimum donation of £100 per month, for a minimum of 12 months. In return, members are championed and recognised with a number of exclusive events and benefits. The first to join the 100 Club was Leucillin Animal Skincare.

Fundraising and Partnerships

Following the appointment of our first full-time Fundraising and Partnerships Manager in 2024, we have been able to focus more specifically on a strategic approach to income generation with an emphasis on building corporate and major donor income, strengthening individual giving opportunities and laying the foundations for a sustainable, more diverse income base.

Team Development

Primary Three-Year Objectives

To grow our staff base to an optimum level, including more dedicated resources to education, fundraising and research and with all colleagues achieving personal fulfilment as well as contributing to organisational effectiveness.

To establish a broad, engaged and supported volunteer base providing both specialist and generic support in the charity's key strategic areas.

Impact in 2024/25

Our team

This past year, we undertook a strategic review of our internal structure to ensure we have the right expertise to deliver on our evolving mission. In November 2024 we appointed a Research and Scientific Outreach Manager to lead our research and scientific activities, and shortly after the end of the financial year we welcomed an Administration and Finance Manager to streamline operations and strengthen governance.

During the year we were delighted to welcome Dr Mary Fraser, a qualified vet who specialises in medical and veterinary education, as our Vice Chair of Trustees - and we announced world history author and storyteller, Christopher Lloyd and Intensive Care Consultant, Dr Matt Morgan, as our Patrons.

Governance

Primary Three-Year Objective

Reach and maintain levels and range of governance, risk management, policy, process and infrastructure suited to the size, scope and aspirations of Humanimal Trust; support this with a broad, diverse and engaged Board and Committee membership and regularly reviewed policy and governance documentation.

Impact in 2024/25

The Board approved the creation and appointment of a new Board role, Vice Chair, with a view to the successful candidate transitioning to the role of Chair, subject to appropriate review by the Board before confirmation. At the invitation of the Board, to ensure a smooth period of recruitment for a Vice Chair and transition to the role of Chair, Professor Roberto La Ragione was invited by the Board to remain in post as Chair until the transition was complete.

Subsequently, Dr Mary Fraser was appointed as our first Vice Chair indicating a commitment to further strengthen our governance by adding yet more skills to the Board as well as providing more explicit support to the Chair. Following Dr Fraser's transition to the role of Chair later in 2025, recruitment of a new Vice Chair will commence.

With the unanimous agreement of the Board, following in depth discussions, it was agreed that the terms of office of Dineke Abbing (as Company Secretary, from October 2024) and Ben Marshall (as trustee from July 2025) should be extended. Both decisions were considered to be in the best interest of the charity.

In the case of Dineke Abbing, this was largely due to the lack of appropriate candidates for the role of Company Secretary. However, Company Secretary duties are now hoped to be passed to the new Administration and Finance Manager in due course, with the support and oversight from one of the trustees.

In the case of Ben Marshall, his departure from the Board would lead to an imbalance in the number of human medical specialists, recruitment advertising for such candidates having been unsuccessful. Efforts will continue to identify such candidates in conjunction with the Vice Chair role becoming available later in the year.

2025/26 and beyond

As we build on the momentum of the past year, our priorities for 2025/26, the last year of our current strategy, reflect our commitment to further accelerating the One Medicine movement and creating lasting, system-wide change in human and animal medicine.

Over the next 12 months we will:

- Strengthen fundraising and awareness initiatives, with a particular focus on deepening our engagement with corporate supporters and major donors.
- Launch a UK-wide and international consultation to shape an inclusive and forward-thinking ethical framework for One Medicine, guided by expert input and diverse perspectives.
- Build a stronger evidence base for One Medicine, by:
 - developing a digital One Medicine Evidence Centre as a hub for case studies, data and impact.

- Launching a One Medicine Business Directory to showcase organisations and services that support or exemplify One Medicine principles;
- gathering and sharing compelling real-life stories to demonstrate the tangible impact of One Medicine on humans AND animals;
- revamp and relaunch our One Medicine Network (was Humanimal Hub), and foster meaningful collaboration between medical and veterinary professionals, researchers, and cross-disciplinary stakeholders;
- deliver funding to selected research studies through our Connections Award programme and Cancer Discovery Fund, advancing the shared understanding of disease and treatment across species;
- enhance visibility and thought leadership by: increasing our presence at key conferences and events through speaking opportunities and panels; contributing high-quality content to professional, trade and academic publications, reinforcing the importance and credibility of One Medicine; and,
- deepen relationships with policymakers, regulators and parliamentary stakeholders, and host a parliamentary reception to showcase our progress, build alliances and influence key decision-makers.

HUMANIMAL TRUST IN A NUTSHELL

Our vision

We want a world where both humans and animals have better opportunities to benefit equally from medical progress because vets, doctors and researchers routinely collaborate and share – this is One Medicine.

Our purpose

We drive collaboration between doctors, vets and researchers so that all humans and animals benefit from medical progress, but not at the expense of an animal's life.

Our long term goals

- Human and animal health have demonstrably improved as a result of One Medicine.
- One Medicine is widely understood and embraced by both the public and professionals.
- There is sufficient funding and robust public policy to support collaboration.
- There is no scientific need and no legal requirement for laboratory animal testing.
- Collaboration between human and animal medicine is the norm, and the sharing of knowledge and research in pursuit of better health for all species is commonplace.
- There is an established One Medicine curriculum (across the four nations and with global influence) from early years to continuous professional development (CPD), meaning professionals arrive in human and veterinary roles with an established One Medicine mindset.

History

Humanimal Trust was established in May 2014 by Professor Noel Fitzpatrick, known globally as a ground-breaking orthopaedic-neuro veterinary surgeon. As a vet he experienced personally the deep divide between human and animal medicine and saw how unfair this was. Frustrated by the lack of opportunities to share what he was learning from day-to-day practice, or to benefit from relevant learning from human medicine, he decided to create the platform himself. This laid the foundations for the work the Trust does today, removing barriers and seeking to close the divide between human and animal medicine. Since those beginnings, the Trust has started to establish a powerful evidence base and to build understanding of both the principle and the potential of One Medicine. This evidence informs mechanisms to reduce, refine and replace laboratory animal tests. By sharing non-animal research methods, and studying naturally occurring disease, we will make more rapid progress. Based in Godalming, Surrey, Humanimal Trust is a registered charity in England and Wales, and in Scotland, operating and influencing worldwide.

Why One Medicine?

As far back as Aristotle in Ancient Greece, convergence between human and animal physiology was a normal part of science. Divergence began in the nineteenth century, but an increasing focus on the welfare, rights and conservation of animals in recent times has led to renewed interest. Human and veterinary healthcare can and should advance hand in hand. Technological advances in non-animal research models, as well as in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point

of the study of disease does not need to involve death. A two-way street between human and veterinary medicine is both possible and necessary for humans and animals to benefit equitably from cutting edge advances. One Medicine recognises that progress in both human and veterinary medicine depends on sharing technologies and research that recognise overlapping biological characteristics.

What we do

We **influence** legislative, policy and practice change. We work with today's vets, doctors and researchers, funders, legislators and policy makers. We seek to identify those of the future and inspire them with our passion and belief in One Medicine.

We facilitate **collaboration** between human and veterinary medicine, by creating opportunities for professionals to come together.

We increase **awareness** and improve understanding of One Medicine, engaging the public, researchers, doctors, vets and policymakers, showing the evidence and demonstrating the case for change.

We fund, facilitate and share the **research** needed to evidence the impact of One Medicine and foster the skills and knowledge needed to make it a reality.

Through **education**, we inspire everyone of all ages to take the One Medicine message forward for the benefit of future generations of both humans and animals.

How we do it

We make the right conversations happen between the right people. We start them, facilitate them and make sure they continue. We are accessible and inclusive, providing many opportunities for collaboration. We catalyse change.

We invite people to come to our One Medicine Network (formerly Humanimal Hub) – first digital and ultimately physical too – where interaction and learning can take place and humans and animals both benefit from the sharing of knowledge.

We build the evidence base for One Medicine; we listen, we gather, we share. Such evidence is the firm foundation for a credible vision of hope.

We work with the authority and pragmatism that comes from our experience and the confidence that comes from our passion and belief. We work with integrity. We defuse professional confrontation, build bridges and seek to instill a spirit of compassion, respect, and mutual benefit.

What we believe

We believe a world is possible, where humans and animals benefit equally and at the same time from advances in medicine. This is reciprocity.

We believe that equitable advances in both human and animal medicine can be achieved more quickly, if there is closer collaboration and mutually beneficial learning. This is One Medicine. We believe and advocate that this approach will lead to progressively fewer laboratory animal tests until one day they become

obsolete.

We believe in sponsoring only research that helps - and learns from – non-animal research methods, and/or animals being treated for naturally occurring disease – not the use of experimental animal models.

We believe that technological advances in non-animal research models, as well as in the diagnosis and analysis of naturally occurring disease mean that for the first time in history, the end point of the study of disease does not need to be the death of an animal.

Even with experimental therapies, such as for cancer, if we share what we already know from veterinary clinical practice and consensual clinical trials with animals, we have the potential to save the lives of both humans and animals without the need to sacrifice a healthy animal's life.

However, there are still too few validated non-animal test alternatives for assessing safety of new drugs and medical devices for human use and laboratory animal testing is still required by Law. This must change. Our intent is that with One Medicine, such testing will become obsolete.

In the meantime, we are committed to - and strongly advocate investment in - the 3 R's: a reduction in animal testing, refinement and replacement of animal tests wherever possible. We also believe in a fourth R: reciprocity. Most current laboratory animal testing is for the sole, often arguable benefit of humans and not the animal concerned or its species.

Currently too little is invested in developing treatments for animals. If veterinary clinical trials were linked to human drug development, for example, resources could be saved, and treatments developed more quickly for both humans and animals.

We believe that the world would be fairer and more respectful for humans and animals if One Medicine were more widely understood and delivered.

One Medicine has a very specific focus on reciprocity. It differs from One Health. One Health seeks better health through addressing risks at the interface between humans, animals and their environments. While One Health may intend to help animals alongside humans, in reality priority is too often given only to human health and wellbeing.

With support and information from Humanimal Trust, we believe everyone can contribute to One Medicine, through giving, advocating, learning or educating. Anyone can talk to their vet or their doctor about One Medicine.

Our purpose is not to endorse any particular lifestyle, including vegetarian or vegan, nor are we an animal rights organisation. These are personal choices and beliefs and not part of One Medicine.

We believe we all share responsibility for creating a fairer society, with better opportunities to benefit equitably from medical progress for humans and animals. However, we believe the greatest responsibility lies with vets, doctors, researchers and scientists worldwide. There is currently no formal platform for the sharing of knowledge between human and veterinary medicine. We seek to change that.

We believe that if we miss this opportunity, we will all pay the price in wasted time, wasted money, and the wasted lives of both humans and animals.

FINANCIAL REVIEW

Income for the year ended 31st May 2025 amounted to £925,715 (£522,970 in 2023/24).

The charity had a net surplus of unrestricted income over expenditure for the year of £462,715 (net surplus of £169,359 in 2023/24) and a net surplus of £nil of restricted income over expenditure (£nil in 2023/24), resulting in total funds of £973,787 carried forward as at 31st May 2025 (£511,072 at 31st May 2024).

Investment Powers and Policy

To date, funds have been held on current account at the charity's bank earning modest interest income. In view of the increased cash balance and in accordance with the charity's forecasts, a proportion of the funds is being transferred to ensure a higher rate of return.

Reserves Policy and Going Concern

Reserves are required to bridge the gaps between the spending and the receipt of income, and to cover unforeseen circumstances. The charity will normally seek to hold sufficient unrestricted reserves to cover six months of operations, which will enable its work to continue uninterrupted.

The charity has more than sufficient funds to cover six months of outgoings at the present time and as such the trustees present the accounts on a going concern basis.

REFERENCE AND ADMINISTRATIVE DETAILS

Charity number: Registered in England and Wales, number 1156927

Registered in Scotland, number SC048960

Principal Office: Eashing Barns, Halfway Lane, Eashing, Surrey GU7 2QQ, United Kingdom

Our advisors:

Accountants:

Radford & Sergeant Limited, Quatro House, Lyon Way, Frimley Road, Camberley, Surrey GU16 7ER

Bankers:

CAF Bank, Kings Hill Avenue, West Malling, Kent, ME19 4JQ

Trustees

The trustees serving during the year and since the year-end were as follows:

Prof Roberto La Ragione (Chair from 11 Oct 2018 to 9 September 2025)	Appointed for three years to August 2019 Re-appointed for three years to August 2022 Re-appointed for three years to August 2025 Re-appointed for three years to August 2028
Prof Noel Fitzpatrick	Appointed indefinitely
Ms Dineke Abbing	Appointed for three years to May 2017 Re-appointed for three years to May 2020 Re-appointed for three years to May 2023 Re-appointed for three years to May 2026
Dr Ben Marshall	Appointed for three years to July 2019 Re-appointed for three years to July 2022 Re-appointed for three years to July 2025 Re-appointed for three years to July 2028
Miss Anna Radford	Appointed October 2022, in post until 7 December 2024
Ms Lorna (Laurie) Dennard	Appointed for three years to September 2026
Dr Mary Fraser (Chair since 9 September 2025)	Appointed for three years to October 2027

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

Humanimal Trust is a Charitable Incorporated Organisation (CIO) governed by a Constitution dated 6th May 2014 and as last amended 11th April 2023, and is registered as a charity with the Charity Commission. Membership of the CIO is restricted to the serving trustees.

Appointment of trustees

As set out in the Constitution there must be a minimum of three trustees. Apart from the first charity trustees, every trustee must be appointed for a term of three years by a resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

Trustee induction and training

The charity trustees will make available to each new charity trustee, on or before their first appointment:

- (a) a copy of the current version of the Constitution; and
- (b) a copy of the CIO's latest Trustees' Annual Report and financial statements.

New trustees undergo an orientation meeting to brief them on: their legal obligations under charity and company law, the Charity Commission guidance on public benefit, and inform them of the content of the Constitution, the committee and decision-making processes, the business plan and recent financial performance of the charity. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role.

Organisation

The board of trustees, which can have up to twelve members, administers the charity and normally meets quarterly at a minimum. The board may from time to time establish sub-committees and two such committees are currently active: (1) for matters relating to medical and science review (Science Committee) and (2) for matters relating to finance and audit (Finance and Audit Committee).

Related parties and co-operation with other organisations

None of the trustees receive remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity and a university or research institution, sponsor, donor or commercialisation partner must be disclosed to the full board of trustees in the same way as any other contractual relationship with a related party.

Pay policy for senior staff

All trustees provide their time freely and no trustee received remuneration. However, trustees are entitled to receive reimbursement of expenses incurred on behalf of the charity. Staff remuneration is set and reviewed by the trustees in accordance with resourcing strategy and financial status.

Risk management

The trustees have a risk management strategy which comprises:

- an annual review of the principal risks and uncertainties that the charity faces;
- the establishment of policies, systems and procedures to mitigate those risks identified in the annual review; and
- the implementation of procedures designed to minimise or manage any potential impact on the charity should those risks materialise.

Financial sustainability continues to be a principal area of risk for the charity. Income from legacies has been a major contributor to overall income over the past four years and other sources of income are being actively pursued with a view to build a regular and varied, sustainable stream of income.

Trustees' responsibilities in relation to the financial statements

The charity trustees are responsible for preparing a trustees' annual report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity law requires the charity trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing the financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with charity law. They are also responsible for safeguarding the assets of the charity and hence taking reasonable steps for the prevention and detection of fraud and other irregularities. The trustees are responsible for the maintenance and integrity of the charitable and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

By order of the Board of Trustees

Dr Mary Fraser, Chair

Date: 24 November 2025

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE HUMANIMAL TRUST

I report on the financial statements of Humanimal Trust for the year ended 31 May 2025 on pages 25 to 32.

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the Charities Act) and that an independent examination is needed. It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act) and to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

1. which gives me reasonable cause to believe that in any material respect, the requirements:

- to keep accounting records in accordance with section 130 of the Charities Act; and
- to prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act

have not been met; or

2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Kim Swain MA (Oxon) FCA

Date: 25 November 2025

*Radford & Sergeant Limited
Chartered Accountants
Quatro House
Lyon Way
Frimley Road
Camberley
Surrey GU16 7ER*

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE PERIOD FROM 1 JUNE 2024 TO 31 MAY 2025

		Unrestricted Funds	Restricted Funds	Total Funds	Total Funds
	Note	2025	2025	2025	2024
Income from:		£		£	£
Donations and legacies	3, 4	920,154		920,154	519, 264
Charitable activities	6	4,865		4,865	3,011
Other income	7	696		696	695
Total Income		925,715	-	925,715	522,970
Expenditure on:					
Raising funds	8	110,349		110,349	59,180
Charitable activities	8	352,651		352,651	294,431
Total Expenditure		463,000	-	463,800	353,611
Net income/(expenditure) and net movement in funds		462,715	-	462,715	169,359
Reconciliation of funds:					
Total funds brought forward		461,134	49,938	511,072	341,713
Total funds carried forward		923,849	49,938	973,787	511,072

BALANCE SHEET AS AT 31 MAY 2025

	Note	Total funds 2025 £	Total funds 2024 £
Fixed assets:			
Intangible assets	10	-	766
Tangible assets	11	899	1,191
Current assets:			
Stock	12	29,172	13,627
Debtors	13	12,174	23,956
Cash at bank and in hand		968,515	488,277
Total current assets		1,009,861	525,860
Liabilities:			
Creditors: Amounts falling due within one year	14	36,973	16,745
Net current assets		972,888	509,115
Total net assets		973,787	511,072
The funds of the charity:			
Restricted income funds		49,938	49,938
Unrestricted funds		923,849	461,134
Total charity funds		973,787	511,072

Approved by the Board of Trustees on 24 November 2025 and signed on its behalf by

Dr Mary Fraser, Chair of the Board of Trustees

NOTES TO THE FINANCIAL STATEMENTS

1 Accounting Policies

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts (Charities SORP (FRS 102)) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Humanimal Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) Preparation of the accounts on a going concern basis

The accounts are prepared on a Going Concern basis.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Fixed assets

Intangible assets relate to the trade mark costs of the Humanimal Trust logo for charitable purpose and are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation at 10% straight line annually plus any accumulated impairment losses.

Tangible fixed assets are stated at their historic cost price less accumulated depreciation. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for use. The asset's residual values, useful lives and depreciation methods are reviewed if there is an indication of significant change since the last reporting date.

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment - 20% straight line, and Computer equipment - over 3 years.

e) Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Trust's work or for specific research projects being undertaken by the Trust. As at 31 May 2025 the Trust's funds consisted of £923,969 of unrestricted funds (2023/24: £461,134) and £49,938 of restricted funds (2023/24: £49,938). The restricted funds of £49,938 are a legacy to be utilised for a cancer related project.

f) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Expenditure is classified under the following activity headings:

- Expenditure on raising funds; includes the cost of goods sold, payment processing fees, plus fundraising specific materials, supplies and travel.
- Expenditure on charitable activities; includes website design and maintenance, fees of independent examiners, delivery of strategic objective activities.

Governance is included in expenditure on charitable activities. The Trust initially identifies the cost of its support functions. It then identifies those costs which relate to the governance function. Having identified its governance costs, the remaining support costs together with the governance costs are apportioned between the charitable activities undertaken in the year. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

g) Stock

Stock relates to merchandising items and books for resale and is valued at the lower of cost and net realisable value, after allowance for obsolete and slow-moving items.

h) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered.

Prepayments are valued at the amount prepaid net of any trade discounts due.

i) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Cash in transit is included.

2 Legal status of the Trust

The Trust is a Charitable Incorporated Organisation and has no share capital.

3 Income from donations and legacies

The Trust benefits greatly from the involvement and enthusiastic support of its volunteers. In accordance with FRS 102 and the Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the accounts.

During the year to 31 May 2025 the Trust gratefully received £40,660 from general donations, plus a £100 corporate donation. The Trust furthermore received unrestricted income from legacies totalling £879,394.

	2025	2024
	£	£
General Gifts (including Gift Aid reclaimable)	40,660	78,439
Corporate and Charity Donations	100	500
Legacies	879,394	440,325
	920,154	519,264

4 Restricted Income

The Trust did not receive any restricted income in the year ended 31st May 2025 (£nil in 2023/24).

	2025	2024
	£	£
Balance brought forward	49,938	49,938
Restricted income received	-	-
Expenditure incurred	-	-
Balance carried forward	49,938	49,938

5 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

As at 31 May 2025, following some members of the team having left during the course of the year, the staff team was made up of the Chief Executive Officer, Fundraising and Partnerships Manager and Research and Scientific Outreach Manager. All other activities of the charity were carried out by volunteers, freelance contractors or consultants and there were no other remunerated members of staff.

The charity trustees were not paid nor received any other benefits from employment with the Trust. No charity trustee received payment for professional or other services supplied to the charity.

Support costs are directly allocated to activities where possible. The remuneration of the Chief Executive Officer is allocated 84% to charitable activities and the remainder to raising funds. The same applied to the remuneration of the Development Manager and Operations Manager. Remuneration of the Schools Education Manager was allocated to charitable activities. Remuneration of the Fundraising and Partnerships Manager is allocated to raising funds. Remuneration of the Research and Scientific Outreach Manager is allocated to charitable activities.

6 Charitable activities

The Trust generated income from merchandise and book sales during the year of £3,218 (£931 in 2023/24) and net proceeds of £1,647 (£2,080 in 2023/24) from the One Medicine Lottery scheme.

7 Other Income

The Trust received £696 of interest income from funds held in its current account (£695 in 2023/24).

8 Expenditure

Principal expenditure included £110,349 to cover the cost of raising funds (£59,180 in 2023/24) and £352,651 towards the cost of delivery of the Trust's charitable objectives (£294,431 in 2023/24). The latter included £54,456 specific to education (£71,986 in 2023/24). £10,109 was expended towards the ongoing maintenance of the Humanimal Hub (now One Medicine Network) (£12,665 in 2023/24).

Independent examiner's fees	2025	2024
	£	£
Independent examination	2,760	2,640
Accounts preparation	1,200	1,200
	3,960	3,840

9 Corporate Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

10 Intangible Assets

Owing to the introduction of a new logo, the net book value of the trademarks of the original logo has been disposed of.

	Trademarks	Totals
	£	£
COST		
At 1 June 2024	960	960
Additions	-	-
Disposals	960	960
At 31 May 2025	-	-
DEPRECIATION		
At 1 June 2024	99	99
Charge for year	95	95
Eliminated on disposal	194	194
At 31 May 2025	-	-
NET BOOK VALUE		
At 31 May 2025	-	-
At 31 May 2024	861	861

11 Tangible Assets

	Office equipment £	Computer equipment £	Totals £
COST			
At 1 June 2024	1,672	3,063	4,735
Additions		290	290
Disposals			
At 31 May 2025	<u>1,672</u>	<u>3,353</u>	<u>5,025</u>
DEPRECIATION			
At 1 June 2024	1,640	1,904	3,544
Charge for year	8	574	582
Disposals			
At 31 May 2024	<u>1,648</u>	<u>2,478</u>	<u>4,126</u>
NET BOOK VALUE			
At 31 May 2025	<u>24</u>	<u>875</u>	<u>899</u>
At 31 May 2024	<u>32</u>	<u>1,159</u>	<u>1,191</u>

12 Stock

	2025 £	2024 £
General merchandise	-	586
Books	29,172	13,041
	<u>29,172</u>	<u>13,627</u>

The book stock relates to the book “We Are All Animals” (the sequel to “Humanimal”) which has been on general release since April 2025.

13 Debtors

The Debtors balance of £12,174 as at 31 May 2025 is made up of prepaid costs in regards the Humanimal Hub, insurance, database management and membership fees, a deposit for the charity’s inaugural Golf Day in September 2025 and an outstanding invoice in relation to the same.

	2025 £	2024 £
Debtors	550	-
Prepayments	11,624	23,956
	<u>12,174</u>	<u>23,956</u>

14 Creditors

The Creditors balance of £36,973 as at 31 May 2025 was made up of trade creditors and income tax, national insurance and pension contributions due in June 2025, along with accrued cost for services received but not yet billed and deferred income in relation to the September 2025 Golf Day.

	2025	2024
	£	£
Trade creditors	17,342	7,733
Taxes and NI	2,829	3,063
Other creditors	692	984
Accrued expenses and deferred income	16,110	4,965
	36,973	16,745

15 Related Parties

There were no related party transactions during the year.

HUMANIMAL TRUST

England & Wales - Charity number 1156927

Accounts



A Charity registered

in England and Wales - charity Number: 1156927

in Scotland - charity Number: SC048960

Annual Report and Financial Statements

Period from 1 June 2023 to 31 May 2024

The trustees are pleased to present their annual report together with the financial statements of the charity for the year ended 31st May 2024.

The financial statements comply with the Charities Act 2011, the Constitution of Humanimal Trust, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102).

CHAIR'S REPORT

As I approach the end of my second term as the Chair of Humanimal Trust's Board of Trustees, it is an ideal opportunity for me to look both backwards with pride and forwards with confidence. May 2024, the final month of the year to which this report applies, marked the 10th anniversary of the Trust's foundation. We can reflect with satisfaction on ten years of hard work, success and learning since Professor Noel Fitzpatrick's gem of an idea took its first steps as Humanimal Trust in May 2014.

We are keen to celebrate the One Medicine story, but also to rededicate ourselves to the Trust's goals with renewed focus and momentum. Our next ten years will provide us with the opportunity to demonstrate proof of the One Medicine concept. We are determined to demonstrate how One Medicine can have a practical impact on research and practice collaboration, coal-face delivery and reciprocal real-time benefit to both human and animal patients. We are proud of how far we have come, but will never rest on our laurels. We are still a young, small, developing charity, but we have a firm foundation and a powerful vision. What we have already achieved is thanks to the efforts of our team and the donations and voluntary support we receive from so many people, but there is always more to do.

2023-24 saw progress on many fronts. Having weathered the storms of COVID-19 and managed our resources during the cost-of-living crisis, we now find ourselves in a stable position to invest in the future in the ways we have always envisaged. This includes investment in fundraising and awareness, further emphasis on education and an increased ability to expand our influence and activity in the research field.

The growing influence of our Science Committee, along with the establishment of an Education Expert Advisory Group and a high-level One Medicine Panel are testament to our commitment to expand our networks and influence in this area, and our ability to attract the highest calibre of professional expertise.

As we publish this report, our CEO Joe Bailey has just marked her second year in post by leading the charity through a great year and with the support of her team, increasing the visibility, credibility and impact of our One Medicine message.

My thanks as always go to my fellow trustees, always passionate and generous with their wisdom, time and experience. Thanks also to every person or organisation that has lent their support to us this year – donating, running or attending events, signing our pledge, or simply spreading the word. This is what will ultimately achieve our goals. Finally, a special thank you to all our committee members and advisers, volunteers and staff. Your commitment to One Medicine is humbling. I am proud to have served as your Chair for the last six years.

The next chapter of our story is just beginning!

Professor Roberto La Ragione, Chair of the Board of Trustees

CHIEF EXECUTIVE OFFICER'S REPORT

My second annual report for Humanimal Trust comes at the end of a whirlwind year that I am immensely proud to say has seen the charity make significant progress in awareness, income and influence. Once grasped, the concept of One Medicine really is a 'no-brainer'. Of course, humans and animals should benefit equitably from scientific advances. Of course, it makes no sense for animals to be harmed or killed as part of research which does not even benefit their species. Of course, both human and animal patients deserve a fair deal. That's why Humanimal Trust exists, to turn the concept into reality!

Our tenth anniversary year began in May 2024, a fitting culmination of a fabulous twelve months. It's so gratifying to see how the often very challenging early years of the charity – planting the seeds, and nurturing the growth of reputation and awareness, with very limited resources – are finally beginning to blossom.

In the last year I have been particularly proud of our growing networks and influence. The One Medicine message is finding real traction. In April, we convened a high-level One Medicine Panel of globally recognised medical and scientific experts. The panel members have now continued their work as a Task and Finish group to help support us in forming the right messaging in both human and animal medicine as well as affiliated fields and advise on engagement with professionals and professional bodies as well as regulators and legislators, hopefully bringing about collaborative and engagement opportunities. Wider interest in the panel also led to an invitation for me to join the globally important UK One Health Coordination Group.

Also launched in 2023/24 was our Public Guardian Involvement and Engagement group, helping us to shape a One Medicine Ethical Framework to support collaboration and delivery of research in veterinary practice.

The staff and volunteer team we are building now has the broadest range of skills ever. We will appoint new marketing/communications and scientific outreach roles in the coming year.

Our presence at the Blenheim Palace Autumn Fair raised awareness with new audiences and offered new educational sessions to younger audiences. The publication with our friends at What on Earth Books of a new edition of *Humanimal*, a book for children about the similarities between humans and animals, was also a highlight. It inspired a project to provide free books to schools, children's hospitals and hospices, helping us to reach the next generation of vets, doctors, scientists and nurses. A second book - *We Are All Animals* – will be published in autumn 2024.

By the time I write the introduction to my third annual report next year, I would like to report that we have completed a successful funding call for a One Medicine cancer project, made significant progress in policy influencing and achieved further expansion of our education programmes into new age groups and homeschooling. We look to publish a One Medicine handbook for student and professional audiences and will also begin to make progress in establishing One Medicine Societies in UK universities with international twinning opportunities. My aim is to establish a new programme for One Medicine Scholarships. And finally, I hope to fulfil our founder's desire to embrace a new 3Rs in the next decade - that of Respect-a universal recognition and appreciation that we are all animals, Reciprocity-a fair deal so that humans and animals can benefit from equal medical progress, and, Regulation-to achieve change in regulatory bias, to recognise that One Medicine is vital for the health of all beings.

It is a privilege to be part of such an incredibly dedicated, compassionate and determined team. We are convinced now is the time to connect, time to innovate, time to act for One Medicine. The time is right now to do the right thing!

Joe Bailey, Chief Executive Officer

OUR IMPACT IN 2023/24

THE YEAR IN REVIEW

A. Highlights

Strategy

Our new three-year strategy was launched in 2023, following a review of the previous five-year strategy. The new strategy focuses particularly on expansion of networks and influence across research, policy and education as well as building on income generation and awareness activities from the previous strategy period. Our I-CARE (Influence, Collaboration, Awareness, Research, Education) mantra will continue to be used externally for ease of explanation of our work but reporting will be simplified internally.

One Medicine Expert Panel

In April 2024, a high-level panel of experts was convened to discuss what One Medicine meant to each of them individually and how it could be used practically to improve collaboration and get a better deal for human and animal patients. It was a landmark event which has led to several subsequent opportunities and developments. One in particular is that the panel members have formed a One Medicine Task and Finish Group to help drive forward the One Medicine message, and support Humanimal Trust by providing expert consideration and advice, and developing engagement activities to help grow our professional audience. The panel event was covered by the Vet Record and extracts of the discussion are available to view as videos. Publicity about the panel led to an invitation to the CEO Joe Bailey to join the influential UK One Health Coordination Group (UKOHCG).

What On Earth Books – Humanimal and We Are All Animals

Building on a strategic relationship that has been growing over the last three years, Humanimal Trust and global publishers What on Earth Books continued to work together. The original *Humanimal* book, aimed at younger readers, was republished with a rebranded dust jacket and launched at the Blenheim Autumn Fair. The book provided an impetus to launch a popular new programme of free books to schools, children's hospitals and hospices. Work has started on a second book *We Are All Animals*, for publication in autumn 2024.

Presentations and Conferences

In June 2023 Joe Bailey and Iva Hauptmannova went to Brussels for the Annual Conference of Eurogroup for Animals, with the opportunity to meet with the Science group and discuss One Medicine.

In September 2023 Joe Bailey gave a presentation at the Eurogroup for Animals leadership webinar.

In July 2023, Iva Hauptmannova presented our definition of One medicine at the INTERACT Conference in Oklahoma.

In October 2023, Joe Bailey attended the All-Party Dog Advisory Welfare Group at the House of Commons.

In November 2023, Joe Bailey and Iva Hauptmannova gave a presentation on One Medicine at the UK Health Security Agency Conference.

In May 2024, Iva Hauptmannova attended the Ecological Genome Project workshops which took place in Geneva over two days, and provided examples of how One Medicine can contribute to future health solutions. The workshop provided a fantastic opportunity for Humanimal Trust to participate in an international collaboration and contribute to a global discussion. The outcomes of the workshops will be published.

A number of the Board members also presented at veterinary and medical conferences.

PGIE

Our Public and Guardian Involvement and Engagement group is now set up and beginning to scope a One Medicine ethical framework to support collaboration and delivery of research in veterinary practice

Webinar Series

This continued across the year and proved successful with a range of audiences. Speakers included Professor Nicholas Dodman, Professor Richard Doughty, Professor Roberto La Razione and Professor Noel Fitzpatrick.

Videos

Professor Noel Fitzpatrick filmed four new information videos for a public audience, providing examples of One Medicine in action.

Blenheim Autumn Fest

Blenheim weekend (30 Sept/1 Oct 2023) provided Humanimal Trust an opportunity to meet new audiences and talk to both adults and children about One Medicine. Highlights included a talk from founder Professor Noel Fitzpatrick, a week of activities for young people led by Rachel Jackson and based on the *Humanimal* book referred to above, culminating in an appearance from author Chris Lloyd on the weekend itself. Our stall, staffed by our wonderful volunteers, attracted hundreds of visitors.

Humanimal Hub

The Humanimal Hub, our free online forum and interactive space where leading minds in human and animal medicine can meet, collaborate and share knowledge and research, continued to grow in influence. 322 people are now approved members. A review of the Hub was initiated and plans for both streamlining and expansion are being put in place.

Website

An upgraded website is being developed, along with refreshed visual identity, for launch later in 2024.

Humanimal Pledge

The Humanimal Pledge continues to be an important engagement tool for the Trust. The number of pledges increased to 20,737 during the year. A review of future pledge campaigns is under way seeking more opportunities for pledgers to engage with the charity in a variety of ways.

InterNICHE

In early 2023, Humanimal Trust gave funding support to a series of videos as part of an InterNICHE programme on humane education and training in medicine, veterinary medicine and biological science – and the replacement of animal experiments by working with teachers to introduce alternatives and with students to support freedom of conscience. The videos were launched in 2024.

Research Funding Call

In late 2023 a funding call was launched for One Medicine-related projects. Unfortunately, none of the submissions were deemed appropriate to fund. However, a substantial new call is being planned in 2024/5 with a more specific focus on cancer, one of the prominent disease areas that affect both humans and animals. Several smaller funding calls focusing on collaboration are also planned.

Education Strategy

The Trust's education programme continued to expand, with the launch of a new education strategy in 2024. A particular boost came from the Humanimal book referred to above, which provided the impetus for a series of related lesson plans. Lesson plans for the second book, *We Are All Animals*, are in production.

New materials are being produced for younger pupils, teachers and homeschooled pupils.

New lessons for 16+ students are now rolled out weekly and have featured in *Animal Therapy* magazine.

Our second Creative Awards received 143 entries (up from 113) from 15 countries (United Kingdom, South Korea, India, Turkey, Hong Kong, Iran, Spain, Malaysia, Indonesia, US, Poland, Hungary, Uruguay, Kenya and Germany).

A talk was also given by our Education Manager Rachel Jackson at the University of Wrexham on 2nd May to a group of Year 3 veterinary nurse students. As a result, we are now discussing inclusion of One Medicine as part of their Veterinary Nursing in the Community module.

There is a strong focus on building a network of One Medicine Societies based in UK universities, and eventually twinning with those overseas.

Income Generation

We are very grateful to all our supporters who continue to give regularly. This year we saw an increase in one-off cash donations, including a great number who supported Noel Fitzpatrick and Joe Bailey in their respective marathon runs. The total of individual giving in the year (including Gift Aid) amounted to £78,439.

Legacies

A total of four legacies were received during 2023/24 totalling £440,325.

Commemorative Impact Report

To celebrate the charity's anniversary a 10-year impact report was published in May 2024.

Challenge 10

Also launched in May 2024 was a year-long programme of fundraising and awareness activity under the banner Challenge 10.

Individual Fundraising Achievements

Special mentions go to a few individual fundraisers:

- Our founder Professor Noel Fitzpatrick and CEO Joe Bailey each ran a marathon as part of our Challenge 10 campaign, raising an impressive £31,300 and £1,415, respectively.
- Dawn Armstrong, with the residents at Whitelaw Court, Dunfermline, raised £2,257 towards Noel's marathon.
- Bev Hunt, who has raised £1,091 so far by committing to walk 55 walks of 5 miles or more around the Cornish Coastline, by her 55th birthday.
- Karen Tommy raised £185 from a solo cycling challenge.

People

Towards the end of 2023 Claire Whitlock (Fundraising) left the Trust. We welcomed our temporary Marketing and Development Support Manager, Bo Olufsen, in January 2024 and our new Fundraising and Partnerships Manager, Sarah Colbourne, at the end of April 2024.

Our new trustee, Laurie Dennard, attended her first full Board meeting in September 2023 and has now taken on the further role of Chair of the Income Generation Group.

Professor Roberto La Ragione is approaching the end of his second term as Chair of the Board of Trustees and has also served as a trustee prior to that. As his current term ends in October 2024, Professor La Ragione offered to continue in the role on an interim basis until a successor is identified. The Board agreed that this would be in the best interests of the charity and is continuing its search for a successor.

The Board also considered it to be in the best interests of the charity to ask Dineke Abbing to continue for a further term of three years in the role of Treasurer unless a suitable successor is found in the meantime.

A review of Board roles and succession planning has also taken place. In late 2024 we plan to recruit a new Vice Chair and further expand our Board and Committee membership. Two new staff roles will also be progressed: Research and Scientific Outreach Manager and Communications and PR Manager.

Our new Education Expert Group, chaired by Dr. Mary Fraser, demonstrates our commitment to educating the next generation of doctors, vets, nurses and allied professionals about One Medicine. This must be a generational change and our ability to develop innovative approaches will rely heavily on this group's expertise.

The One Medicine Task and Finish Group established following the ground-breaking One Medicine Panel in April 2024 demonstrates the calibre of those now engaged with Humanimal Trust and the One Medicine journey. The panel consists of Professor Roberto La Ragione, Professor Noel Fitzpatrick, Dr Mary Fraser, Dr Helen Cohen, Dr Matt Morgan, Dr Ron Daniels, and Dr Danny Chambers MP.

Since the year-end we have divided our existing Income Generation, Finance and Audit Committee into two new entities. First, an Income Generation Group, chaired by Laurie Dennard (trustee) and tasked with identifying and pursuing new income generation opportunities in conjunction with our Fundraising and Partnerships Manager. Second, a separate Finance and Audit Committee, which will continue to be chaired by Dineke Abbing (Treasurer) and advise the Board on these matters.

B. Review of 2023/24 Key Activities

Our objectives for 2023-24 were driven by our new three-year strategy 2023-2026, having completed a review of our previous five-year strategy to 2023. The period covered the lead up to our 10th anniversary year.

Our indicators of success are sometimes relevant to more than one work-stream. For instance, sign-ups to either the Pledge or the Humanimal Hub are indicators of progress in influence, awareness, and collaboration. Where this is the case, progress is recorded under one, rather than all the five work-streams.

I – Influence

Primary Three-Year Objective

- Position Humanimal Trust as an influencer and global focal point for One Medicine bringing together and activating all those with a One Medicine outlook to drive awareness, understanding, law, guidance, funding and clinical practice within a clear ethical framework.

Impact Summary 2023/24

This financial year we continued to expand our networks directly and through memberships and collaborations (such as InterNICHE, Eurogroup for Animals and World Federation for Animals), with a view to enhancing our influence on learning, policy and practice. We achieved noticeable growth of presence in professional and academic circles. While our plans to gain more visibility in UK and national parliaments have been pushed back to take account of the political environment and elections, this will be a major focus going forwards. New membership of the UKOHCG and the range of high-profile speaking engagements referred to above (Highlights) demonstrate our increasing visibility and influence and our ability to attract high calibre individuals to our networks and committees.

C - Collaboration

Primary Three-Year Objective

- Foster and demonstrate impact of greater collaboration both in research and at the clinical coalface between human and veterinary medicine, underpinned by fewer barriers and greater mutual respect.

Impact Summary 2023/24

This financial year through relationships established via our One Medicine Panel, we have been able to set up a One Medicine Task and Finish Group consisting of several high-profile experts in their respective human and

veterinary medical fields. We continued to use the Hub as a focus for engagement and collaboration, whilst reviewing its effectiveness as an engagement tool and ways in which its membership and impact could be expanded. We sought to maximise the value of existing MoUs and began the pilot project to establish a One Medicine Society at the University of Surrey. Our support for InterNICHE's humane education project came to fruition as the video materials were published. Attendance at events increased with more invitations to speak at significant conferences and seminars and our own first webinar series proved successful, leading to plans to repeat in 2024/5. Potential for further activity with those organisations with whom we have MoUs is being reviewed.

A – Awareness

Primary Three-Year Objectives

- Achieve high and consistent visibility and resonance of brand; clarity of understanding of the distinct meaning and purpose of One Medicine; public and professional propensity to support and engage. This will in turn lead to measurable increases in the credibility and influence of One Medicine and of income generation opportunities.
- Establish and embed PGIE (Public and Guardian Involvement and Engagement) as a parallel approach to the established PPIE (Public, Patient Involvement and Engagement).
- Human medical professionals to be targeted more directly through One Medicine messaging route. Focus other student and professional awareness building using the opportunities created by One Health especially with vets, as a conduit to deliver One Medicine messaging.
- Target other priority audiences for PR, social and engagement activity.
- Create new VIP influencers/ambassadors' strategy focused on specialist VIPs (including our own Board and committees) who are influential in their own areas, rather than only 'big name' celebrities.
- Scope PGIE and plan route to promotion/adoption (also part of an ethical framework).

Impact Summary 2023/24

We invested further during this financial year, in awareness-building following our most successful year to date on this front in 2022/23, using the approaching anniversary year to enhance opportunities. However, a change of personnel and duties in the communications team led to a hiatus in proactive work, which began to pick up again at the end of the year, and recruitment for a Communications and PR Manager will commence in the new financial year. Some presence in professional publications was achieved in the Vet Record and Animal Therapy, for example. In terms of professional awareness, as referenced elsewhere, our visibility and influence have steadily increased over the year, and we will continue to push forward. The PGIE group now exists, is meeting regularly and is making good progress in its work to develop a One Medicine ethical framework.

R – Research

Primary Three-Year Objective

- Show evidence of the impact of Humanimal Trust-funded research-related activity on both scientific knowledge and professional practice in both human and veterinary medicine, including:
 - a significant reduction in the use of laboratory animal models
 - an increase in the development of non-animal alternatives
 - at least one funder to add reciprocity into their guidance for funding.

Impact Summary 2023/24

With the support of our increasingly active Science Committee, this financial year we have enhanced our knowledge of the potential for One Medicine-related research. We launched our first small-grant funding rounds but were disappointed with the number and standard of applications. New calls will be published later in 2024. Discussions continued with third parties about possible co-funding opportunities. Scoping of possibilities for student scholarships began. Staff and volunteer sessions on research issues continued, as did efforts to recruit more volunteers – the latter being successful in terms of committees and panels but less so in terms of local volunteers.

E – Education

Primary Three-Year Objective

- Full One Medicine Curriculum framework drafted and in wide consultation following completion of initial pilot programmes, with associated materials (downloadable and print) made available for a range of age-groups and initial CPD programmes piloted.

Impact Summary 2023/24

In this financial year, the launch and promotion of the Humanimal book provided the centerpiece of our education engagement with younger audiences, with dozens of free copies distributed. Plans for a second volume were also agreed with our friends at What on Earth Books and a series of associated lesson plans created. At the same time, we built on our successful school's pilot programme, with a series of learning resources for older students (16+). We began to scope the possibility of a network of One Medicine Societies and ran a second highly successful creative awards programme. Our Education Expert Panel was established, with Dr. Mary Fraser as Chair. The plan for CPD resources was reviewed and pushed back to 2024/5. Collectively, the above will start to form the basis of a lifelong One Medicine Curriculum in the longer term.

Income

Primary Three-Year Objective

- Achieve sustainable income and steady pipelines from diverse sources at a level that allows us the security to invest in steady growth in staff and activity so that we can achieve organisational goals and objectives.

Impact Summary 2023/24

Unfortunately, in this financial year the departure of our fundraising manager and a period of recruitment delayed some of the planned activity but, with the arrival of Sarah Colbourne as Fundraising and Partnerships Manager, work towards the strategic objective is now under way. Income from corporate sources, having seen an upturn in the previous two years, fell short of expectation. However, a particularly good year for legacy income meant that overall, this was the second highest level of income for the charity in a single year. Some of this is

now being invested in sustainable fundraising streams, including reviews of the Champions Scheme, a new Pledge campaign, sponsorship opportunities and VIP patrons.

Team Development

Primary Three-Year Objectives

- To grow our staff base to an optimum level, including more dedicated resources to education, fundraising and research and with all colleagues achieving personal fulfilment as well as contributing to organisational effectiveness.
- To establish a broad, engaged and supported volunteer base providing both specialist and generic support in the charity's key strategic areas.

Impact Summary 2023/24

As referred to elsewhere in this report, the departure and recruitment of staff is a natural cycle in every organisation but did lead to a period where much was expected of a small core team. Recruitment of a Fundraising and Partnerships Manager and Marketing and Development Support manager meant that the team regained momentum in the second half of the year. Plans to recruit a Scientific and Research Outreach Manager and a Communications and PR Manager will further enhance capacity in some priority areas in 2024/25.

Governance

Primary Three-Year Objective

- Reach and maintain levels and range of governance, risk management, policy, process and infrastructure suited to the size, scope and aspirations of Humanimal Trust; support this with a broad, diverse and engaged Board and Committee membership and regularly reviewed policy and governance documentation.

Impact Summary 2023/24

During the financial year, the establishment of the Education Expert Group, Income Generation Group, Finance and Audit Committee and continuing growth in influence of the Science Committee all demonstrate a continuing commitment to good governance and to the pursuit of the best available advice and guidance from experts in their fields. Succession plans for the Chair and a review of trustee roles and succession more generally will see recruitment of a Vice Chair in 2024/25.

C. 2024/25 and Beyond

Looking forwards, our strategic priorities for the remainder of the current three-year strategy are as follows.

Influence

We will seek to amplify our words, deeds and impacts by influencing others to become allies and advocates. Over time we wish to position Humanimal Trust at the heart of a global One Medicine network. By engaging and collaborating with today's organisations, policy makers, politicians, academics and researchers – and identifying and inspiring those of the future - we will influence policy, mindset, funding, education and clinical practice.

Collaboration

Collaboration is at the core of One Medicine. It describes how we behave as an organisation and is the basis of our aspiration for future relationships between human and veterinary medicine. We will promote and expand The Humanimal Hub as an effective real-time collaboration space; create workshop, seminar and conference opportunities, directly collaborate with international like-minded organisations, to inspire wider collaboration, amplify our voice and open new research and funding opportunities.

Awareness

Continuing to increase awareness of Humanimal Trust and One Medicine underpins our ability to raise funds, influence public and professional audiences and achieve change in human and veterinary medical education, research and practice. We will run communications and engagement programmes, bringing One Medicine awareness and the notion of a fair deal for humans and animals into the mainstream, turning the lay public as well as professionals into informed advocates.

Research

We will fund, engage with and promote research that shows the potential of One Medicine to demonstrate reciprocity and produce tangible results that can positively affect human and animal outcomes. We will build the One Medicine evidence base, demonstrating One Medicine in action. By spreading our resources across a wider range of relatively smaller but tangible shorter-term research-related activities, we will create more case studies to reinforce the case for One Medicine.

Education

Education underpins our entire strategic approach. Only by educating the next generation of professionals - starting at the very earliest stage - will we change the professional landscape for One Medicine. We will engage in education from pre-school to CPD and beyond with the ultimate aim of developing a One Medicine Curriculum. We will develop and roll out evaluated pilot school engagements. Everything we do will be viewed through an 'education lens'. More young people will have the opportunity to engage with One Medicine at school, college and university, emerging with One Medicine mindsets as they enter relevant professions.

HUMANIMAL TRUST IN A NUTSHELL

Who We Are

Humanimal Trust drives collaboration between vets, doctors and researchers so that all humans and animals benefit from sustainable and equal medical progress, but not at the expense of an animal's life. This is One Medicine.

As a charity, we are unique leaders and drivers of this vision in the clinical environment and in public. As individuals, we **advocate** One Medicine in our professions as well as in our work for the Trust.

History

Humanimal Trust was established in May 2014 by Professor Noel Fitzpatrick, known globally as a ground-breaking orthopaedic-neuro veterinary surgeon. As a vet he experienced personally the deep divide between human and animal medicine and saw how unfair this was. Frustrated by the lack of opportunities to share what he was learning from day-to-day practice, or to benefit from relevant learning from human medicine, he decided to create the platform himself. This laid the foundations for the work the Trust does today, removing barriers and seeking to close the divide between human and animal medicine. Since those beginnings, the Trust has started to establish a powerful evidence base and to build understanding of both the principle and the potential of One Medicine. This evidence informs mechanisms to reduce, refine and replace laboratory animal tests. By sharing non-animal research methods, and studying naturally occurring disease, we will make more rapid progress. Based in Godalming, Surrey, Humanimal Trust is a registered charity in England and Wales, and in Scotland, operating and influencing worldwide.

Why One Medicine?

As far back as Aristotle in Ancient Greece, convergence between human and animal physiology was a normal part of science. Divergence began in the nineteenth century but an increasing focus on the welfare, rights and conservation of animals in recent times has led to renewed interest. Human and veterinary healthcare can and should advance hand in hand. Technological advances in non-animal research models, as well as in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to involve death. A two-way street between human and veterinary medicine is both possible and necessary for humans and animals to benefit equitably from cutting edge advances.

One Medicine recognises that progress in both human and veterinary medicine depends on sharing technologies and research that recognise overlapping biological characteristics.

What we do

We **influence** legislative, policy and practice change. We work with today's vets, doctors and researchers, funders, legislators and policy makers. We seek to identify those of the future and inspire them with our passion and belief in One Medicine.

We facilitate **collaboration** between human and veterinary medicine, by creating opportunities for professionals to come together.

We increase **awareness** and improve understanding of One Medicine, engaging the public, researchers, doctors, vets and policymakers, showing the evidence and demonstrating the case for change.

We fund, facilitate and share the **research** needed to evidence the impact of One Medicine and foster the skills and knowledge needed to make it a reality.

Through **education**, we inspire everyone of all ages to take the One Medicine message forward for the benefit of future generations of both humans and animals.

How we do it

We make the right conversations happen between the right people. We start them, facilitate them and make sure they continue. We are accessible and inclusive, providing many opportunities for collaboration. We catalyse change.

We invite people to come to our Humanimal Hub – first digital and ultimately physical too – where interaction and learning can take place and humans and animals both benefit from the sharing of knowledge.

We build the evidence base for One Medicine; we listen, we gather, we share. Such evidence is the firm foundation for a credible vision of hope.

We work with the authority and pragmatism that comes from our experience and the confidence that comes from our passion and belief. We work with integrity. We defuse professional confrontation, build bridges and seek to instil a spirit of compassion, respect, and mutual benefit.

What we believe

We believe a world is possible, where humans and animals benefit equally and at the same time from advances in medicine. This is reciprocity.

We believe that equitable advances in both human and animal medicine can be achieved more quickly, if there is closer collaboration and mutually beneficial learning. This is One Medicine. We believe and advocate that this approach will lead to progressively fewer laboratory animal tests until one day they become obsolete.

We believe in sponsoring only research that helps - and learns from – non-animal research methods, and/or animals being treated for naturally occurring disease – not the use of experimental animal models.

We believe that technological advances in non-animal research models, as well as in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to be the death of an animal.

Even with experimental therapies, such as for cancer, if we share what we already know from veterinary clinical practice and consensual clinical trials with animals, we have the potential to save the lives of both humans and animals without the need to sacrifice a healthy animal's life.

However, there are still too few validated non-animal test alternatives for assessing safety of new drugs and medical devices for human use and laboratory animal testing is still required by Law. This must change. Our intent is that with One Medicine such testing will become obsolete.

In the meantime, we are committed to - and strongly advocate investment in - the 3 R's: a reduction in animal testing, refinement and replacement of animal tests wherever possible. We also believe in a fourth R: reciprocity. Most current laboratory animal testing is for the sole, often arguable benefit of humans and not the animal concerned or its species.

Currently too little is invested in developing treatments for animals. If veterinary clinical trials were linked to human drug development, for example, resources could be saved, and treatments developed more quickly for both humans and animals.

We believe that the world would be fairer and more respectful for humans and animals if One Medicine were more widely understood and delivered.

One Medicine has a very specific focus on reciprocity. It differs from One Health. One Health seeks better health through addressing risks at the interface between humans, animals and their environments. While One Health may intend to help animals alongside humans, in reality priority is too often given only to human health and wellbeing.

With support and information from Humanimal Trust, we believe everyone can contribute to One Medicine, through giving, advocating, learning or educating. Anyone can talk to their vet or their doctor about One Medicine.

Our purpose is not to endorse any particular lifestyle, including vegetarian or vegan, nor are we an animal rights organisation. These are personal choices and beliefs and not part of One Medicine.

We believe we all share responsibility for creating a fairer society, with better opportunities to benefit equitably from medical progress for humans and animals. However, we believe the greatest responsibility lies with vets, doctors, researchers and scientists worldwide. There is currently no formal platform for the sharing of knowledge between human and veterinary medicine. We seek to change that.

We believe that if we miss this opportunity, we will all pay the price in wasted time, wasted money, and the wasted lives of both humans and animals.

FINANCIAL REVIEW

Income for the year ended 31st May 2024 amounted to £522,970 (£206,670 in 2022/23).

The charity had a net surplus of unrestricted income over expenditure for the year of £169,359 (net deficit of (£117,146) in 2022/23) and a net surplus of restricted income over expenditure of £nil (£4,938 in 2022/23) resulting in total funds of £511,072 carried forward as at 31st May 2024 (£341,713 at 31st May 2023).

Investment Powers and Policy

To date, funds have been held on current account at the charity's bank earning modest interest income. The trustees are monitoring the cash balances of the charity with a view to seeking a higher rate of return.

Reserves Policy and Going Concern

Reserves are required to bridge the gaps between the spending and the receipt of income, and to cover unforeseen circumstances. The charity will normally seek to hold sufficient unrestricted reserves to cover six months of operations, which will enable its work to continue uninterrupted.

The charity has more than sufficient funds to cover six months of outgoings at the present time and as such the trustees present the accounts on a going concern basis.

REFERENCE AND ADMINISTRATIVE DETAILS

Charity number: Registered in England and Wales, number 1156927
Registered in Scotland, number SC048960

Principal Office: Eashing Barns, Halfway Lane, Eashing, Surrey GU7 2QQ, United Kingdom

Our advisors: Accountants:
Radford & Sergeant Limited, Building 3, Watchmoor Park, Camberley GU15 3YL
Bankers:
CAF Bank, Kings Hill Avenue, West Malling, Kent, ME19 4JQ

Trustees

The trustees serving during the year and since the year-end were as follows:

Prof Roberto La Ragione (Chair since 11 Oct 2018)	Appointed for three years to August 2019 Re-appointed for three years to August 2022 Re-appointed for three years to August 2025
Prof Noel Fitzpatrick	Appointed indefinitely
Ms Dineke Abbing	Appointed for three years to May 2017 Re-appointed for three years to May 2020 Re-appointed for three years to May 2023 Re-appointed for three years to May 2026
Dr Ben Marshall	Appointed for three years to July 2019 Re-appointed for three years to July 2022 Re-appointed for three years to July 2025
Miss Anna Radford	Appointed for three years to October 2025
Ms Laurie Dennard	Appointed for three years to September 2026

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

Humanimal Trust is a Charitable Incorporated Organisation (CIO) governed by a Constitution dated 6th May 2014 and as last amended 11th April 2023, and is registered as a charity with the Charity Commission. Membership of the CIO is restricted to the serving trustees.

Appointment of trustees

As set out in the Constitution there must be a minimum of three trustees. Apart from the first charity trustees, every trustee must be appointed for a term of three years by a resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

Trustee induction and training

The charity trustees will make available to each new charity trustee, on or before his or her first appointment:

- (a) a copy of the current version of the Constitution; and
- (b) a copy of the CIO's latest Trustees' Annual Report and financial statements.

New trustees undergo an orientation meeting to brief them on: their legal obligations under charity and company law, the Charity Commission guidance on public benefit, and inform them of the content of the Constitution, the committee and decision-making processes, the business plan and recent financial performance of the charity. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role.

Organisation

The board of trustees, which can have up to twelve members, administers the charity and normally meets quarterly at a minimum. The board may from time to time establish sub-committees and three such committees had been active since July 2016: (1) for matters relating to medical and science review – during 2022/23 formalised as the Science Committee, (2) for matters relating to fundraising and marketing, and (3) for matters relating to finance and audit. In 2020 the latter two committees merged into one Income Generation, Finance and Audit Committee (IGFA). Since the May 2024 year-end the IGFA Committee has been split back into a Finance and Audit Committee and a separate income generation working group.

Related parties and co-operation with other organisations

None of the trustees receive remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity and a university or research institution, sponsor, donor or commercialisation partner must be disclosed to the full board of trustees in the same way as any other contractual relationship with a related party.

Pay policy for senior staff

All trustees provide their time freely and no trustee received remuneration. However, trustees are entitled to receive reimbursement of expenses incurred on behalf of the charity. Staff remuneration is set and reviewed by the trustees in accordance with resourcing strategy and financial status.

Risk management

The trustees have a risk management strategy which comprises:

- an annual review of the principal risks and uncertainties that the charity faces;
- the establishment of policies, systems and procedures to mitigate those risks identified in the annual review; and
- the implementation of procedures designed to minimise or manage any potential impact on the charity should those risks materialise.

Financial sustainability continues to be a principal area of risk for the charity. Income from legacies has been a major contributor to overall income over the past three years and other sources of income are being actively pursued with a view to build a regular and varied, sustainable stream of income.

Trustees' responsibilities in relation to the financial statements

The charity trustees are responsible for preparing a trustees' annual report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity law requires the charity trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing the financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with charity law. They are also responsible for safeguarding the assets of the charity and hence taking reasonable steps for the prevention and detection of fraud and other irregularities. The trustees are responsible for the maintenance and integrity of the charitable and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

By order of the Board of Trustees

Professor Roberto La Ragione, Chair

Date: 29 October 2024

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE HUMANIMAL TRUST

I report on the financial statements of Humanimal Trust for the year ended 31 May 2024 on pages 22 to 29.

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the Charities Act) and that an independent examination is needed. It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act) and to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

1. which gives me reasonable cause to believe that in any material respect, the requirements:
 - to keep accounting records in accordance with section 130 of the Charities Act; and
 - to prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act

have not been met; or

2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Kim Swain MA (Oxon) FCA

Date: 30 October 2024

***Radford & Sergeant Limited
Chartered Accountants
Building 3
Watchmoor Park
Camberley
Surrey GU15 3YL***

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE PERIOD FROM 1 JUNE 2023 TO 31 MAY 2024

	Note	Unrestricted Funds 2024 £	Restricted Funds 2024	Total Funds 2024 £	Total Funds 2023 £
Income from:					
Donations and legacies	3, 4	519,264		519, 264	203,472
Charitable activities	6	3,011		3,011	2,437
Other income	7	695		695	761
Total Income		522,970	-	522,970	206,670
Expenditure on:					
Raising funds	8	59,180		59,180	100,820
Charitable activities	8	294,431		294,431	218,058
Total Expenditure		353,611	-	353,611	318,878
Net income/(expenditure) and net movement in funds		169,359	-	169,359	(112,208)
Reconciliation of funds:					
Total funds brought forward		291,775	49,938	341,713	341,713
Total funds carried forward		461,134	49,938	511,072	341,713

BALANCE SHEET AS AT 31 MAY 2024

	Note	Total funds 2024 £	Total funds 2023 £
Fixed assets:			
Intangible assets	10	766	861
Tangible assets	11	1,191	492
Current assets:			
Stock	12	13,627	17,501
Debtors	13	23,956	12,939
Cash at bank and in hand		488,277	331,614
Total current assets		525,860	362,054
Liabilities:			
Creditors: Amounts falling due within one year	14	16,745	21,694
Net current assets		509,115	340,360
Total net assets		511,072	341,713
The funds of the charity:			
Restricted income funds		49,938	49,938
Unrestricted funds		461,134	291,775
Total charity funds		511,072	341,713

Approved by the Board of Trustees on 29 October 2024 and signed on its behalf by

Professor Roberto La Ragione, Chair

NOTES TO THE FINANCIAL STATEMENTS

1 Accounting Policies

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Humanimal Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) Preparation of the accounts on a going concern basis

The accounts are prepared on a Going Concern basis.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Fixed assets

Intangible assets relate to the trade mark costs of the Humanimal Trust logo for charitable purpose and are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation at 10% straight line annually plus any accumulated impairment losses.

Tangible fixed assets are stated at their historic cost price less accumulated depreciation. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for use. The asset's residual values, useful lives and depreciation methods are reviewed if there is an indication of significant change since the last reporting date. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment - 20% straight line, and Computer equipment - over 3 years.

e) Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Trust's work or for specific research projects being undertaken by the Trust. As at 31 May 2024 the Trust's funds consisted of £461,134 of unrestricted funds (2022/23: £291,775) and £49,938 of restricted funds (2022/23: £49,938).

f) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Expenditure is classified under the following activity headings:

- Expenditure on raising funds; includes the cost of goods sold, payment processing fees, plus fundraising specific materials, supplies and travel.
- Expenditure on charitable activities; includes website design and maintenance, fees of independent examiners, delivery of strategic objective activities.

Governance is included in expenditure on charitable activities. The Trust initially identifies the cost of its support functions. It then identifies those costs which relate to the governance function. Having identified its governance costs, the remaining support costs together with the governance costs are apportioned between the charitable activities undertaken in the year. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

g) Stock

Stock relates to merchandising items and books for resale and is valued at the lower of cost and net realisable value, after allowance for obsolete and slow-moving items.

h) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

i) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Cash in transit is included.

2 Legal status of the Trust

The Trust is a Charitable Incorporated Organisation and has no share capital.

3 Income from donations and legacies

The Trust benefits greatly from the involvement and enthusiastic support of its volunteers. In accordance with FRS 102 and the Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the accounts.

During the year to 31 May 2024 the Trust gratefully received £78,439 from general donations, mostly online, plus a £500 corporate donation. The Trust furthermore received unrestricted income from legacies totalling £440,325.

	2024	2023
	£	£
General Gifts (including Gift Aid reclaimable)	78,439	53,317
Corporate and Charity Donations	500	9,300
Legacies	440,325	135,917
	519,264	198,534

4 Restricted Income

The Trust did not receive any restricted income in the year ended 31st May 2024 (£4,938 in 2022/23).

	2024	2023
	£	£
Balance brought forward	49,938	45,000
Restricted income received	-	4,938
Expenditure incurred	-	-
Balance carried forward	49,938	49,938

5 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

As at May 2024 the Trust's team was made up of a Chief Executive Officer, Development Manager (p/t), Operations Manager, Schools Education Manager (p/t), Fundraising and Partnerships Manager and a temporary Marketing and Development Support Manager. All other activities of the charity were carried out by volunteers, freelance contractors or consultants and there were no other remunerated members of staff.

The charity trustees were not paid nor received any other benefits from employment with the Trust. No charity trustee received payment for professional or other services supplied to the charity.

Support costs are directly allocated to activities where possible. The remuneration of the Chief Executive Officer, Development Manager, Operations Manager and Marketing and Development Support Manager is allocated 84% to charitable activities and the remainder to raising funds. Remuneration of the Schools Education Manager is allocated to charitable activities. Remuneration of the Fundraising and Partnerships Manager is allocated to raising funds.

6 Charitable activities

The Trust generated income from merchandise and book sales during the year of £931 (£92 in 2022/23) and net proceeds of £2,080 (£2,345 in 2022/23) from the One Medicine Lottery scheme.

7 Other Income

The Trust received £695 of interest income from funds held in its current account (£761 in 2022/23).

8 Expenditure

Principal expenditure included £59,180 to cover the cost of raising funds (£100,820 in 2022/23) and £294,431 towards the cost of delivery of the Trust's charitable objectives (£218,058 in 2022/23). The latter included £71,986 specific to education (£63,524 in 2022/23). £12,665 was expended towards the ongoing maintenance of the Humanimal Hub (£11,654 in 2022/23).

Independent examiner's fees	2024	2023
	£	£
Independent examination	2,640	2,640
Accounts preparation	1,200	1,200
	3,840	3,840

9 Corporate Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

10 Intangible Assets

	Trademarks	Totals
	£	£
COST		
At 1 June 2023	960	960
Additions	-	-
At 31 May 2024	<u>960</u>	<u>960</u>
DEPRECIATION		
At 1 June 2023	99	99
Charge for year	<u>95</u>	<u>95</u>
At 31 May 2024	<u>194</u>	<u>194</u>
NET BOOK VALUE		
At 31 May 2024	<u>766</u>	<u>766</u>
At 31 May 2023	<u>861</u>	<u>861</u>

11 Tangible Assets

	Office equipment £	Computer equipment £	Totals £
COST			
At 1 June 2023	1,632	4,153	5,785
Additions	40	1,109	1,149
Disposals		(2,199)	(2,199)
At 31 May 2024	<u>1,672</u>	<u>3,063</u>	<u>4,735</u>
DEPRECIATION			
At 1 June 2023	1,573	3,720	5,293
Charge for year	67	383	450
Disposals		(2,199)	(2,199)
At 31 May 2024	<u>1,640</u>	<u>1,904</u>	<u>3,544</u>
NET BOOK VALUE			
At 31 May 2024	<u>32</u>	<u>1,159</u>	<u>1,191</u>
At 31 May 2023	<u>59</u>	<u>433</u>	<u>492</u>

12 Stock

	2024 £	2023 £
General merchandise	586	782
Books	13,041	16,719
	<u>13,627</u>	<u>17,501</u>

The book stock relates to the book “Humanimal” which has been on sale since Autumn 2023. Some books have been utilised for school projects and some will be distributed to both schools and hospitals.

13 Debtors

The Debtors balance of £23,956 as at 31 May 2024 is made up of prepaid costs in regards the Humanimal Hub, database management and membership fees, and the book “We Are All Animals” which is published in Autumn 2024.

	2024 £	2023 £
Sundry debtors	-	39
Prepayments	23,956	12,900
	<u>23,956</u>	<u>12,939</u>

14 Creditors

The Creditors balance of £16,745 as at 31 May 2024 was made up of trade creditors and income tax, national insurance and pension contributions due in June 2024, along with accrued cost for services received but not yet billed.

	2024	2023
	£	£
Trade creditors	7,733	13,218
Taxes and NI	3,063	3,123
Other creditors	984	711
Accrued expenses	4,965	4,642
	16,745	21,694

15 Related Parties

There were no related party transactions during the year.

HUMANIMAL TRUST

England & Wales - Charity number 1156927

Accounts



A Charity registered

in England and Wales - charity Number: 1156927

in Scotland - charity Number: SC048960

Annual Report and Financial Statements

Period from 1 June 2022 to 31 May 2023

The trustees are pleased to present their annual report together with the financial statements of the charity for the year ended 31st May 2023.

The financial statements comply with the Charities Act 2011, the Constitution of The Humanimal Trust, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102).

CHAIR'S REPORT

In August 2022, I was delighted to welcome Humanimal Trust's new Chief Executive Officer, Joe Bailey, to the team. This was an important step forward for the charity, bringing charity experience, passion and a fresh focus on purpose, team development and income generation. Joe's experience at RSPCA Assured and her wide network across human and animal science, policy and welfare stands the charity in good stead as we approach our tenth anniversary.

I was also very happy to welcome a new trustee to the Board: Miss Anna Radford. Anna is a Consultant Paediatric Surgeon and Urologist at Hull University Teaching Hospitals NHS Trust, Consultant Paediatric Urologist at Leeds Teaching Hospitals NHS Trust, and Honorary Senior Clinical Lecturer at Hull York Medical School. Her expertise will undoubtedly add a great deal to our team. A further trustee recruitment phase in 2023 led to the recruitment of marketing and fundraising specialist Laurie Dennard, who started to work with us from September 2023.

After navigating several challenging years, not least because of COVID-19 and the cost-of-living crisis, the Trust was fortunate to be able to invest in growth of the team, in turn offering greater opportunity for increased activity and achievement of our goals. Sarah Harper, a long-standing volunteer, became Operations and Relationships Manager, while a part-time Fundraising Manager (Claire Whitlock), Communications and Development Manager (Nigel Palmer), Education Manager (Rachel Jackson) and freelance research support (Iva Hauptmannova) mean that the range of expertise available to the charity has been transformed. Sadly, we said goodbye to Jo Blake, Development Manager, mainstay of the charity and its most senior staff member for more than six years, who departed with the organisation's gratitude and best wishes for a new role in Ireland. Dr Tracey King, our Research and Outreach Manager, also moved on to new challenges with our sincere thanks and best wishes.

Our volunteers – whether in governance and advisory roles, such as trustees and committee members, or engaged in fundraising, awareness and support all over the country – are our mainstay. I would like to thank them all for their time, energy and commitment to the Trust. To demonstrate commitment to our volunteers, we have designed a new volunteer strategy, led by our volunteer coordinator Karen Brooks and Sarah Harper, which we hope will bring us new volunteers and help the Trust to recognise and support all our current volunteers even more effectively.

For the Board, having emerged from the pandemic financially stable, our particular priority alongside supporting the new team, has been to ensure our new three-year organisational strategy makes best use of our resources and is both ambitious and deliverable. With the first year of that strategy covering the year leading up to our tenth anniversary, the trustees are determined to see further progress towards our long-term objectives. This report highlights areas of progress over the past year and signposts some of our aspirations for the years ahead. The solid foundations we have been patiently building for the last nine years, give us confidence that our next steps will drive One Medicine more firmly into the public and professional mainstream. A fair deal for humans and animals is not an unreasonable aspiration – but its achievement would be truly cause for celebration.

Professor Roberto La Ragione, Chair of the Board of Trustees

CHIEF EXECUTIVE'S REPORT

Having joined Humanimal Trust as Chief Executive in August 2022, this is my first annual report for the charity. I moved from RSPCA Assured, part of a very large two-hundred-year-old charity that is part of the national culture, and taking up the baton of a small, but ambitious and growing charity was an enormous opportunity for me. I am determined to use the experience of my years in the sector – as employee and volunteer for both large and small organisations – to lead Humanimal Trust to the prominence and impact it deserves.

One Medicine, our core focus, is truly a 'no-brainer'. Why should animals and humans not benefit equitably from advances in science and medicine? All patients of all species should benefit from the fruits of research. Why should animals have to be harmed or killed as part of medical research which does not even benefit their own species, when non-animal alternatives are ever more widely available and there is so much to learn from everyday veterinary practice? Patients are at the heart of all we do, by helping them and sharing their data, their stories, we can help so many more in the future. We will improve lives; we will save lives.

The time has come for a determined commitment on the part of the scientific and medical communities to invest in alternatives; for human and veterinary medical worlds to genuinely communicate and collaborate. There is so much to gain for all species.

Arriving in a charity whose staff and volunteer team has given everything over the past few years to ensure it emerges fighting fit from the pandemic and the cost-of-living crisis has been nothing short of inspiring. I will give nothing less than my own total commitment to ensuring this charity achieves its goal of a world where One Medicine is the norm.

My immediate priorities have been to review and update our organisational strategy, giving us a clear path for the next three years, then to recruit new team members to deliver it. Raising the funds and increasing our support to deliver those plans must now be our absolute focus. Our tenth anniversary in 2024 will be an opportunity for us all to celebrate what we have already achieved and to rededicate ourselves to even greater success and to a One Medicine future. Neither humans nor animals deserve anything less.

Joe Bailey, Chief Executive

OUR IMPACT IN 2022/23

THE YEAR IN REVIEW

a. Highlights

People: In August 2022, Humanimal Trust appointed a new Chief Executive, Joe Bailey, who took over leadership of the charity at an important point in its life. Having emerged healthily from the pandemic, despite a number of challenges, the charity was ready to begin the next phase of its development with several new recruits, an updated strategy and renewed ambition as it approached its tenth anniversary year.

New colleagues are now offering a wider range of expertise across a number of new roles outlined in the Chair's report. A new volunteer strategy, with an emphasis on recruitment and recognition of the wide range of volunteer skills we need and nurture is now in place. A full review of our staff and volunteer policies and procedures was also begun during the year and completed later in 2023.

As part of our commitment to growth and evolution at Board level, one new trustee, Miss Anna Radford, a Consultant Paediatric Surgeon, was appointed in October 2022. Laurie Dennard, with particular experience in marketing and fundraising, was appointed following a new recruitment round at the end of the 2022/23 financial year and began her tenure at the September 2023 Board meeting. Our Income Generation, Finance and Audit Committee was also augmented by the addition of Hannah Windmill, whose legal and events expertise has been most welcome.

Our Science Committee welcomed a number of new members and was formally inaugurated (see below).

Strategy: As the previous five-year strategy came towards its end, the Board approved a new three-year strategy to take the organisation forward into its tenth anniversary year and beyond. Enhancing our commitment to the five I-CARE workstreams (Influence, Collaboration, Awareness, Research, Education) the new strategy sharpens our focus on specific stretching but achievable outcomes in each of those areas. There is a particular emphasis on education as an underpinning to everything we do – and on the identification of more, smaller-scale research-related activities to engage and excite the support of public and professional audiences alike.

Humanimal Webinar Series

Launched in May 2023 to coincide with our ninth anniversary, the new Humanimal webinar series will run approximately monthly for the next year, culminating in a live event to coincide with the tenth anniversary in May 2024. With so many opportunities for human and animal patients alike to benefit from collaboration, the webinars will showcase a wide variety of professionals involved in making One Medicine happen, discussing a range of topics for veterinary and human medical clinicians, as well as researchers, those interested in One Medicine and the work of Humanimal Trust, plus schools, universities and others.

Humanimal Podcast Series

Building on the first series, launched in 2021-22, the second series focussed on a range of topics from the roots and history of One Medicine to current practical and ethical challenges. There were 420 listens during the year, however a decision was made not to proceed with a third series and to give greater priority to the webinar series (above) in the coming year. We are however happy to take part in other podcasts, and will continue to do so.

What On Earth Books – Humanimal

Building on a strategic partnership that has been growing over the last two years, Humanimal Trust and global publishers What on Earth Books agreed to work together on two books carrying the name *Humanimal* aimed at younger readers, as part of Humanimal Trust's increasing commitment to One Medicine education. The first book has been rebranded with our dust jacket and launched in early Autumn at an event at Blenheim Palace. The follow-up book in the series, 'We Are All Animals', will be published in 2024 in association with What on Earth Books.

Humanimal Hub: The Humanimal Hub, our free online forum and interactive space where leading minds in human and animal medicine can meet, collaborate and share knowledge and research, continued to grow in scale and influence. 274 people are now approved members.

Humanimal Pledge: Although the Humanimal Pledge was not promoted heavily in the last year, there are still around 20,000 signatories committed to champion One Medicine.

UTOMIC: Although agreed in 2021/22, our memorandum of understanding with the Netherlands-based UTOMIC was publicly announced in November 2022. The Utrecht Translational One Medicine Innovation Centre (UTOMIC) at the University of Utrecht in The Netherlands, works to further medical progress for human and animal patients, with the shared goal of making animal testing obsolete in human and veterinary medicine through collaboration.

INTERACT: Building on the 2022 memorandum of understanding with Oklahoma State University (OSU) College of Veterinary Medicine's Institute for Translational and Emerging Research in Advanced Comparative Therapy (INTERACT), Humanimal Trust co-sponsored and participated in an international conference attended by a global audience people to explain the uniqueness of One Medicine and its relationship to other concepts such as One Health.

InterNICHE: As part of its commitment to collaborating through partnerships, the Trust signed a memorandum of understanding with InterNICHE - the International Network for Humane Education - which aims for high quality, fully humane education and training in medicine, veterinary medicine and biological science – and the replacement of animal experiments by working with teachers to introduce alternatives and with students to support freedom of conscience. Humanimal Trust gave funding support to a series of videos as part of this programme.

Eurogroup for Animals: Humanimal Trust joined Eurogroup as a member of its science group, becoming part of an international network of nearly 100 organisations.

World Federation for Animals: Humanimal Trust also joined WFA, a global body bringing together over 50 animal organisations.

Network of influence: Alongside our collaborative partnerships and new memberships (above), we continued to broaden contact with scientists, academics and educationalists in Europe, N. and S. America and Australasia, promoting opportunities for collaboration and learning. Groundwork on more direct engagement with the UK, Scottish and Welsh Parliaments also began in earnest.

Research: The most significant step taken in 2022/3 was the formal establishment of our Science Committee to provide the trustees of Humanimal Trust with recommendations for funding projects and to provide assurance that projects proposed for funding meet Humanimal Trust requirements and standards. Members of the committee are globally recognised specialists in their fields and in areas of priority to Humanimal Trust. As our ability to fund research grows, their individual and collective expertise and networks will be invaluable.

As a result of the departure of former research staff, the appointment of a new CE and new trustees, planned research calls did not take place during the financial year. However, a call was launched in July 2023 and will be reported on in the following year's annual report.

Humanimal Trust has supported two projects primarily funded by Action Medical Research over the past two years. The second of these has now completed and submitted its report. Humanimal Trust will now be sharing the results with veterinary and other networks to explore possible benefits to animals of this important study into antibiotic resistance and infection control in critically ill children.

Education: The Trust's education programme took a major step forward this year with several significant initiatives. As well as the *Humanimal* book in association with What on Earth Books referred to above, our first schools pilot to explore engagement with One Medicine principles for senior pupils took place at the Royal Latin School in Buckingham. The project was completed and evaluated, giving valuable insight and data for further development of our schools engagement programme.

Our first international Creative Awards, aimed at age groups from 7 to 18, invited submissions in any medium on the theme of One Medicine. 113 entries (87 from the UK) were received with winners in each category awarded prizes and attracting international media attention.

Media and Publications: This year a further expansion in media coverage was achieved. The Trust's activities attracted the attention of local and digital media (both lay and specialist). Professional and academic publications featured Humanimal Trust on a more regular basis. Nearly 50 items reaching nearly 17 million readers showed steady development of our visibility. Social media also continued to thrive with a total of in excess of 20,000 followers across our social channels.

Income Generation and Events

As for all charities, the fundraising environment has been challenging. However, a number of legacies were very gratefully received totalling over £140,000.

We continued our development of a support network for higher-level donors, both individual and corporate, including a reception at the Farmers Club in Whitehall Court, London. We continue to be grateful for the support of Corrigan Gore and Leucillin and look forward to building our base of support over the next year.

2092 individual donations were received during the year from 197 regular givers, 30 Humanimal Champions and 65 cash donors.

Our Stronger Together at Christmas collaboration meant that donations to Humanimal Trust were matched with Christmas pet food/goody packs from the Natural Pet Centre, distributed by Blue Cross, a fine example of human-animal benefit in the face of a cost-of-living crisis. Nearly £500 was raised from this activity.

Local events and individual sponsored challenges began to take place again following the lifting of lockdown restrictions and we are grateful for all these voluntary efforts on our behalf, particularly the following:

- Emily Bircham, and friends, raised a huge £305 for Humanimal Trust by holding a fun dog show.
- Bev Hunt for continued her challenge to complete 55 sponsored walks for Humanimal Trust to mark her 55th birthday. Despite the interference of the pandemic, the challenge continued, with photos from the trip being compiled in a calendar to raise further funds.
- Park School for Girls in Ilford, raised £1300 after choosing Humanimal Trust as their charity of the year.

b. 2022/23 Specific Objectives and Impact

Our specific objectives for 2022-23 were driven by our 5-year strategy but with a view both to the approaching tenth anniversary and the upcoming strategy review. Post-pandemic and in the light of cost-of-living uncertainty, Humanimal Trust remained cautious and focused in its use of funds and generation of income but determined to continue to deliver our purpose and to generate support.

Our indicators of success are sometimes relevant to more than one work-stream. For instance, sign-ups to either the Pledge or the Humanimal Hub are indicators of progress in influence, awareness, and collaboration. Where this is the case, progress is recorded under one, rather than all of the five work-streams and is cross-referenced where appropriate.

The summaries below make reference to the highlights above in the context of each of the five activity streams.

Principal focus areas in 2022/23 were:

- Focused awareness building with professional, lay, youth, trade and specialist funder audiences.
- Partnerships, networks and collaborations: placing Humanimal Trust at the centre of a One Medicine network of influence.
- Education-related activity, developing pilot programmes and beginning development of a One Medicine curriculum.
- Research funding, engagement and influencing activity based on achieving a wider scope of visibility and outcomes from limited resources.
- All of the above to be supported by greater emphasis on our newly developed ICARE messaging, which offers a huge opportunity to refocus our engagement and communication activities.

In turn these were to be made possible by two core 'enabling' or 'capacity-building' activities:

- Volunteer strategy
- Income generation

Staff and governance development also remained underlying priorities.

I - Influence

5-Year Strategic Objective:

As the evidence for One Medicine grows, we will continue to share knowledge with policy-makers and politicians to inform better legislation.

2022/23 Objective:

- ***Establish credible and effective presence and relationships with regulatory and membership veterinary, medical and associated bodies.***

This area began to bear fruit in 2022/23, building a foundation for further expansion and impact in subsequent years. Membership of both Eurogroup and the World Federation for Animals greatly expanded our network of collaborative organisations. Invitations for us to participate in events organised by other organisations continued, including presentations in the Czech Republic and the USA.

This remains an area we wish to develop further as resources allow and plans were initiated in mid-2023 for a long-term programme of activity designed to engage more directly with policy-makers over the next few years. This included establishment of a public affairs working group and plans to engage with the All-Party Group on Animal Welfare. Humanimal Trust wishes to be seen as the centre of a network of influence for One Medicine. A growing number of individuals and organisations are now part of our global network. The Humanimal Hub, Humanimal Pledge, webinar and podcast series and PR programme all reinforce this activity.

C - Collaboration

5-year Strategic Objective:

We aim to demonstrably increase collaboration between medical and veterinary professionals, to maximise value and minimise delays in progress.

2022/23 Objectives:

- ***Continue to raise awareness of The Hub, including the new App, and use it to generate active collaboration and sharable content.***
- ***Build on existing - and continue to seek new partnerships to expand visibility and influence.***
- ***Fuel debate and raise expectations for collaboration across human and veterinary medicine.***

As above, Hub membership and activity is also a measure of success in terms of demonstrating collaboration. Hub members increased to 274, below the target of 350 but a healthy 10% increase since 2021/22.

Our priority in the next year is to encourage more regular engagement from Hub members and to find ways of refreshing content more regularly. The Hub continues to be important in building of networks and partnerships as referred to elsewhere in this report.

The formal announcement of our partnership with UTOMIC and our first participation in an event organised by INTERACT showed that these memorandums of understanding have already given practical benefit. The new partnership with InterNICHE and our support for its work in humane education again showed the practical value of such partnerships and their direct relevance to One Medicine.

Humanimal Trust also teamed up with Rest Easy Method to create a number of downloadable resources, aimed at supporting young people in recognising and managing their emotional wellbeing, and that of others, across species.

We have also begun to talk to UK research charities with a view to potential collaboration, such as Sarcoma UK.

A - Awareness

5-year Strategic Objective:

We aim to measurably increase public, professional and political awareness, understanding and acceptance of One Medicine.

2022/23 Objective:

- ***Demonstrate continued increase in awareness of Humanimal Trust and One Medicine among key target audiences (professional, lay public, youth, trade and specialist funders).***

Awareness objectives overlap with a number of others, so indicators of success are shared in some cases. While the Hub remains our principal regular contact point for professional audiences, membership has remained quite static and we would value a higher level of engagement from members, contributing comments, ideas, articles and collaboration opportunities, so we will be looking at ways of improving this in the coming year.

Presentations to international audiences continued, including participation in the international INTERACT conference on One Health and One Medicine and a presentation to a scientific conference in the Czech Republic.

For lay audiences, traditional, social and other digital media continued to prove successful for building general awareness, along with local talks, which continued to be popular whenever volunteers were able to deliver them.

From the start of June 2022 to the end of May 2023, 18 community talks (5 more than last year) were given to 348 attendees, some leading to coverage in local media.

Our website remained a core point of contact with 31,512 visits.

Our second series of Podcasts was launched - Humanimal Connection 2 – building on the first series but with a greater focus on the history of One Medicine and on ethics. The series was aimed at both professional and informed lay audiences and provided helpful feedback about the needs of both, leading to a decision to focus more on webinars for professional audiences and other channels of communication for lay audiences.

Media coverage remained positive with fewer different titles but more examples of regular coverage in certain trade and professional publications and in higher circulation titles. 26 titles in total covered Humanimal Trust activities, a total reach of 16,903,616 readers – an increase of 29% on the previous year.

Coverage included:

- | | |
|---|--------------------------------|
| • Andover Advertiser | • Vet Times (x3) |
| • Birkenhead News | • Vet X |
| • Biz News Post | • Veterinary Practice (x2) |
| • Charity Today (x6) | • The Week |
| • DVM360 (x4) | |
| • Daily Record | Total Reach: 16, 903, 616 |
| • Greatest Hits Radio (Surrey and E. Hants) | |
| • Head Topics | |
| • Hull Daily Mail | Social media reach: |
| • Ilford Recorder | |
| • In Your Area (Exeter) | • Facebook: 11,000 followers |
| • In Your Area (Wirral) | • X (Twitter): 7,043 followers |
| • Lynn News | • Instagram: 1,506 followers |
| • Moma | • LinkedIn: 237 followers |
| • Newcastle Chronicle | • Youtube: 476 subscribers |
| • Newcastle Journal | |
| • News Medical | |
| • Pet News 2Day | |
| • Prize Finder | |
| • School Reading List | |
| • Super Lucky Di | |
| • Vet Click (x8) | |

R - Research

5-year Strategic Objective:

We aim to improve and accelerate the growing understanding of the complex interactions between animal and human biological characteristics, the similarities between them and the opportunities arising from them. We want to repaint the landscape in which medicine is researched and received; redefining the language of respectful interaction between species at the clinical coalface.

2022/23 Objective:

- ***Achieve greater influence and visibility for research engagement activity through implementation of agreed new focus on wider range of more cost-effective funding options.***

The most significant research step taken in 2022/23 was the full inauguration of the Science Committee. Seven independent members were invited to join the Committee, along with two trustees (Professor Roberto La Ragione (Chair) and Miss Anna Radford). Secretariat for the group is provided by Dr Iva Hauptmannova. The quality and reputation of the Committee's membership speaks volumes about how far the Trust has come in terms of its ability to attract the very highest calibre of engagement.

Alongside the Chair of Trustees Professor Roberto La Ragione and Trustee Miss Anna Radford, the following are now members of the Humanimal Trust Science Committee:

Helen Ballantyne - Clinical Nurse Specialist for Living Kidney Donation; Registered Veterinary Nurse.

Dr Margarida Simoes – human nurse and veterinary doctor; European Centre for Disease Prevention and Control (ECDC) Fellow; Resident of the European College of Veterinary Public Health.

Associate Professor Benjamin Capps - Associate Professor in Clinical Ethics at Dalhousie University; Chair of the Human Genome Organisation (HUGO) Committee on Ethics, Law and Society.

Professor Matthew Breen - Professor of Genomics; Oscar J. Fletcher Distinguished Professor of Comparative Oncology Genetics in the Department of Molecular Biomedical Sciences at the North Carolina State University College of Veterinary Medicine.

Dr James Yeates - Trained veterinarian; CEO of the World Federation for Animals; member of the Scottish Government Animal Welfare Commission and DEFRA Animal Welfare Committee.

Professor Ali Mobasher - Professor of Musculoskeletal Biology at the University of Oulu, Finland; Chief Researcher and International Advisor at the State Research Institute Centre for Innovative Medicine in Vilnius, Lithuania; Visiting Professor at Sun Yat-sen University, China; Advisor to the World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging at Université de Liège, Belgium.

Professor Ashish Ranjan – Endowed Professor in the College of Veterinary Medicine at Oklahoma State University, USA; Director of the Institute for Translational and Emerging Research in Advanced Comparative Therapy (INTERACT).

Dr Richard Doughty – Trained veterinarian, medical doctor and consultant pathologist at Akershus University Hospital, Norway.

Two expert advisers also agreed to join us: Mary Fraser of the Royal College of Physicians in Edinburgh and Hana Hybasek Dzurikova, an education specialist in human and veterinary medicine, based in Slovakia.

The period of recruitment of the Committee, along with a change of staff in the research area of the team meant that a planned research call was pushed back into early 2023/24 but the expansion of research engagement overall was significant. Aside from a new wave of relationship building, the relationships with INTERACT and UTOMIC referred to elsewhere in this report began to show practical benefit. Early groundwork was also laid for long term development of an ethical framework for One Medicine and a new approach to public engagement in veterinary treatment, called PGIE (Public, Guardian Involvement and Engagement). We continued to promote research relevant to One Medicine ethos through the Humanimal Hub.

Our support for two research studies, principally funded by Action Medical Research, has now come to an end, with both projects now completed. The second of these, looking at infection prevention and its impact on antimicrobial resistance in critically ill children (led by Dr Nazima Pathan, Lecturer in Paediatric Intensive Care at

the University of Cambridge) is now being reviewed by our Science Committee who will consider sharing with a wider audience to allow discussion of potential benefit to animal patients.

E – Education

5-year Strategic Objective:

We aim to inspire everyone to take the One Medicine message forward as a credible vision of hope for future generations of humans and animals.

2022/23 Objectives:

- ***Develop One Medicine curriculum.***
- ***Increase awareness of and engagement with Humanimal Trust and One Medicine among children and young people.***
- ***Increase awareness and engagement with Humanimal Trust and One Medicine among future vets, doctors and animal welfare professionals.***

The appointment of a member of staff with specific focus on this area of work has transformed our capacity to deliver against this objective. Our first fully planned, delivered and evaluated pilot programme with a UK school, namely the sixth form at Royal Latin School in Buckingham, allowed us to test approaches to introducing discussion of One Medicine, with curriculum relevance and school buy-in. Excellent feedback from the school means we will be developing and delivering further pilots. There will also be new materials for use by medical societies for teachers and pupils to download from our website. We are now looking at other age groups and schools to partner with.

Our first Creative Awards for children aged 7-18 across a range of age categories, gave a global audience the opportunity to show what One Medicine meant to them through any creative medium of their choice. 113 entries were received, including 26 from outside the UK. The quality of the entries was high and the messages contained in them, inspiring. Judges included Professor Noel Fitzpatrick and owner of What on Earth Books, Christopher Lloyd.

The Trust's relationship with What on Earth Books was further cemented this year with our agreement to proceed with a book project for younger readers aged 6-9, an important part of our educational approach. An existing book which shared the name *Humanimal* with the Trust, was reprinted and a second book is being produced collaboratively and looking at the close relationship between humans and animals in terms of our bodies and what makes us better when we are injured or ill.

Work also began on a programme designed to build a network of One Medicine Societies in colleges and universities around the UK.

Enabling Objective - Income

2022/23 Objectives:

- ***Achieve sustainable income level and replenish reserves.***
- ***Increase total income and broaden range of sustainable income streams.***
- ***Develop major giving pipeline: individuals, corporates, trusts.***

The year was once again characterised by careful ongoing control of expenditure, selective investment in fundraising, awareness education and research activities and maintenance of staff wellbeing, while team recruitment and long-term strategy took centre stage. Recruitment of a Fundraising Manager – the Trust’s first – was a big step forward in commitment to long term focus on driving sustained income.

Regular income from donors from the Champions Scheme and from a range of challenge, digital and other streams such as our lottery, Amazon Smile, Facebook fundraising and in memory giving all continued to contribute to steady income through the year. We received 2,092 individual donations during the year from 197 regular givers, 30 Humanimal Champions and 65 cash donors.

Local fundraising and challenge events also began to return post-pandemic, albeit slowly, as referred to in the highlights section above.

We are grateful for the support of our major donors both individual and corporate. We continue to work alongside corporate supporters such as Corrigan Gore and are grateful to them for sponsoring our supporter engagement event at the Farmers’ Club in Whitehall Court, London.

However, it was once again as a result of a combination of long-term investment in both the Humanimal Trust brand and Noel Fitzpatrick’s own profile, along with specific legacy marketing and good stewardship, that a number of major gifts and legacies made the real difference to the charity’s ability to plan more confidently for the future.

In all, five legacies with a total value of £140,855 were received during 2022/23 as follows:

Legacy notified in 2021-22	£20,000
Final instalments of a legacy for which the main amount was received in 2021-22	£49,384
Legacy notified in 2020-2021	£17,454
1 legacy (notified and received during 2022-23)	£32,773
1 legacy (notified in 2020-21)	£21,244

A further legacy was also notified during 2022-23 but not received in-year – the final value is as yet unknown because it is reliant on a house sale.

Overall the income achieved in the year was £206,670.

Enabling Objective - Team Development

2022/23 Objectives:

- ***Continue to increase staff and volunteer capacity to deliver business plan and strategy.***
- ***Significantly grow volunteer base across two streams:***
 - ***local volunteer network of lay and science volunteers.***
 - ***shadow volunteer structure for key organisational tasks.***

As referred to in the highlights section and the Chair's report, the recruitment of a Chief Executive, new trustees and committee members and several specialist members of staff, is a further sign of the charity's intention to deliver against its strategy and purpose and to invest wisely in the right expertise and experience to do so.

The team collaborated with the Chief Executive in developing a new long-term strategy - subsequently approved by the Board - and a first-year business plan which reflected the optimism and excitement about the new possibilities presented by the newly expanded team and its collective expertise.

Alongside the induction and team-building, a review of staff policies and procedures as well as well-being provision also took place and continued into the following financial year. Specialist agency Citation have been appointed as our HR advisors.

As referred to in the Chair's report, two senior staff – Jo Blake and Dr Tracey King - left the organisation with the thanks and gratitude of everyone at the Trust.

Work was completed on a new volunteer strategy, including a greater focus on more consistent recruitment, support and recognition; seeking more volunteers with specialist skills, especially in education and science, and ensuring better volunteer engagement with the charity's work.

Enabling objective - Governance

2022/23 Objectives:

- ***Continue to develop and review governance and policy framework.***
- ***Continue to develop diversity and capacity of Board and Committees.***
- ***Appoint further members to Science Committee and activate.***
- ***Appoint further members to Expert Panel and activate.***
- ***Review contribution and composition of Income Generation, Finance and Audit.***

This report covers elsewhere the recruitment of new trustees and committee members and the establishment of the Science Committee. The Board continued to reinforce its commitment to good governance and continuing to learn and improve its own knowledge and expertise in this area. The annual trustee review once again meant that each trustee had the opportunity to share privately with the Chair, their views on their own contribution and that of the Board as a whole. The organisation's governance manual, risk register, policies and procedures

were reviewed and approved by trustees as they are every year. This year Citation were appointed with specific expertise in HR to review staff policies and procedures and the employee handbook.

2023/24 and beyond - looking forward with our new three-year strategy

The next twelve months will see a step-change in activity as we approach our 10th anniversary – a year of celebration and rededication to our goal of a world where One Medicine and a fair deal for both humans and animals are the norm.

Our commitment to presenting One Medicine consistently through an education 'lens' will strengthen. Continuation of our schools education programme, the launch of at least one children's book, the launch of One Medicine Societies in colleges and universities, support for school MedSocs and consideration of continuous professional development are all on the agenda.

A significant presence at the Blenheim Autumn Fair, a new Christmas fundraising Campaign, a series of '10' themed fundraising events and a new drive to recruit people to sign the Humanimal Pledge for One Medicine are all highlights for the year.

We will seek to maximise our memberships of Eurogroup for Animals and the World Federation for Animals, our relationships with InterNICHE, INTERACT and UTOMIC and our new contacts with the UK Health Security Agency, whose conference we are attending. Our public affairs plans include an event at the Houses of Parliament and a series of engagement with the parliaments and assemblies of the UK, Scotland and Wales.

The launch of our new 2023-26 strategy - and accompanying fundraising and volunteer strategies will underpin and guide all our work, which remains focused on our five I-CARE activities.

Specifically, our strategic priorities for the next three years can be summarised as follows:

Influence

We will seek to amplify our words, deeds and impacts by influencing others to become allies and advocates. Over time we wish to position Humanimal Trust at the heart of a global One Medicine network. By engaging and collaborating with today's organisations, policy makers, politicians, academics and researchers – and identifying and inspiring those of the future - we will influence policy, mindset, funding, education and clinical practice.

Collaboration

Collaboration is at the core of One Medicine. It describes how we behave as an organisation and is the basis of our aspiration for future relationships between human and veterinary medicine. We will promote and expand the Humanimal Hub as an effective real-time collaboration space; create workshop, seminar and conference opportunities, directly collaborate with international like-minded organisations, to inspire wider collaboration, amplify our voice and open new research and funding opportunities.

Awareness

Continuing to increase awareness of Humanimal Trust and One Medicine underpins our ability to raise funds, influence public and professional audiences and achieve change in human and veterinary medical education,

research and practice. We will run communications and engagement programmes, bringing One Medicine awareness and the notion of a fair deal for humans and animals into the mainstream, turning the lay public as well as professionals into informed advocates.

Research

We will fund, engage with and promote research that shows the potential of One Medicine to demonstrate reciprocity and produce tangible results that can positively affect human and animal outcomes. We will build the One Medicine evidence base, demonstrating One Medicine in action. By spreading our resources across a wider range of relatively smaller but tangible shorter-term research-related activities, we will create more case studies to reinforce the case for One Medicine.

Education

Education underpins our entire strategic approach. Only by educating the next generation of professionals - starting at the very earliest stage - will we change the professional landscape for One Medicine. We will engage in education from pre-school to CPD and beyond with the ultimate aim of developing a One Medicine Curriculum. We will develop and roll out evaluated pilot school engagements. Everything we do will be viewed through an 'education lens'. More young people will have the opportunity to engage with One Medicine at school, college and university, emerging with One Medicine mindsets as they enter relevant professions.

HUMANIMAL TRUST IN A NUTSHELL

Who We Are

Humanimal Trust drives collaboration between vets, doctors and researchers so that all humans and animals benefit from sustainable and equal medical progress, but not at the expense of an animal's life. This is One Medicine.

What we do:

I care - We care - Do you?

- We care about the health and wellbeing of both humans and animals.
- We care about groundbreaking medical progress that benefits humans and animals alike.
- We care that the value of a life should not depend on species.
- We care about all human and veterinary medical and research professionals learning from and with each other, throughout their education and career, to benefit all humans and animals.
- We care about collaborating to get the very best results for patients, regardless of their species.
- We care about reciprocity - humans and animals should benefit equitably from medical progress.
- We care that more needs to be done to make animal testing obsolete in both human and veterinary medicine.
- We care about the health of all humans and animals everywhere.
- We care about One Medicine.

Influence – We care about bringing together everyone who knows and cares about One Medicine to create a road map for change in public policy and at the clinical coalface.

Collaboration – We care about creating opportunities to bring together human and veterinary professionals and students to learn from one another by demonstrating One Medicine at work.

Awareness – We care that more people should know and understand the benefits of One Medicine for humans and animals, about non-animal alternatives to experimental models supporting progress in both human and animal medicine, and how much human and animal medicine can learn from one another's clinical practice.

Research – We care about research – funding it, encouraging it, supporting it, shouting about it – that could benefit humans and animals without the use of experimental animal models.

Education – We care about learning – we care that every child should learn about the connections between humans and animals; about veterinary and human medical students learning together and from one another; about professionals learning continuously from their peers.

How we do it

We care about prompting the right conversations between the right people. We start them, facilitate them and make sure they continue. We are accessible, inclusive and collaborative – and we care about catalysing change in thought and action.

We care about building a One Medicine community; a network of influence with Humanimal Trust at its heart. We invite healthcare and research students and professionals to come to our free digital meeting space, the Humanimal Hub, to connect and learn so that humans and animals both benefit from the sharing of knowledge.

We care about building the evidence base for One Medicine; we listen, we gather, we share research, ideas and stories. Such evidence is the firm foundation for a credible vision of hope that One Medicine will one day become the norm.

We care about showing both the authority and pragmatism that come from our experience and the confidence that comes from our passion and belief. We work with integrity. We defuse professional confrontation, build bridges and seek to instil a spirit of compassion, respect and mutual benefit.

History

Humanimal Trust was established in May 2014 by Professor Noel Fitzpatrick, known globally as a ground-breaking orthopaedic-neuro veterinary surgeon. As a vet he experienced personally the deep divide between human and animal medicine and saw how unfair this was. Frustrated by the lack of opportunities to share what he was learning from day-to-day practice, or to benefit from relevant learning from human medicine, he decided to create the platform himself. This laid the foundations for the work the Trust does today, removing barriers and seeking to close the divide between human and animal medicine. Since those beginnings, the Trust has started to establish a powerful evidence base and to build understanding of both the principle and the potential of One Medicine. This evidence informs mechanisms to reduce, refine and replace laboratory animal tests. By studying naturally occurring disease, we will make more rapid progress. Based in Godalming, Surrey, Humanimal Trust is a registered charity in both England and Wales, and in Scotland, influencing worldwide.

Why One Medicine?

As far back as Aristotle in Ancient Greece, convergence between human and animal physiology was a normal part of science. Divergence began in the nineteenth century but an increasing focus on the welfare, rights and conservation of animals in recent times has led to renewed interest. Human and veterinary healthcare can and should advance hand in hand. Technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to involve the death of an animal. A two-way street between human and veterinary medicine is both possible and necessary for humans and animals to benefit equitably from cutting edge advances. One Medicine recognises that progress in both human and veterinary medicine depends on sharing technologies and research that recognise overlapping biological characteristics.

What we believe?

We believe a world is possible, where humans and animals benefit equally and at the same time from advances in medicine. This is reciprocity.

We believe that equitable advances in both human and animal medicine can be achieved more quickly, if there is closer collaboration and mutually beneficial learning. This is One Medicine. We believe and

advocate that this approach will lead to progressively fewer laboratory animal tests until one day they become obsolete.

We believe in funding only research that helps - and learns from - animals being treated for naturally occurring disease – not the use of experimental animal models.

We believe that technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to involve the death of an animal. Even with experimental therapies, such as for cancer, if we share what we already know from veterinary clinical practice and consensual clinical trials with animals, we have the potential to save the lives of both humans and animals without the need to sacrifice a healthy animal's life.

However, there are still too few validated non-animal test alternatives for assessing safety of new drugs and medical devices for human use and laboratory animal testing is still required by Law. This has to change. Our intent is that with One Medicine such testing will become obsolete.

In the meantime, we are committed to - and strongly advocate investment in - the 3 R's: a reduction in animal testing, refinement and replacement of animal tests wherever possible. We also believe in a fourth R: reciprocity. Most current laboratory animal testing is for the sole, often arguable benefit of humans and not the animal concerned or its species.

Currently too little is invested in developing treatments for animals. If veterinary clinical trials were linked to human drug development, resources could be saved and treatments developed more quickly for both humans and animals.

We believe that the world would be fairer and more respectful for humans and animals if One Medicine were more widely understood and delivered.

One Medicine has a very specific focus on reciprocity. It differs from One Health. One Health seeks better health through addressing risks at the interface between humans, animals and their environments. While One Health may intend to help animals alongside humans, in reality priority is too often given only to human health and wellbeing.

With support and information from Humanimal Trust, we believe everyone can contribute to One Medicine, through giving, advocating, learning or educating. Anyone can talk to their vet or their doctor about One Medicine.

Our purpose is not to endorse any particular lifestyle, including vegetarian or vegan, nor are we an animal rights organisation. These are personal choices and beliefs and not part of One Medicine.

We believe we all share responsibility for creating a fairer society, with better opportunities to benefit equitably from medical progress for humans and animals. However, we believe the greatest responsibility lies with vets, doctors, researchers and scientists worldwide. There is currently no formal platform for the sharing of knowledge between human and veterinary medicine. We seek to change that.

We believe that if we miss this opportunity we will all pay the price in wasted time, wasted money, and the wasted lives of both humans and animals.

FINANCIAL REVIEW

Income for the year ended 31st May 2023 amounted to £206,670 (£694,878 in 2021/22).

The charity had a net deficit of unrestricted income over expenditure for the year of (£117,146) (net surplus of £385,673 in 2021/22) and a net surplus of restricted income over expenditure of £4,938 (£37,715 in 2021/22) resulting in total funds of £341,713 carried forward as at 31st May 2023.

Investment Powers and Policy

To date, funds have been held on current account at the charity's bank earning modest interest income; funds have not been actively invested. The trustees will monitor the cash balances of the charity and will make decisions as to the appropriateness of this policy going forward.

Reserves Policy and Going Concern

Reserves are required to bridge the gaps between the spending and the receipt of income, and to cover unforeseen circumstances. The charity will normally seek to hold sufficient unrestricted reserves to cover six months of operations, which will enable its work to continue uninterrupted.

The charity has more than sufficient funds to cover six months of outgoings at the present time and as such the trustees present the accounts on a going concern basis.

REFERENCE AND ADMINISTRATIVE DETAILS

Charity number: Registered in England and Wales, number 1156927

Registered in Scotland, number SC048960

Principal Office: Eashing Barns, Halfway Lane, Eashing, Surrey GU7 2QQ, United Kingdom

Our advisors: Accountants:

Radford & Sergeant Limited, Building 3, Watchmoor Park, Camberley GU15 3YL

Bankers:

CAF Bank, Kings Hill Avenue, West Malling, Kent, ME19 4JQ

Trustees

The trustees serving during the year and since the year-end were as follows:

Prof Roberto La Ragione (Chair since 11 Oct 2018)	Appointed for three years to August 2019 Re-appointed for three years to August 2022 Re-appointed for three years to August 2025
Prof Noel Fitzpatrick	Appointed indefinitely
Ms Dineke Abbing	Appointed for three years to May 2017 Re-appointed for three years to May 2020 Re-appointed for three years to May 2023 Re-appointed for three years to May 2026
Dr Ben Marshall	Appointed for three years to July 2019 Re-appointed for three years to July 2022 Re-appointed for three years to July 2025
Miss Anna Radford	Appointed for three years to October 2025
Ms Laurie Dennard	Appointed for three years to September 2026

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

Humanimal Trust is a Charitable Incorporated Organisation (CIO) governed by a Constitution dated 6th May 2014 and as last amended 28th May 2019, and is registered as a charity with the Charity Commission. Membership of the CIO is restricted to the serving trustees.

Appointment of trustees

As set out in the Constitution there must be a minimum of three trustees. Apart from the first charity trustees, every trustee must be appointed for a term of three years by a resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

Trustee induction and training

The charity trustees will make available to each new charity trustee, on or before his or her first appointment:

- (a) a copy of the current version of the Constitution; and
- (b) a copy of the CIO's latest Trustees' Annual Report and financial statements.

New trustees undergo an orientation meeting to brief them on: their legal obligations under charity and company law, the Charity Commission guidance on public benefit, and inform them of the content of the Constitution, the committee and decision-making processes, the business plan and recent financial performance of the charity.

Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role.

Organisation

The board of trustees, which can have up to twelve members, administers the charity and normally meets quarterly at a minimum. The board may from time to time establish sub-committees and three such committees had been active since July 2016: (1) for matters relating to medical and science review – during 2022/23 formalised as the Science Committee, (2) for matters relating to fundraising and marketing, and (3) for matters relating to finance and audit. In 2020 the latter two committees merged into one Income Generation, Finance and Audit Committee (IGFA).

Related parties and co-operation with other organisations

None of the trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity and a university or research institution, sponsor, donor or commercialisation partner must be disclosed to the full board of trustees in the same way as any other contractual relationship with a related party.

Pay policy for senior staff

All trustees provide their time freely and no trustee received remuneration. However, trustees are entitled to receive reimbursement of expenses incurred on behalf of the charity. Staff remuneration is set and reviewed by the trustees in accordance with resourcing strategy and financial status.

Risk management

The trustees have a risk management strategy which comprises:

- an annual review of the principal risks and uncertainties that the charity faces;
- the establishment of policies, systems and procedures to mitigate those risks identified in the annual review; and
- the implementation of procedures designed to minimise or manage any potential impact on the charity should those risks materialise.

Financial sustainability continues to be a principal area of risk for the charity. Income from legacies has been a major contributor to overall income over the past couple of years and other sources of income are being actively pursued with a view to build a regular and varied, sustainable stream of income.

Trustees' responsibilities in relation to the financial statements

The charity trustees are responsible for preparing a trustees' annual report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity law requires the charity trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing the financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with charity law. They are also responsible for safeguarding the assets of the charity and hence taking reasonable steps for the prevention and detection of fraud and other irregularities. The trustees are responsible for the maintenance and integrity of the charitable and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

By order of the Board of Trustees

Professor Roberto La Ragione, Chair

Date: 18.12.2023

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE HUMANIMAL TRUST

I report on the financial statements of Humanimal Trust for the year ended 31 May 2023 on pages 25 to 32.

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the Charities Act) and that an independent examination is needed. It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act) and to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

1. which gives me reasonable cause to believe that in any material respect, the requirements:
 - to keep accounting records in accordance with section 130 of the Charities Act; and
 - to prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act

have not been met; or

2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Kim Swain MA (Oxon) FCA

Date: 18.12.2023

***Radford & Sergeant Limited
Chartered Accountants
Building 3
Watchmoor Park
Camberley
Surrey GU15 3YL***

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE PERIOD FROM 1 JUNE 2022 TO 31 MAY 2023

	Note	Unrestricted Funds 2023 £	Restricted Funds 2023	Total Funds 2023 £	Total Funds 2022 £
Income from:					
Donations and legacies	3, 4	198,534	4,938	203,472	692,841
Charitable activities	6	2,437		2,437	2,037
Other income	7	761		761	
Total Income		201,732	4,938	206,670	694,878
Expenditure on:					
Raising funds	8	100,820		100,820	102,369
Charitable activities	8	218,058		218,058	169,121
Total Expenditure		318,878		318,878	271,490
Net income/(expenditure) and net movement in funds		(117,146)	4,938	(112,208)	423,388
Reconciliation of funds:					
Total funds brought forward		408,921	45,000	453,921	30,533
Total funds carried forward		291,775	49,938	341,713	453,921

BALANCE SHEET AS AT 31 MAY 2023

	Note	Total funds 2023 £	Total funds 2022 £
Fixed assets:			
Intangible assets	10	861	413
Tangible assets	11	492	543
Current assets:			
Stock	12	17,501	916
Debtors	13	12,939	11,551
Cash at bank and in hand		331,614	463,467
Total current assets		362,054	475,934
Liabilities:			
Creditors: Amounts falling due within one year	14	21,694	22,969
Net current assets		340,360	452,965
Total net assets		341,713	453,921
The funds of the charity:			
Restricted income funds		49,938	45,000
Unrestricted funds		291,775	408,921
Total charity funds		341,713	453,921

Approved by the Board of Trustees on 18.12.2023

and signed on its behalf by

Professor Roberto La Ragione, Chair

NOTES TO THE FINANCIAL STATEMENTS

1 Accounting Policies

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Humanimal Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) Preparation of the accounts on a going concern basis

The accounts are prepared on a Going Concern basis.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Fixed assets

Intangible assets relate to the trade mark costs of the Humanimal Trust logo for charitable purpose and are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation at 10% straight line annually plus any accumulated impairment losses.

Tangible fixed assets are stated at their historic cost price less accumulated depreciation. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for use. The asset's residual values, useful lives and depreciation methods are reviewed if there is an indication of significant change since the last reporting date. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment - 20% straight line, and Computer equipment - over 3 years.

e) Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Trust's work or for specific research projects being undertaken by the Trust. As at 31 May 2023 the Trust's funds consisted of £291,895 of unrestricted funds (2021/22: £408,921) and £49,938 of restricted funds (2021/22: £45,000).

f) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Expenditure is classified under the following activity headings:

- Expenditure on raising funds; includes the cost of goods sold, payment processing fees, plus fundraising specific materials, supplies and travel.
- Expenditure on charitable activities; includes website design and maintenance, fees of independent examiners, delivery of strategic objective activities.

Governance is included in expenditure on charitable activities. The Trust initially identifies the cost of its support functions. It then identifies those costs which relate to the governance function. Having identified its governance costs, the remaining support costs together with the governance costs are apportioned between the charitable activities undertaken in the year. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

g) Stock

Stock relates to merchandising items and books for resale and is valued at the lower of cost and net realisable value, after allowance for obsolete and slow-moving items.

h) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

i) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Cash in transit is included.

2 Legal status of the Trust

The Trust is a Charitable Incorporated Organisation and has no share capital.

3 Income from donations and legacies

The Trust benefits greatly from the involvement and enthusiastic support of its volunteers. In accordance with FRS 102 and the Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the accounts.

During the year to 31 May 2023 the Trust gratefully received £53,317 from general donations, mostly online, plus £9,300 from corporate donations. The Trust furthermore received unrestricted income from legacies totalling £135,917.

	2023	2022
	£	£
General Gifts (including Gift Aid reclaimable)	53,317	74,018
Corporate and Charity Donations	9,300	78,500
Legacies	135,917	495,323
	198,534	647,841

4 Restricted Income

The Trust received £4,938 of restricted income in the year ended 31st May 2023 (£45,000 in 2021/22). This sum was the residual part of a major legacy and is restricted for use towards the cost of work that aims to contribute to the prevention, treatment or cure of cancer.

	2023	2022
	£	£
Balance brought forward	45,000	7,285
Restricted income received	4,938	45,000
Expenditure incurred		(7,285)
Balance carried forward	49,938	45,000

5 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

Throughout the year the Trust had the continued support from its Development Manager. The Science Officer left the Trust in August 2022. The Development Manager was joined by an Operations Manager and a Chief Executive Officer in October and November 2022 respectively. All other activities of the charity were carried out by volunteers, freelance contractors or consultants and there were no other remunerated members of staff.

The charity trustees were not paid nor received any other benefits from employment with the Trust. No charity trustee received payment for professional or other services supplied to the charity.

Support costs are directly allocated to activities where possible. The remuneration of the Development Manager and Operations Manager is allocated 84% to charitable activities and the remainder to raising funds. Remuneration of the CEO is allocated 60% to charitable activities and the remainder to raising funds. Remuneration of the Science Officer is allocated to charitable activities.

6 Charitable activities

The Trust generated income from merchandise sales during the year of £92 (£775 in 2021/22) and net proceeds of £2,345 (£1,262 in 2021/22) from the One Medicine Lottery scheme.

7 Other Income

The Trust received £761 of interest income from funds held in its current account (£nil in 2021/22).

8 Expenditure

Principal expenditure included £100,820 to cover the cost of raising funds (£102,369 in 2021/22) and £217,938 towards the cost of delivery of the Trust's charitable objectives (£169,921 in 2021/22). The latter included £63,524 specific to education which now underpins the Trust's strategy. £11,654 was expended towards the ongoing maintenance of the Humanimal Hub (£41,746 in 2021/22).

Independent examiner's fees	2023	2022
	£	£
Independent examination	2,640	2,600
Accounts preparation	1,200	1,120
	3,840	3,720

9 Corporate Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

10 Intangible Assets

	Trademarks	Totals
	£	£
COST		
At 1 June 2022	420	420
Additions	540	540
At 31 May 2023	960	960
DEPRECIATION		
At 1 June 2022	7	7
Charge for year	92	92
At 31 May 2023	99	99
NET BOOK VALUE		
At 31 May 2023	861	861
At 31 May 2022	413	413

11 Tangible Assets

	Office equipment £	Computer equipment £	Totals £
COST			
At 1 June 2022	1,632	3,708	5,340
Additions	-	445	445
At 31 May 2023	<u>1,632</u>	<u>4,153</u>	<u>5,785</u>
DEPRECIATION			
At 1 June 2022	1,253	3,544	4,797
Charge for year	<u>320</u>	<u>176</u>	<u>496</u>
At 31 May 2023	<u>1,573</u>	<u>3,720</u>	<u>5,293</u>
NET BOOK VALUE			
At 31 May 2023	<u>59</u>	<u>433</u>	<u>492</u>
At 31 May 2022	<u>379</u>	<u>164</u>	<u>543</u>

12 Stock

	2023 £	2022 £
General merchandise	782	916
Books	16,719	
	<u>17,501</u>	<u>916</u>

Just before the end of the financial year, the Trust purchased stock of the book “Humanimal” produced in a new branded dust jacket. The books will be on sale from Autumn 2023 onward and some will be utilised for school projects.

13 Debtors

The Debtors balance of £12,939 as at 31 May 2023 is largely made up of prepaid costs in regards the Humanimal Hub, database management and membership fees, along with a small balance on the Trust’s Paypal account.

	2023 £	2022 £
Sundry debtors	39	32
Prepayments	12,900	11,519
	<u>12,939</u>	<u>11,551</u>

14 Creditors

The Creditors balance of £21,694 as at 31 May 2023 was made up of trade creditors and income tax, national insurance and pension contributions due in June 2023, along with accrued cost for services received but not yet billed.

	2023	2022
	£	£
Trade creditors	13,218	12,148
Taxes and NI	3,123	1,219
Other creditors	711	450
Accrued expenses	4,642	9,152
	21,694	22,969

15 Related Parties

There were no related party transactions during the year.

HUMANIMAL TRUST

England & Wales - Charity number 1156927

Accounts



A Charity registered

in England and Wales - charity Number: 1156927

in Scotland - charity Number: SC048960

Annual Report and Financial Statements

Period from 1 June 2021 to 31 May 2022

The trustees are pleased to present their annual report together with the financial statements of the charity for the year ended 31st May 2022.

The financial statements comply with the Charities Act 2011, the Constitution of The Humanimal Trust, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102).

CHAIR'S REPORT

As we enter the final year of our current five-year strategy, looking back on 2021/22 has provided us with an opportunity to reflect on how much has changed since the strategy was agreed in 2018. A global pandemic, war in Europe, a global fuel crisis, a cost of living crisis and four different Prime Ministers in six years were not on anybody's SWOT analysis. The impact on us all as individuals – some far more acute than others – and on Society as a whole, was inevitable. It has affected charities in different ways, too. Some have deservedly experienced a new wave of support for their work. Others, like Humanimal Trust, seeking longer term change and less focused on urgent grass roots impact, have found it more challenging to break through into public consciousness, not least because opportunities to meet the public face to face have been extremely limited.

With that in mind, it is all the more heartening for Humanimal Trust trustees to be able to report a successful year and a healthy level of income, allowing us to plan for the future with much greater confidence. 2021/22 was also the year Humanimal Trust began to engage with a number of significant new corporate and individual supporters, whom we hope will remain with us for the long term. With more of that kind of support we can really forge forward with One Medicine, so that humans and animals benefit reciprocally from medical research and not at the cost of an animal's life. We'd particularly like to thank Leucillin and Corrigan Gore for their enthusiasm, support and commitment.

In late 2021 we published our first impact report, looking back at the first seven years of the charity's life. We are very demanding of ourselves. Nothing will be enough until One Medicine becomes the norm. However, our impact report showed that we should be proud of the progress we have made as a new, small charity. The last year has been the same. We asked a lot of ourselves and despite having to focus on ensuring the charity was financially fit as we emerged from the pandemic, we can still point to many achievements. As we look forward to a new strategy period from 2023, we are excited about a new-found focus in the way we drive forward our agenda. Our five work areas spell out I-CARE, which sums up the way we feel, our supporters feel, and we hope everybody will one day feel about One Medicine:

- **Influence** – We care about bringing together everyone who cares about One Medicine to create a road map for change in public policy, in education and at the clinical coalface.
- **Collaboration** – We care about creating opportunities for human and veterinary professionals and students to learn from one another by demonstrating One Medicine at work.
- **Awareness** - We care that people should know and understand the benefits of One Medicine for humans and animals, about non-animal alternatives to laboratory models supporting animal as well as human medicine and to how much human and animal medicine can learn from one another's clinical practice – saving time, money and lives.
- **Research** – We care about research – funding it, facilitating it, shouting about it – that could benefit humans and animals without using laboratory animal models.

- **Education** – We care about learning – every child learning about the connections between humans and animals; veterinary and human medical students learning with and from one another; practitioners and clinicians learning continuously from their peers.

We believe that education is key to One Medicine. Only by learning about the similarities between humans and animals from the earliest stage, to collaboration in the most advanced science and clinical practice, will we change the world for good. For that to happen we must ensure that the best research, clinical practice and learning, benefiting both humans and animals, are funded, encouraged and promoted. The past year has given us a chance to regroup, refocus and renew our commitment. We are determined that the next year and beyond will see One Medicine move firmly into the mainstream of consciousness, research and clinical practice. I'd like to conclude by thanking the tireless staff of Humanimal Trust, our volunteers, supporters, advisors and my fellow trustees, who collectively continue to steer the charity through challenging times towards our long-term goals and aspirations.

I Care – We Care – Do you?

Professor Roberto La Ragione

Chair of the Board of Trustees

OUR IMPACT IN 2021/22

THE YEAR IN REVIEW

a. Highlights

Humanimal Trust One Medicine Day Symposium: In May 2021, Humanimal Trust's inaugural global One Medicine Symposium: *Stronger Together*, brought together more than 100 scientists, clinicians and students from around the world to discuss practical ways forward for One Medicine. The event provoked contacts and potential collaborations and helped to build the global One Medicine network. A working group built around a number of participants has continued to collaborate and support Humanimal Trust's own developing work.

One Medicine Day Seminar: In May 2022, attracting interest from more than 100 people worldwide and picking up the thread of the symposium, the One Medicine Day Seminar: *One Medicine in Action* focused on:

- What joined up approaches or collaboration would look like in action and how to provide more opportunities
- How to raise greater awareness of the benefits of One Medicine approaches

Like the symposium before it, the seminar created new connections, broadened the One Medicine Network and encouraged participants to think more proactively about how to convey the distinctive history, definition and purpose of One Medicine, whilst encouraging collaborative engagement with those from One Health or One Welfare backgrounds.

Humanimal Hub: The Humanimal Hub, our free online forum and interactive space where leading minds in human and animal medicine can meet, collaborate and share knowledge and research, continued to grow in scale and influence. 250 people are now approved members, up from 204 in 2020/21.

Humanimal Pledge: We continued to engage with ever wider audiences through the Humanimal Trust Pledge for One Medicine, with over 20,000 signatories now committed to champion One Medicine.

INTERACT: We announced a memorandum of understanding with Oklahoma State University (OSU) College of Veterinary Medicine's Institute for Translational and Emerging Research in Advanced Comparative Therapy (INTERACT), which aims to promote research into the development of new therapeutic and diagnostic platforms for use in both veterinary and human medicine.

UTOMIC: We established a working relationship with the Utrecht Translational One Medicine Innovation Centre (UTOMIC), which aims to accelerate One Medicine Research, helping human and veterinary patients, while at the same time reducing the need for laboratory animals in biomedical and veterinary research.

One Health Lessons: We participated in activities organised by One Health Lessons, which develops lessons for children and adults so that they can understand the inextricable connection between human health and the health of animals, plants, and the environment.

Network of influence: We continued to broaden contact with scientists, academics and educationalists in Europe, N. and S. America and Australasia, promoting opportunities for collaboration and learning.

Research impact:

Humanimal Trust has supported two projects, primarily funded by Action Medical Research, with two grants of £5,000 each. The first of these completed in 2022 while the second is ongoing.

The first study, led by Professor Hall-Scraggs at University College London focuses on juvenile idiopathic arthritis (JIA). Patients with JIA have a disease which causes inflammation of their joints. This leads to pain, joint deformity, disability and reduced quality of life. There are newer 'biologic' drugs now available that suppress joint inflammation, but these are expensive and can have side effects, the most serious being life-threatening infection. Magnetic resonance imaging (MRI) scans can show inflammation of joints. By measuring inflammation in patients with juvenile idiopathic arthritis the study was able to help optimise their treatment by showing how much inflammation is present and whether it changes with treatment.

The second Action Medical Research study, considering infection prevention and its impact on antimicrobial resistance in critically ill children, led by Dr Nazima Pathan, Lecturer in Paediatric Intensive Care at the University of Cambridge, is ongoing.

Media and Publications: This year a significant expansion in media coverage was achieved. The Trust's activities attracted the attention of local and digital media (both lay and specialist). Professional and academic publications featured Humanimal Trust on a more regular basis, such as British Medical Journal (BMJ), Animal Therapy Magazine and Nursing Times.

Events: We organised or took part in the following events to meet the public and spread the One Medicine message – Paws for a Picnic Autumn Fair, VET Festival, three DogFest events, and talks were given to 13 community groups totalling approximately 450 attendees throughout the year. There were also high-profile speaking engagements at a conference organised by INTERACT (Professor Roberto La Ragione) and the International Veterinary Students Association (Jo Blake).

Education: Emerging from both the One Medicine Symposium and ongoing strategic development of an educational programme, Humanimal Trust committed to the long-term development of a One Medicine curriculum and began development of pilot activities with educational establishments.

Legacies: A total of five major legacies were notified or received during 2021/22, totalling just over £540,000.

Paws for a Picnic: The Trust's first mass participation event was launched in Spring 2021, with the significant and very welcome support of Lyvlee Ltd. via *Leucillin*, backed by an ongoing digital advertising and PR campaign.

Building donor support: 2021/22 saw a concerted effort to build relationships with corporate, trust and individual givers whose commitment to One Medicine was represented by significant levels of support. Thanks to Quantity Surveyors, Corrigan Gore who sponsored an engagement dinner at Mark's Club, Mayfair as well as looking at other ways of supporting the charity.

A supporter event was also held at Fitzpatrick Referrals, hosted by our founder Noel Fitzpatrick. This event also signalled the launch of a new giving scheme for supporters able to make higher-level gifts, known as Humanimal Visionaries and Patrons.

Ongoing development of existing fundraising schemes continued, including the Champions regular giving scheme, in memory giving, the newly launched One Medicine Lottery and *Ripples* scheme.

Podcast: First Humanimal Trust podcast series launched - Humanimal Connection. Success laid groundwork for second series in 2022/3 with over 250 listens and more than 30% outside the UK.

b. 2021/22 Specific Objectives and Impact

Our specific objectives for 2021-22 remained rooted in our 5-year strategic objectives. However, with the impact of Covid19, economic and cost of living uncertainty, Humanimal Trust, like many charities, had to remain agile and focused on ensuring immediate continuity of income and expenditure. This meant that, although the 5-year objectives and associated KPIs remained in place, some were reviewed, revised or rescheduled over the course of the year.

Our indicators of success are sometimes relevant to more than one work-stream. For instance, sign-ups to either the Pledge or the Humanimal Hub are indicators of progress in influence, awareness, and collaboration. Where this is the case, progress is recorded under one, but not all of the five work-streams and cross-referenced where appropriate.

Principal focus areas in 2021/22 were:

- ***Awareness building with professional, public and specialist funding audiences***
- ***Income generation***
- ***Partnership building (for both income generation and scientific/educational purposes)***
- ***Network building and influence marketing***

I - Influence

5-Year Strategic Objective:

As the evidence for One Medicine grows, we will continue to share knowledge with policy-makers and politicians to inform better legislation.

2021/22 Objective:

Establish credible and effective presence and relationships with regulatory and membership veterinary, medical and associated bodies

This remains an area we wish to develop further as resources allow. Invitations for us to participate in events organised by other organisations have increased, as has the willingness of other organisations to take part in

our own. While we cannot yet point to clear evidence of having changed national or international policy frameworks to reflect a commitment to One Medicine specifically, we can see that the language of collaboration and reciprocity, as well as an apparent commitment to reduce, refine and replace laboratory animal models, are slowly beginning to reflect Humanimal Trust's aspirations.

Humanimal Trust wishes to be seen as the centre of a network of influence for One Medicine. A growing number of individuals and organisations are now part of our global network. The Humanimal Hub, Humanimal Pledge, podcast series and PR programme all reinforce this area of activity. In 2022/23 we aim to increase our engagement with policy makers, including the All Party Group on Animal Welfare and other all-party or back-bench committees in the UK parliament.

C - Collaboration

Strategic objective 2:

We aim to demonstrably increase collaboration between medical and veterinary professionals, to maximise value and minimise delays in progress.

2021/22 Objectives:

- ***Continue to raise awareness of The Hub and use it to generate active collaboration***
- ***Seek new partnership collaborations to further visibility and influence***
- ***Maximise mutual benefit of collaboration with Action Medical Research***
- ***Fuel debate and raise expectations for collaboration***

As above, Hub membership and activity is also a measure of success in terms of demonstrating collaboration.

Hub members increased to 250, below the target of 300 but a healthy increase on 204 in 2020/21. The Hub is encouraging conversations and we are aware of at least one active collaboration that began as a result of an introduction on the Hub. The Hub has also been important in the building of networks and partnerships as referred to elsewhere in this report.

As well as encouraging collaboration between others, it is important for Humanimal Trust to build both formal and informal long-term relationships with like-minded organisations with whom joint efforts can push forward the One Medicine agenda. In the past year, three relationships in particular stand out: UTOMIC, INTERACT and One Health Lessons, the latter two of which are now subjects of Memoranda of Understanding with Humanimal Trust. We envisage a range of collaborations from network-sharing and event participation to joint promotional and perhaps research-related activity.

Initial conversations regarding possible joint activities also began with Rest Easy Method (mental health education), Montessori (educational outreach), Royal National Orthopaedic Hospital (exploring possible opportunities for collaboration) and various publishing companies.

Our support for two studies, principally funded by Action Medical Research, continued to demonstrate our ongoing commitment to research collaboration. These are described in more detail below.

A - Awareness

5-year Strategic Objective:

We aim to measurably increase public, professional and political awareness, understanding and acceptance of One Medicine.

2021/22 Objective:

- ***Demonstrate continued increase in awareness of Humanimal Trust and One Medicine among key target audiences (public, veterinary and medical)***

Awareness objectives overlap with a number of others, so indicators of success are shared in some cases. For professional audiences, particular focus was given to expanding membership of the Humanimal Hub, our free online forum and interactive space for doctors, vets, nurses, researchers, GPs and related professionals. Although growth in membership is steady rather than rapid, the quality of membership and the resulting expansion of a One Medicine network of influence with Humanimal Trust at the centre, is extremely valuable. Greater emphasis is now being placed on encouraging Hub members to collaborate, participate in One Medicine-related activities, volunteer for the Trust and encourage peers to join.

Membership of the Hub covers a wide range of professions including:

Other:	26% (rounded)
Vet surgeon/vet therapist:	16%
Researcher:	9%
Nurse:	9%
Vet student:	8%
Bioscience/bioengineering:	7%
Scientist:	5%
Staff/vols:	4%
Vet nurse:	4%
GP:	3%
Medical student:	2%
Science Lecturer:	2%
Specialist/Consultant surgeon:	2%
Pharmacist:	1%

Talks to professional and science audiences also restarted, with talks given to the International Veterinary Students Association, INTERACT and an increasing number of invitations to speak at a range of conferences and events being received for the current year.

For lay audiences, traditional, social and other digital media continued to prove successful for building general awareness, along with continuation of our successful events and talks programmes, which were rejuvenated from late 2021 following relaxing of Covid restrictions.

Public talks began to take place again from late in 2021. To the end of May 2022, 13 talks were given to approximately 450 attendees, some leading to coverage in local media.

Our website remained a core point of contact with 3,320 visits between One Medicine Day, 6 May 2021 through until 6 May 2022, a 50% increase on the same period for the prior year..

Our first series of Podcasts was launched - Humanimal Connection – which began to establish a new audience-connection and an opportunity to explore more deeply the ways in which One Medicine is reflected in everything from conservation or protecting wild animals from poachers, to marine biology and food production. A second series has been commissioned for 2022/23.

Media coverage increased steadily this year, and along with it, audience-reach, particularly in scientific, specialist and local media. More than 40 titles in total covered Humanimal Trust activities, a total reach of 13,124,260 readers. Although specific audience reach has not been measured previously, we know this is a significant improvement in visibility for the trust year on year. Coverage included:

- | | |
|------------------------------------|-------------------------------|
| • Animal Therapy Magazine | • Newcastle Upon Tyne Journal |
| • British Medical Journal (BMJ) | • South Wales Echo |
| • Nursing Times | • Western Mail |
| • Vet Times | • Western Morning News |
| • theknowledgereview.com | • Whitchurch Herald |
| • Recruitment.Gov | • Wirral Globe |
| • www.vetclick.com | • Wishaw Press |
| • www.veterinary-practice.com | • Index Digital |
| • www.vetnurse.co.uk | • www.chooseyourevent.co.uk |
| • www.vetreport.net | • www.eventbrite.co.uk |
| • www.vetsurgeon.org | • www.inyourarea.co.uk |
| • Argus (Brighton) | • www.list.co.uk |
| • Bath Chronicle | • www.tdpelmedia.com |
| • Birkenhead News | • www.wherecanwego.co.uk |
| • Chichester Observer | • Visit Surrey |
| • The Chronicle | • Essential Surrey |
| • Derby Telegraph | • nigeriannewsdirect.com |
| • Devon Daily | • Voice of Nigeria |
| • Dorset Echo | |
| • Exeter Daily | |
| • Express and Star (Wolverhampton) | |
| • Hull Daily Mail | |
| • Ilford Recorder | |
| • Leicester Mercury | |
| • Liverpool Echo | |

TOTAL REACH: 13,124,260

Social media reach:

- | | |
|--------------|-------------------|
| • Facebook: | 11,000K followers |
| • Twitter: | 7,043 followers |
| • Instagram: | 1,506 followers |
| • LinkedIn: | 237 followers |
| • Youtube: | 476 subscribers |

R - Research

Strategic Objective 4:

We aim to improve and accelerate the growing understanding of the complex interactions between animal and human biological characteristics, the similarities between them and the opportunities arising from them.

We want to repaint the landscape in which medicine is researched and received; redefining the language of respectful interaction between species at the clinical coalface.

2021/22 Objectives:

- ***Fund at least one significant new research proposal with One Medicine ethos***
- ***Fund at least one Proof of Concept award***
- ***Launch and deliver first One Medicine Challenge and Learning Awards***
- ***Maximise mutual benefit of grant-linked donation to Action Medical Research and consider second-year funding.***
- ***Build One Medicine evidence base***

The difficult circumstances of the pandemic limited our ability to fund new research projects but that did not prevent us from actively promoting research relevant to One Medicine ethos through the Humanimal Hub or from laying the groundwork for a series of new research initiatives that are now planned for 2022/3. Recruitment to the new Science Committee continued and the infrastructure for new research calls began to be put in place. New research plans for 2022/23 include undergraduate projects chosen through a 'sandpit' event, as well as proof of concept studies, education and creative awards.

Of the two studies funded by Action Medical Research and supported by Humanimal Trust, one was completed and one is still active:

Professor Hall-Craggs' work at University College London focused on juvenile idiopathic arthritis (JIA). Patients with JIA have a disease which causes inflammation of their joints. This leads to pain, joint deformity, disability and reduced quality of life. There are newer 'biologic' drugs now available that suppress joint inflammation, but these are expensive and can have side effects, the most serious being life-threatening infection. Magnetic resonance imaging (MRI) scans can show inflammation of joints. By measuring inflammation in patients with juvenile idiopathic arthritis we aim to help optimise their treatment by showing how much inflammation is present and whether it changes with treatment.

The project report gave the following headlines (edited):

- *We developed an artificial intelligence assisted method of extracting and quantifying the areas of inflammation in the sacroiliac joints (SIJs) of routine scans of SIJ. We have written a paper on this and have submitted it to a medical journal.*
- *We are developing a colour coded picture which shows areas of inflammation in joints and bone. This can be used to show whether inflammation is getting worse (red) or getting better (green). These are known as*

parametric response maps and we have some preliminary work from our SIJ scans which have demonstrated proof of principle.

- We have completed the largest ever study of whole body imaging in juvenile arthritis patients which has shown much more unsuspected inflammation than anticipated. This study is now being written up for publication but has been reported at scientific meetings (and the work won a prize).*
- We have run a Virtual Clinic to get an idea of whether the whole body MRI scans would affect the way that doctors treat their patients. This has been completed by 2 consultant rheumatologists and this shows that the provision of whole body scans would likely alter management decisions in up to 30% of patients with juvenile arthritis. Some of these would get more treatment, and some less. Some would have their appointment intervals changed or have additional/fewer imaging tests.*
- We have disseminated the results of the studies we have conducted widely. We have had presentations at the British Society of Rheumatology, British Society of Paediatric and Adolescent Rheumatology, International Society of Magnetic Resonance in Medicine, and the British Society for Spondyloarthritis.*

This research can also produce transferable data which could be directly applicable in a veterinary setting.

The second Action Medical Research study, considering infection prevention and its impact on antimicrobial resistance in critically ill children (led by Dr Nazima Pathan, Lecturer in Paediatric Intensive Care at the University of Cambridge) is ongoing.

E - Education

Strategic Objective:

We aim to inspire everyone to take the One Medicine message forward as a credible vision of hope for future generations of humans and animals.

2021/22 Objectives:

- Increase awareness of and engagement with Humanimal Trust and One Medicine among children and young people*
- Increase awareness and engagement with Humanimal Trust and One Medicine among future vets, doctors and animal welfare professionals*

Although this area of work was not able to move forward as quickly as we would have liked because of resource limitations and the impact of the pandemic, much progress was made internally. A significant commitment was made by the charity to ensure that an educational focus should characterise everything that we do. A long term change in mindset towards One Medicine depends on addressing the relationship between human and animal health and wellbeing at every stage of learning along with an acceptance that lasting change is generational and depends on us being able to reach out to the next generations of doctors, vets, researchers and caring professionals. From pre-school to continuous professional development, a lifelong One Medicine curriculum is our ultimate aim and during the latter stages of 2021/22, we agreed our first school pilot activities for teenage

pupils and put in place plans for new learning materials for younger pupils. A knowledge exchange scheme for professional learning is now also in planning mode and is hoped to be launched by the end of 2022.

During the year our ability to give talks at universities and colleges or to engage with student societies was limited, with digital contact and promotion of Humanimal Hub membership the main source of engagement. However for younger children, promotion of new learning materials with Montessori ensured our commitment to all age groups continued.

Enabling Objective - Income

2021/22 Objectives:

- ***Achieve sustainable income level and replenish reserves***
- ***Increase total income and broaden range of sustainable income streams***

A truly challenging year was principally characterised by careful ongoing control of expenditure, selective investment in fundraising and awareness activities and maintenance of staff wellbeing. The successful beginnings of corporate partnerships with both Leucillin and Corrigan Gore, along with the charity's first two major donor engagement events, the launch of a mid-level giving programme and the ongoing promotion of our Paws for a Picnic participation event, all signalled a commitment to invest wisely in sustainable income streams.

Regular income from donors and from a range of challenge, digital and other streams such as a new lottery, Amazon Smile, Facebook fundraising, in memory giving and unclaimed fund initiatives all continued to contribute to steady income through the year. A few events towards the end of the financial year and local fundraising activities also began to re-emerge as long-term income opportunities.

However, it was as a result of a combination of long term investment in both the Humanimal Trust brand and Noel Fitzpatrick's own profile, specific legacy marketing and good stewardship, that a number of major gifts and legacies made the real difference to the charity's ability to plan more confidently for the future.

Legacies and major gifts:

During 2021/22 two legacies were received in full, totalling just over £90,000. A substantial interim payment of £450,000 on a third legacy was also received during the year. As at 31 May 2022 three further legacies were in progress. Legacies remain a valuable source of income to the charity and legacy marketing is an important element of our fundraising activity, but equally we seek a more balanced set of income streams in the longer term.

Overall the £348,000 income target for the year was exceeded by almost the same amount, ending the year with total income of just under £695,000 and reserves replenished to a level that allows more confident planning in 2022/23.

Enabling Objective - Team Development:

2021/22 Objective:

- ***Continue to increase staff and volunteer capacity to deliver business plan and strategy***

In a second year so significantly affected by COVID-19, the well-being of staff and volunteers as well as their performance and development was important to the trustees and home-based working was the norm throughout the year, with other support offered as appropriate. Some specific personal development work was undertaken by both permanent staff members and ongoing support and development for volunteers was a year-round priority, with regular online meetings and socials as well as newsletters and a volunteer survey all running through the year. A combination of targeted voluntary and consultancy support provided support, advice and specialist skills where needed. The first ever team day, while taking place digitally, helped to ensure a more coherent approach to long-term planning.

A commitment was made by trustees to support effort to build a more sophisticated UK-wide volunteer structure with volunteers grouped regionally and sharing knowledge and skills more effectively whilst building a sense of 'team' between otherwise quite isolated volunteers. The appointment of a volunteer coordinator, themselves a volunteer, reinforced this commitment to support the volunteer network more actively. A greater focus on seeking volunteers with specialist skills, especially in education and science, also began to take shape during the year as an explicit recognition of the need to expand reach without the resource to expand the staff complement enormously.

Enabling objective - Governance:

2021/22 Objectives:

- ***Continue to develop and review governance and policy framework***
- ***Continue to develop diversity and capacity of Board and Committees***
- ***Appoint further members to Science Committee and activate***
- ***Appoint further members to Expert Panel and activate***
- ***Review contribution of Income Generation, Finance and Audit Committee***

Humanimal Trust's Board continued to reinforce its commitment to good governance and continuing to learn and improve its own knowledge and expertise in this area. The annual trustee review meant that each trustee had the opportunity to share privately with the Chair, their views on their own contribution and that of the Board as a whole. The organisation's governance manual, policies and procedures are reviewed and approved by trustees every year.

Recruitment to the Science Committee restarted, with a view to having sufficient members in time for the first planned research calls in 2022/23. Several members have already accepted invitations to join and a number of prospective members identified.

The Income Generation Finance and Audit Committee continued to monitor financial health during the year, providing advice to the Board through the Treasurer.

The Board itself met more regularly and thanks are due to all trustees, although we were sorry to say goodbye to Dr. Mike Uglow who stepped down after six years' service as a trustee, including two as chair. However, he will continue to make a contribution to the charity through membership of the Science Committee.

c. 2022/23 Looking forward:

We recognise the need to present One Medicine consistently through an education 'lens'. Our absolute priority is to change understanding at every level from pre-school to professional training and development of the relationship between human and animal health and the need for collaboration and reciprocity of benefit to humans and animals.

With that 'lens' in mind, our focus for the next twelve months at least is very clearly on four key areas of activity which will run through all five of our I-CARE strategic workstreams:

- Focused awareness building with professional, lay, youth, trade and specialist funder audiences
- Partnerships, networks and collaborations: placing Humanimal Trust at the centre of a One Medicine web of influence
- Education
- Research funding, engagement and influencing activity based on achieving a wider scope of visibility and outcomes from limited resources

In turn these will be made possible by two core 'enabling' or 'capacity-building' activities:

- Volunteer strategy, with a focus on building a more coherent pattern of local integrated volunteer networks around the UK.
- Income generation, with a focus on building a broad range of sustainable income streams, with a greater emphasis on building up major donor support and volunteer fundraising leadership alongside more established forms of individual giving.

Staff and governance development will also remain underlying priorities.

HUMANIMAL TRUST IN A NUTSHELL

Who We Are

Humanimal Trust drives collaboration between vets, doctors and researchers so that all humans and animals benefit from sustainable and equal medical progress but not at the expense of an animal's life. This is One Medicine.

What we do:

I care - We care - Do you?

- We care about the health and wellbeing of both humans and animals.
- We care about groundbreaking medical progress that benefits humans and animals alike.
- We care that the value of a life should not depend on species.
- We care about all human and veterinary medical and research professionals learning from and with each other, throughout their education and career, to benefit all humans and animals.
- We care about collaborating to get the very best results for patients, regardless of their species.
- We care about reciprocity - humans and animals should benefit equitably from medical progress.
- We care that more needs to be done to make animal testing obsolete in both human and veterinary medicine.
- We care about the health of all humans and animals everywhere.
- We care about One Medicine.

Influence – We care about bringing together everyone who knows and cares about One Medicine to create a road map for change in public policy and at the clinical coalface.

Collaboration – We care about creating opportunities to bring together human and veterinary professionals and students to learn from one another by demonstrating One Medicine at work.

Awareness – We care that more people should know and understand the benefits of One Medicine for humans and animals, about non-animal alternatives to experimental models supporting progress in both human and animal medicine, and how much human and animal medicine can learn from one another's clinical practice.

Research – We care about research – funding it, encouraging it, supporting it, shouting about it – that could benefit humans and animals without the use of experimental animal models.

Education – We care about learning – we care that every child should learn about the connections between humans and animals; about veterinary and human medical students learning together and from one another; about professionals learning continuously from their peers.

How we do it

We care about prompting the right conversations between the right people. We start them, facilitate them and make sure they continue. We are accessible, inclusive and collaborative – and we care about catalysing change in thought and action.

We care about building a One Medicine community; a network of influence with Humanimal Trust at its heart. We invite healthcare and research students and professionals to come to our free digital meeting space, the Humanimal Hub, to connect and learn so that humans and animals both benefit from the sharing of knowledge.

We care about building the evidence base for One Medicine; we listen, we gather, we share research, ideas and stories. Such evidence is the firm foundation for a credible vision of hope that One Medicine will one day become the norm.

We care about showing both the authority and pragmatism that come from our experience and the confidence that comes from our passion and belief. We work with integrity. We defuse professional confrontation, build bridges and seek to instil a spirit of compassion, respect and mutual benefit.

History

Humanimal Trust was established in May 2014 by Professor Noel Fitzpatrick, known globally as a ground-breaking orthopaedic-neuro veterinary surgeon. As a vet he experienced personally the deep divide between human and animal medicine and saw how unfair this was. Frustrated by the lack of opportunities to share what he was learning from day to day practice, or to benefit from relevant learning from human medicine, he decided to create the platform himself. This laid the foundations for the work the Trust does today, removing barriers and seeking to close the divide between human and animal medicine. Since those beginnings, the Trust has started to establish a powerful evidence base and to build understanding of both the principle and the potential of One Medicine. This evidence informs mechanisms to reduce, refine and replace laboratory animal tests. By studying naturally occurring disease, we will make more rapid progress. Based in Godalming, Surrey, Humanimal Trust is a registered charity in both England and Wales, and in Scotland, influencing worldwide.

Why One Medicine?

As far back as Aristotle in Ancient Greece, convergence between human and animal physiology was a normal part of science. Divergence began in the nineteenth century but an increasing focus on the welfare, rights and conservation of animals in recent times has led to renewed interest. Human and veterinary healthcare can and should advance hand in hand. Technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to involve the death of an animal. A two-way street between human and veterinary medicine is both possible and necessary for humans and animals to benefit equitably from cutting edge advances. One Medicine recognises that progress in both human and veterinary medicine depends on sharing technologies and research that recognise overlapping biological characteristics.

What we believe?

We believe a world is possible, where humans and animals benefit equally and at the same time from advances in medicine. This is reciprocity.

We believe that equitable advances in both human and animal medicine can be achieved more quickly, if there is closer collaboration and mutually beneficial learning. This is One Medicine. We believe and advocate that this approach will lead to progressively fewer laboratory animal tests until one day they become obsolete.

We believe in sponsoring only research that helps - and learns from - animals being treated for naturally occurring disease – not the use of experimental animal models.

We believe that technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to involve the death of an animal. Even with experimental therapies, such as for cancer, if we share what we already know from veterinary clinical practice and consensual clinical trials with animals, we have the potential to save the lives of both humans and animals without the need to sacrifice a healthy animal's life.

However, there are still too few validated non-animal test alternatives for assessing safety of new drugs and medical devices for human use and laboratory animal testing is still required by Law. This has to change. Our intent is that with One Medicine such testing will become obsolete.

In the meantime, we are committed to - and strongly advocate investment in - the 3 R's: a reduction in animal testing, refinement and replacement of animal tests wherever possible. We also believe in a fourth R: reciprocity. Most current laboratory animal testing is for the sole, often arguable benefit of humans and not the animal concerned or its species.

Currently too little is invested in developing treatments for animals. If veterinary clinical trials were linked to human drug development, resources could be saved and treatments developed more quickly for both humans and animals.

We believe that the world would be fairer and more respectful for humans and animals if One Medicine were more widely understood and delivered.

One Medicine has a very specific focus on reciprocity. It differs from One Health. One Health seeks better health through addressing risks at the interface between humans, animals and their environments. While One Health may intend to help animals alongside humans, in reality priority is too often given only to human health and wellbeing.

With support and information from Humanimal Trust, we believe everyone can contribute to One Medicine, through giving, advocating, learning or educating. Anyone can talk to their vet or their doctor about One Medicine.

Our purpose is not to endorse any particular lifestyle, including vegetarian or vegan, nor are we an animal rights organisation. These are personal choices and beliefs and not part of One Medicine.

We believe we all share responsibility for creating a fairer society, with better opportunities to benefit equitably from medical progress for humans and animals. However, we believe the greatest responsibility lies with vets, doctors, researchers and scientists worldwide. There is currently no formal platform for the sharing of knowledge between human and veterinary medicine. We seek to change that.

We believe that if we miss this opportunity we will all pay the price in wasted time, wasted money, and the wasted lives of both humans and animals.

FINANCIAL REVIEW

Income for the year ended 31st May 2022 amounted to £694,878 (£156,110 in 2020/21).

The charity had a net surplus of unrestricted income over expenditure for the year of £385,673 (deficit of (£74,013) in 2020/21) and a net surplus of restricted income over expenditure of £37,715 (£7,285 in 2020/21) resulting in total funds of £453,921 carried forward as at 31st May 2022.

Investment powers and policy

To date, funds have been held on current account at the charity's bank, have not been actively invested and no investment income has been earned. The trustees will monitor the cash balances of the charity and will make decisions as to the appropriateness of this policy going forward.

Reserves Policy and Going Concern

Reserves are required to bridge the gaps between the spending and the receipt of income, and to cover unforeseen circumstances. The charity will normally seek to hold sufficient unrestricted reserves to cover six months of operations, which will enable its work to continue uninterrupted.

The charity has more than sufficient funds to cover six months of outgoings at the present time and as such the trustees present the accounts on a going concern basis.

REFERENCE AND ADMINISTRATIVE DETAILS

Charity number: Registered in England and Wales, number 1156927

Registered in Scotland, number SC048960

Principal Office: Eashing Barns, Halfway Lane, Eashing, Surrey GU7 2QQ, United Kingdom.

Our advisors: Accountants:

Radford & Sergeant Limited, Building 3, Watchmoor Park, Camberley GU15 3YL.

Bankers:

CAF Bank, Kings Hill Avenue, West Malling, Kent, ME19 4JQ.

Trustees

The trustees serving during the year and since the year-end were as follows:

Prof. Roberto La Ragione (Chair since 11 Oct 2018)	Appointed for three years to August 2019 Re-appointed for three years to August 2022 Re-appointed for three years to August 2025
Prof. Noel Fitzpatrick	Appointed indefinitely
Ms Dineke Abbing	Appointed for three years to May 2017 Re-appointed for three years to May 2020 Re-appointed for three years to May 2023
Mr. Mike Uglow	Appointed for three years to November 2018 (Chair from 14 th Sept 2016 to 11 Oct 2018) Re-appointed for three years to November 2021 Resigned October 2021
Dr. Ben Marshall	Appointed for three years to July 2019 Re-appointed for three years to July 2022 Re-appointed for three years to July 2025
Miss Anna Radford	Appointed for three years to October 2025

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing Document

Humanimal Trust is a Charitable Incorporated Organisation (CIO) governed by a Constitution dated 6th May 2014 and as last amended 28th May 2019, and is registered as a charity with the Charity Commission. Membership of the CIO is restricted to the serving trustees.

Appointment of trustees

As set out in the Constitution there must be a minimum of three trustees. Apart from the first charity trustees, every trustee must be appointed for a term of three years by a resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

Trustee induction and training

The charity trustees will make available to each new charity trustee, on or before his or her first appointment:

- (a) a copy of the current version of the Constitution; and
- (b) a copy of the CIO's latest Trustees' Annual Report and financial statements.

New trustees undergo an orientation meeting to brief them on: their legal obligations under charity and company law, the Charity Commission guidance on public benefit, and inform them of the content of the Constitution, the committee and decision-making processes, the business plan and recent financial performance of the charity.

Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role.

Organisation

The board of trustees, which can have up to twelve members, administers the charity and normally meets quarterly at a minimum. The board may from time to time establish sub-committees and three such committees had been active since July 2016: (1) for matters relating to medical and science review, (2) for matters relating to fundraising and marketing, and (3) for matters relating to finance and audit. In 2020 the latter two committees merged into one Income Generation, Finance and Audit committee (IGFA).

Related parties and co-operation with other organisations

None of the trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity and a university or research institution, sponsor, donor or commercialisation partner must be disclosed to the full board of trustees in the same way as any other contractual relationship with a related party.

Pay policy for senior staff

All trustees provide their time freely and no trustee received remuneration. However, trustees are entitled to receive reimbursement of expenses incurred on behalf of the charity.

Staff remuneration is set and reviewed by the trustees in accordance with resourcing strategy and financial status.

Risk management

The trustees have a risk management strategy which comprises:

- an annual review of the principal risks and uncertainties that the charity faces;
- the establishment of policies, systems and procedures to mitigate those risks identified in the annual review; and
- the implementation of procedures designed to minimise or manage any potential impact on the charity should those risks materialise.

Financial sustainability has been a continued principal area of risk for the charity. In light of the impact of the Covid-19 pandemic, a 'revival' strategy was implemented in 2020. Income from legacies in 2021-22 has replenished reserves allowing for more confident planning whilst maintaining a prudent approach.

Trustees' responsibilities in relation to the financial statements

The charity trustees are responsible for preparing a trustees' annual report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity law requires the charity trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing the financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with charity law. They are also responsible for safeguarding the assets of the charity and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charitable and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

By order of the Board of Trustees

Professor Roberto La Ragione, Chair

Date: 21 December 2022

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE HUMANIMAL TRUST

I report on the financial statements of Humanimal Trust for the year ended 31 May 2022 on pages 24 to 31.

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the Charities Act) and that an independent examination is needed. It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act) and to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

1. which gives me reasonable cause to believe that in any material respect, the requirements:
 - to keep accounting records in accordance with section 130 of the Charities Act; and
 - to prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act

have not been met; or

2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

***Kim Swain MA (Oxon) FCA
Radford & Sergeant Limited
Chartered Accountants
Building 3
Watchmoor Park
Camberley
Surrey GU15 3YL***

Date: 21 December 2022

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE PERIOD FROM 1 JUNE 2021 TO 31 MAY 2022

	Note	Unrestricted Funds 2022 £	Restricted Funds 2022	Total Funds 2022 £	Total Funds 2021 £
Income from:					
Donations and legacies	3, 4	647,841	45,000	692,841	151,651
Charitable activities	6	2,037		2,037	1,010
Other income	7				3,449
Total Income		649,878	45,000	694,878	156,110
Expenditure on:					
Raising funds	8	102,369		102,369	78,948
Charitable activities	8	161,836	7,285	169,121	143,890
Total Expenditure		264,205	7,285	271,490	222,838
Net income/(expenditure) and net movement in funds		385,673	37,715	423,388	(66,728)
Reconciliation of funds:					
Total funds brought forward		23,248	7,285	30,533	97,261
Total funds carried forward		408,921	45,000	453,921	30,533

BALANCE SHEET AS AT 31 MAY 2022

	Note	Total funds 2022 £	Total funds 2021 £
Fixed assets:			
Intangible assets	10	413	-
Tangible assets	11	543	1,504
Current assets:			
Stock	12	916	893
Debtors	13	11,551	9,972
Cash at bank and in hand		463,467	36,888
Total current assets		475,934	47,753
Liabilities:			
Creditors: Amounts falling due within one year	14	22,969	18,724
Net current assets		452,965	29,029
Total net assets		453,921	30,533
The funds of the charity:			
Restricted income funds		45,000	7,285
Unrestricted funds		408,921	23,248
Total charity funds		453,921	30,533

Approved by the Board of Trustees on 21 December 2022 and signed on its behalf by

Professor Roberto La Ragione, Chair

NOTES TO THE FINANCIAL STATEMENTS

1 Accounting Policies

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Humanimal Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) Preparation of the accounts on a going concern basis

The accounts are prepared on a Going Concern basis.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Fixed assets

Intangible assets relate to the trade mark costs of the Humanimal Trust logo for charitable purpose and are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation at 10% straight line annually plus any accumulated impairment losses.

Tangible fixed assets are stated at their historic cost price less accumulated depreciation. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for use. The asset's residual values, useful lives and depreciation methods are reviewed if there is an indication of significant change since the last reporting date. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment - 20% straight line, and Computer equipment - over 3 years.

e) Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Trust's work or for specific research projects being undertaken by the Trust. As at 31 May 2022 the Trust's funds consisted of £408,921 of unrestricted funds (2020/21: £23,248) and £45,000 of restricted funds (2020/21: £7,285).

f) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Expenditure is classified under the following activity headings:

- Expenditure on raising funds; includes the cost of goods sold, payment processing fees, plus fundraising specific materials, supplies and travel.
- Expenditure on charitable activities; includes website design and maintenance, fees of independent examiners, delivery of strategic objective activities.

Governance is included in expenditure on charitable activities. The Trust initially identifies the cost of its support functions. It then identifies those costs which relate to the governance function. Having identified its governance costs, the remaining support costs together with the governance costs are apportioned between the charitable activities undertaken in the year. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

g) Stock

Stock relates to merchandising items and is valued at the lower of cost and net realisable value, after allowance for obsolete and slow moving items.

h) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

i) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Cash in transit is included.

2 Legal status of the Trust

The Trust is a Charitable Incorporated Organisation and has no share capital.

3 Income from donations and legacies

The Trust benefits greatly from the involvement and enthusiastic support of its volunteers. In accordance with FRS 102 and the Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the accounts.

During the year to 31 May 2022 the Trust gratefully received £74,018 from general donations, mostly online, plus £78,500 from corporate and charity donations. The Trust furthermore received unrestricted income from legacies totalling £495,323.

	2022 £	2021 £
General Gifts (including Gift Aid reclaimable)	74,018	61,651
Corporate and Charity Donations	78,500	5,000
Legacies	495,323	35,000
	647,841	101,651

4 Restricted Income

The Trust received £45,000 of restricted income in the year ended 31st May 2022 (£50,000 in 2020/21). This sum formed part of a major legacy and is restricted for use towards the cost of work that aims to contribute to the prevention, treatment or cure of cancer. The balance of restricted income brought forward from the prior year was expended in full towards the cost of the Humanimal Hub.

	2022 £	2021 £
Balance brought forward	7,285	-
Restricted income received	45,000	50,000
Expenditure incurred	(7,285)	(42,715)
Balance carried forward	45,000	7,285

5 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

Throughout the year the Trust had the continued support from its Development Manager and Science Officer. All other activities of the charity were carried out by volunteers, freelance contractors or consultants and there were no other remunerated members of staff.

The charity trustees were not paid nor received any other benefits from employment with the Trust. No charity trustee received payment for professional or other services supplied to the charity.

Support costs are directly allocated to activities where possible. The remuneration of the Development Manager is allocated 40% to raising funds and the balance to charitable activities. Remuneration of the Science Officer is allocated to charitable activities.

6 Charitable activities

The Trust generated income from merchandise sales during the year of £775 (£1,010 in 2020/21) and net proceeds of £1,262 (£nil in 2020/21) from the One Medicine Lottery scheme.

7 Other Income

The Trust did not receive any Government grants in the year (£3,449 in 2020/21).

8 Expenditure

Principal expenditure included £102,369 to cover the cost of raising funds (£78,948 in 2020/21) and £169,921 towards the cost of delivery of the Trust's charitable objectives (£143,890 in 2020/21). The latter included £41,746 towards the ongoing development and maintenance of the Humanimal Hub (£54,519 in 2020/21).

Independent examiner's fees	2022	2021
	£	£
Independent examination	2,600	2,400
Accounts preparation	1,120	1,080
	3,720	3,480

9 Corporate Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

10 Intangible Assets

	Trademarks	Totals
	£	£
COST		
At 1 June 2021	-	-
Additions	420	420
At 31 May 2022	420	420
DEPRECIATION		
At 1 June 2021	-	-
Charge for year	7	7
At 31 May 2022	7	7
NET BOOK VALUE		
At 31 May 2022	413	413
At 31 May 2021	-	-

11 Tangible Assets

	Office equipment £	Computer equipment £	Totals £
COST			
At 1 June 2021	1,632	3,708	5,340
Additions	-	-	-
At 31 May 2022	<u>1,632</u>	<u>3,708</u>	<u>5,340</u>
DEPRECIATION			
At 1 June 2021	927	2,909	3,836
Charge for year	<u>326</u>	<u>635</u>	<u>961</u>
At 31 May 2022	<u>1,253</u>	<u>3,544</u>	<u>4,797</u>
NET BOOK VALUE			
At 31 May 2022	<u>379</u>	<u>164</u>	<u>543</u>
At 31 May 2021	<u>705</u>	<u>799</u>	<u>1,504</u>

12 Stock

	2022 £	2021 £
Fundraising merchandise	-	346
General merchandise	<u>916</u>	<u>547</u>
	<u>916</u>	<u>893</u>

13 Debtors

The Debtors balance of £11,551 as at 31 May 2022 is made up of prepaid costs in regards the Humanimal Hub and database management along with a small balance on the Trust's Paypal account.

Debtors	2022 £	2021 £
Sundry debtors	32	1
Prepayments	<u>11,519</u>	<u>9,971</u>
	<u>11,551</u>	<u>9,972</u>

14 Creditors

The Creditors balance of £22,969 as at 31 May 2022 was made up of trade creditors and income tax, national insurance and pension contributions due in June 2022, along with accrued cost for services received but not yet billed and residual research grant funding committed to but not yet paid pending completion of the project.

Creditors	2022	2021
	£	£
Trade creditors	12,148	2,276
Taxes and NI	1,219	1,360
Other creditors	450	444
Accrued expenses	9,152	14,644
	22,969	18,724

15 Related Parties

There were no related party transactions during the year.

HUMANIMAL TRUST

England & Wales - Charity number 1156927

Accounts



A Charity registered

in England and Wales - charity Number: 1156927

in Scotland - charity Number: SC048960

Annual Report and Financial Statements

Period from 1 June 2020 to 31 May 2021

The trustees are pleased to present their annual report together with the financial statements of the charity for the year ended 31st May 2021.

The financial statements comply with the Charities Act 2011, the Constitution of The Humanimal Trust, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102).

CHAIR'S REPORT

There will not be a single charity annual report this year that does not refer to the impact of COVID-19. The words 'unprecedented', 'challenging' and 'new normal' have never been used so frequently or with such accuracy and emotional intensity. Rather than repeat what many have said, I will simply acknowledge that this has been Humanimal Trust's most demanding and challenging year, yet in many ways also its most inspirational. At a time when finances as well as people were stretched; income generating opportunities curtailed, events cancelled, offices closed and access to all our audiences severely limited, through it all our staff, volunteers, trustees and supporters pulled together and we are still achieving and ready for new challenges ahead.

In May this year we had the pleasure of publishing an impact report covering the first seven years of our life as a charity and as I mentioned in the introduction to that report:

"Our resolution and conviction that we are making progress with integrity remain strong. Can we achieve much more? We have to. Have we already had an impact? Absolutely."

In the same month, as proof of that conviction, we held our first international symposium on One Medicine Day, 6th May. Bringing together doctors, vets, nurses and researchers from around the world, this ground-breaking event laid down a marker for Humanimal Trust in terms of the global reach and resonance of One Medicine.

Presence in scientific media, academic journals and the beginnings of a series of partnerships with corporate, charitable and academic organisations and individuals in Europe and North America simply reinforces our belief that we are no longer only at the beginning of the journey, but taking significant steps along the road.

The past year has taught us a great deal about resilience, determination and most of all that we are right in our belief that One Medicine's moment has arrived. The global pandemic has shone a light more clearly than ever on the interdependence of human and animal health and wellbeing. Where diseases and conditions are passed between - or simply experienced by both - humans and animals, so there can be research, treatments or vaccines that benefit both humans and animals. Never has it been more important for those working in human or veterinary health – whether in research, clinical practice, nursing or teaching – to collaborate, share learning and move forward more quickly together for the benefit of all humans and animals.

As trustees we took an important decision to begin to widen our conversations with the pharmaceutical industry, seeking areas of common ground whilst remaining clear on our absolute commitment to reciprocity and an eventual end to the need for laboratory animal models.

We owe thanks to so many people. To my fellow trustees and committee members who served during the year, Professor Noel Fitzpatrick, Dr Ben Marshall, Dr Mike Uglow, Dineke Abbing, Stephanie Borne and Martin Richardson, thanks for your support, your constructive challenge and your passion for what the Trust is trying to achieve. To our staff, Jo Blake, Dr Tracey King and Hollie Turner (who moved to pastures new earlier this year), advisers, volunteers and consultants, your skill and hard work is what delivers for us every day. Careful financial management, and a focus on ensuring the charity continued to deliver its purpose and emerged from the pandemic with confidence and stability was the absolute focus of the entire team. To our volunteers, your commitment has helped to keep us going through these challenging times. To our supporters of all kinds – companies, trusts and foundations, individual donors and fundraisers, people who attend events and talks – everything we are able to achieve is thanks to your contribution, your trust and your belief in One Medicine!

Our 2020 report set out objectives for 2020/21. While some plans had to change because of the pandemic, the following review of the year assesses our progress and outlines plans for 2021/22. In many ways, the enforced focus on absolute priorities during these difficult times has actually accelerated progress in some areas and as we emerge to the new world, we are ready to move to the next phase.

As Chair I am both proud of what this small charity has achieved in challenging times and determined that we continue to build momentum in a post-pandemic world where One Medicine is itself simply part of the ‘new normal’.

Professor Roberto La Ragione

Chair of the board of trustees

THE YEAR IN REVIEW

The Humanimal Trust vision states that:

We want a world where both humans and animals have better opportunities to benefit equitably from medical progress because vets, doctors and researchers routinely collaborate and share.

This vision has always been ambitious and audacious, but we remain committed to it and to the belief that collaboration and reciprocity between the worlds of human and veterinary medicine are necessary, possible and more important than ever.

Before the pandemic hit us, the Trust set the following objectives for 2020/21. In every case, expectations were revised during the year as financial, resourcing, event cancellation, lockdown and movement restrictions all played their part in reducing our planned activity – in common with every other charity in the UK. However, the original targets are listed where relevant.

1. Awareness

- *Achieve step change in level of awareness in Humanimal Trust and One Medicine, especially among key target audiences (public, veterinary and medical).*

Humanimal Pledge

The Humanimal Pledge for One Medicine is our principal tool for engaging with the wider public. It offers a simple way for individuals to show their support for One Medicine and to begin a journey of support with us.

The Humanimal Pledge for One Medicine: One Team, One Dream, One Medicine.

- *I pledge to champion One Medicine.*
- *I want human and veterinary medicine to collaborate for all people and all animals.*
- *I want regulatory bodies to actively support One Medicine.*
- *I want to help make animal testing obsolete by supporting its reduction, refinement and replacement.*
- *I want reciprocity – both humans and animals should benefit from sustainable medical progress.*

Our initial target of 2,500 signatories has been significantly beaten with 19,749 achieved by May 2021.

Humanimal Hub Awareness

Membership of the Humanimal Hub continues to be a key driver of awareness with professional audiences. It is an online forum and interactive space that is free to join and use, where leading minds in human and animal medicine can meet, collaborate, initiate and share knowledge and research, driving forward closer cooperation for the benefit of humans and animals.

- Target: 250 registrations by May 2021
- Achieved by June 2021: 204 current active members

Media coverage

We have been unable to fund investment in full media evaluation benchmarking; however, coverage in Innovators Magazine (1.25m reach), a Podcast for medical professionals (The Wilderness Medic - 475 plays) and especially the launch of a Humanimal Trust video editorial package with ITN coinciding with National Biology Week which reached c300,000 people, were particular highlights.

Podcast

As part of our seventh anniversary celebrations, we launched a new podcast, The Humanimal Connection, for anyone who wishes to see a fairer deal in medical advances for both humans and animals, discussing One Medicine approaches in areas such as treating injured terrestrial and marine wildlife, sustainability and mental health.

Episode One featured Dr Johan Marais, Founder of the South African organisation, Saving the Survivors, a team of wildlife vets whose mission is to save every animal that has fallen victim to poaching or traumatic incident. Dr Marais talks about how they have adapted techniques from human medicine to use in the field to treat rhinos with severe facial and gunshot injuries caused by poachers.

Episode Two featured From Humanimal Hub member, Dr Claire Simeone, a marine mammal veterinarian, conservation leader, TED Fellow, Founder and CEO of Sea Change Health, who coined the term 'zoognosis'. Claire talks about how she has applied techniques from human medicine to treat marine mammals.

Speaking/event invitations

These were severely restricted in 2020/21 with only a few online talks taking place rather than the average three per month of the previous year. With a new talk, new volunteers, new training and a new volunteer coordinator in place, it is hoped that talks will take off again in 2021/22.

2. Collaboration

Driving collaboration between vets, doctors and researchers is at the heart of One Medicine. It will take time to see the long-term fruits of our efforts in terms of actual collaborations between specific individuals or institutions, resulting in research outcomes and treatments. However, we can see collaboration beginning in real time through activities we have initiated or delivered. For example, The Humanimal Hub (described above in the section on 'Awareness') is succeeding in bringing vets, doctors, and researchers together.

Our 2020/21 Objectives were:

- *Continue to raise awareness of The Hub and use it to generate active collaboration*
- *Fund new collaborative research programmes*
- *Maximise mutual benefit of collaboration with Action Medical Research*
- *Fuel public debate and raise expectations for collaboration*

Humanimal Hub membership and collaboration

Our latest data suggests that our carefully targeted approach for attracting Hub members is working. The majority of our 204 current members are allied with human or veterinary medicine, or work within the sciences. Based on the answers given by our Hub users when setting up their profiles, human and animal allied professional categories appear to be represented in roughly equal proportions (i.e. 21% veterinary, 17% human, 32% non-clinical mixed sciences, 30% other).

The majority of these Key Performance Indicators (KPIs) were set around the time that the Hub was launched. We thought about and predicted the kind of engagement outcomes that we would like to see happening on the Hub and that we would like to measure.

Now that the Hub is in its second year, we are beginning to understand more about how and where Hub members prefer to engage, and how they like to use the Hub. We tend to see more collaborative engagement take place off the Hub and via email than we first predicted, for example, with the Hub acting instead more as a place to highlight and advertise collaborative opportunities through our newsletter and feed posts.

Members also tend to email us articles and opportunities to advertise, as opposed to posting them directly on the Hub themselves. As we learn more about these emerging engagement trends we are now in a better place to build on our strengths by encouraging engagement that is more likely to yield results, and also set KPIs relevant to the sort of engagement that our Hub members prefer. We will be resetting KPIs for the 2021/2022 business plan.

We have evidence via follow-up discussions with Hub members of at least two incidences where potential ‘pre-collaboration’ conversations have begun between different members. One case where the Hub team received a request from a paediatric urologist looking for an individual or group in veterinary medicine to collaborate with, and another where a US based researcher got in touch with us after reading about work done by UK based researchers who have similar interests. In both cases we were able to bring the researchers together via email and help to initiate introductory conversations.

One Medicine Day Symposium

We were delighted to hold our inaugural One Medicine Day Symposium virtually on Thursday 6 May 2021, the 7th anniversary of the founding of Humanimal Trust. The theme of the Symposium was ‘Stronger Together – How we can take One Medicine forward’ and comprised a number of speaker sessions, a panel discussion, and an address from our Founder, Professor Noel Fitzpatrick.

The aim of the Symposium was to support creation of a roadmap as to how human and veterinary medicine can more routinely work together and how to address the challenges that One Medicine faces. This dynamic and thought-provoking day confirmed to us that in order to continue to push One Medicine forward, we must continue our work to navigate some complicated pathways, and overcome some difficult hurdles. The Symposium identified several key themes:

- A requirement for clear and robust ethical and regulatory research frameworks which can better support and encourage a One Medicine research approach.
- A need to improve cross-disciplinary knowledge sharing by vets, doctors, nurses and researchers, for example through research journals publishing high-quality, peer-reviewed One Medicine research.
- Improved awareness of (and access to) One Medicine in medical, veterinary, nursing and scientific higher education programmes of study- where vets, doctors, nurses, clinical professionals and researchers of the future are currently in training.

The symposium was attended by over 100 delegates from all areas of human and animal science and healthcare. The feedback was overwhelmingly positive, and demonstrated huge enthusiasm and appetite for change. The Symposium also highlighted the significant energy, momentum and drive that exists to ensure One Medicine is finally brought into the mainstream. The symposium provided a real platform for shared learning, and demonstrated the importance of building bridges, developing stronger links, closer relationships and greater collaborative practices.

3. Education

From primary-age children, through secondary, further and higher education to professional CPD, we are determined to ensure that One Medicine is part of everybody's learning about human and animal health, so that future generations see One Medicine approaches as the norm, rather than the exception.

Our 2020/21 Objective was:

- ***Raise awareness of and engagement with Humanimal Trust and One Medicine among future vets, doctors and animal welfare professionals.***

There was a particular desire to improve awareness among students and university lecturers and also to identify student ambassadors. Initial discussions took place with potential ambassadors, but progress was again interrupted by the pandemic. However, the groundwork was laid for activity to successfully ramp up when the lockdown ended.

Well-received educational materials on our website for younger children led to a contact from Montessori which in turn has resulted in the launch of a relationship to disseminate materials more widely later in 2021.

4. Research

Research is expensive, challenging and often with impacts that are only seen long into the future. However, the speed of development of COVID19 vaccines showed that when funding is available and both public and political will align, things can move more quickly. Our original 2020/22 objectives were as follows:

- ***Establish first full Humanimal Trust research funding round***
- ***Fund at least one significant new research proposal with One Medicine ethos***
- ***Broaden funding routes through seed/top-up funding and learning-related awards***
- ***Build One Medicine evidence base***

As well as the impact of the pandemic on funding, these objectives were overtaken by our developing relationship with Action Medical Research and the decision to offer grant-linked donations to two of their funded projects with the potential to help both humans and animals.

- ***Maximise mutual benefit of grant-linked donation to Action Medical Research and consider second-year funding.***

We are proud to be collaborating with children's medical charity Action Medical Research to help support two ongoing child-focused medical research studies. Both studies have the potential to benefit animals as well as children and to demonstrate the value of One Medicine, sharing learning between the worlds of human and veterinary medicine. As with so many aspects of One Medicine, we believe we are stronger together and hope there will be future similar collaborations:

Preventing infections and reducing the risk of antibiotic-resistant infections in critically ill children

The first study focuses on Humanimal Trust's core aim of finding new ways to improve infection control and antibiotic resistance. Antibiotic resistance is a global problem, affecting humans and animals. Our funding is helping Dr Nazima Pathan at the University of Cambridge build crucial knowledge about whether a new treatment affects the risk of antibiotic-resistant infection developing in critically-ill children who are being treated in intensive care.

Juvenile idiopathic arthritis: personalising drug treatment

The second study fits neatly into another of our core aims, finding new ways to treat bone and joint disease. Professor Margaret Hall-Craggs at University College London is developing specialised magnetic resonance scans to help doctors measure joint inflammation more accurately and to choose the best drug treatment for children with juvenile idiopathic arthritis. This research work shows real transferrable potential, as inflammatory and degenerative joint conditions can affect animals too.

Humanimal Trust made awards of £5,000 to each these projects in 2020. Both of these projects are still active and are due to complete within the next two years.

Understanding how osteosarcoma spreads

We are also directly supporting Professor Matthew Allen and his team at the University of Cambridge to study the bone cancer osteosarcoma. They want to find better ways to predict which patients have a higher risk of their cancer spreading. Osteosarcoma is the most common malignant bone cancer in dogs and humans, and for both species, treatment options are relatively limited.

The researchers want to help improve treatment of osteosarcoma by finding better ways to predict how a patient's bone cancer is likely to progress and spread. To do this, the team are analysing different tumour samples from dogs with osteosarcoma, and comparing the molecular and genetic profiles of the samples. This type of information can help to form the basis of new methods to help vets and doctors better tailor treatment for their patients.

The researchers hope that the results of this work will not only contribute to existing understanding of osteosarcoma in humans and animals, but could also lead to new ways of predicting and ultimately even controlling or preventing the growth and spread of bone cancers to other organs.

The five most common cancers are predominantly fatal because they spread to other parts of the body – highlighting just why this research is so crucial.

Humanimal Trust gave a larger funding award to this project in 2019. The project is still active and is due to complete within the next two years.

5. Influence

As well as seeking to impact on long term change through public and professional awareness, professional collaboration, education and research funding, it is also important to engage with all those regulatory and membership bodies whose role in human and veterinary medicine is wide-ranging. Both directly and through professional networks, ensuring One Medicine is front and centre in these organisations is crucial.

2020/21 Objective:

- ***Establish credible and effective presence and relationships with regulatory and membership veterinary and medical bodies and associated bodies***

Although the pandemic restricted this activity, the increasing visibility of the charity through our Symposium, Hub, media presence and widening network showed we are beginning to gain traction.

6. Income

The cancellation of local fundraising events, volunteer fundraising and many national events from which we could have benefitted, combined to impact on the charity's income in 2020/21. Our original target was to raise £400k gross, based on the pattern of previous years along with a range of planned new initiatives. However, the final income for the year was £ 156,111. While we had planned to

- *Increase total income and broaden range of sustainable income streams*

we did use the opportunity to review our approach to corporate, trust and major donor fundraising and invested in building relationships with all of those areas which we hope will bear fruit in coming years.

7. Team Development

In part thanks to the pandemic and some restrictions in other areas, we were able to continue to deliver our **2020/21 Objective**:

- *Continue to increase staff and volunteer capacity to deliver business plan and strategy*

Introducing personal development programmes for staff, broadening the base of specialist professional input on both paid and voluntary basis, all added to the team's skill-base, capacity and resilience.

8. Governance

Lockdown provided an opportunity for reflection and review. As well as the annual review of policies and the organisation's Governance Manual, the Board agreed updated policies on corporate relationships and other organisational partnerships.

The **2020/21 Objectives** were all addressed to varying degrees:

- *Continue to develop and review governance and policy framework*
- *Develop diversity and capacity of Board and Committees*
- *Appoint first Science Committee*
- *Begin to build Expert Panel*
- *Appoint first Finance, Income and Audit Committee*

A new trustee was appointed with a very different skills and experience base from the existing board, with a commitment to go further along this road. The first members of both our Science Committee and our Expert Panel were identified and the Income Generation, Finance and Audit committee was established to scrutinise these matters and provide the Board with further advice and assurance in these challenging times.

HUMANIMAL TRUST IN A NUTSHELL

Who We Are

Humanimal Trust drives collaboration between vets, doctors and researchers so that all humans and animals benefit from sustainable and equal medical progress but not at the expense of the life of an animal. This is One Medicine. As a charity, we are unique leaders and drivers of this vision in the clinical environment and in public. As individuals, we advocate One Medicine in our professions as well as in our work for the Trust.

History

Humanimal Trust was established in May 2014 by Professor Noel Fitzpatrick, known globally as a ground-breaking orthopaedic-neuro veterinary surgeon. As a vet he experienced personally the deep divide between human and animal medicine and saw how unfair this was. Frustrated by the lack of opportunities to share what he was learning from day to day practice, or to benefit from relevant learning from human medicine, he decided to create the platform himself. This laid the foundations for the work the Trust does today, removing barriers and seeking to close the divide between human and animal medicine. Since those beginnings, the Trust has started to establish a powerful evidence base and to build understanding of both the principle and the potential of One Medicine. This evidence informs mechanisms to reduce, refine and replace laboratory animal tests; by studying naturally occurring disease, we will make more rapid progress with this. Based in Godalming, Surrey, Humanimal Trust is a registered charity in England and Wales and in Scotland, influencing worldwide.

Why One Medicine?

One Medicine recognises that progress in both human and veterinary medicine depends on sharing technologies and research that recognise overlapping biological characteristics. As far back as Aristotle in Ancient Greece, convergence between human and animal physiology was a normal part of science. Divergence began in the nineteenth century but an increasing focus on the welfare, rights and conservation of animals in recent times has led to renewed interest. Human and veterinary healthcare can and should advance hand in hand. Technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to be death. A two-way street between human and veterinary medicine is both possible and necessary for humans and animals to benefit equitably from cutting edge advances.

What we do

We increase **awareness** and improve understanding of One Medicine, engaging the public, researchers, doctors, vets and policymakers, showing the evidence and demonstrating the case for change.

We facilitate **collaboration** between human and veterinary medicine, by creating opportunities for professionals to come together.

Through **education**, we inspire everyone to take the One Medicine message forward for the benefit of future generations of both humans and animals.

We fund, facilitate and share the **research** needed to evidence the impact of One Medicine and foster the skills and knowledge needed to make it a reality.

We **influence** legislative, policy and practice change. We work with today's vets, doctors and researchers, funders, legislators and policy makers. We seek to identify those of the future and inspire them with our passion and belief in One Medicine.

How we do it

We make the right conversations happen between the right people. We start them, facilitate them and make sure they continue. We are accessible and inclusive, providing many opportunities for collaboration. We catalyse change.

We invite people to come to our Humanimal Hub – first digital and ultimately physical too – where interaction and learning can take place and humans and animals both benefit from the sharing of knowledge.

We build the evidence base for One Medicine; we listen, we gather, we share. Such evidence is the firm foundation for a credible vision of hope.

We work with the authority and pragmatism that comes from our experience and the confidence that comes from our passion and belief. We work with integrity. We defuse professional confrontation, build bridges and seek to instill a spirit of compassion, respect and mutual benefit.

What we believe

We believe that equitable advances in both human and animal medicine can be achieved more quickly, if there is closer collaboration and mutually beneficial learning. This is One Medicine. We believe and advocate that this will lead to progressively fewer laboratory animal tests until one day they become obsolete.

We believe that technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to be death.

One Medicine has a very specific focus. It is not the same as One Health, which has a broader purpose including the relationships between humans, animals *and their environments*.

We believe that the world would be fairer and more respectful for humans and animals if One Medicine were more widely understood and delivered.

We are committed to the 3 R's: a reduction in animal testing, refinement and replacement of animal tests wherever possible. We also believe in a fourth R: reciprocity.

We believe a world is possible, where animals and humans benefit equally and at the same time from advances in medicine. This is reciprocity.

We believe in sponsoring only research that helps animals affected by naturally occurring disease – not the use of experimental animal models.

With support and information from the Humanimal Trust, we believe everyone can contribute to One Medicine, through giving, advocating, learning or educating. Anyone can talk to their vet or their doctor about One Medicine.

Our purpose is not to endorse any particular lifestyle, including vegetarian or vegan, nor are we an animal rights organisation. These are personal choices and beliefs and not part of One Medicine.

We believe we all share responsibility for creating a fairer society, with better opportunities to benefit equitably from medical progress for humans and animals. However we believe the greatest responsibility lies with vets, doctors, researchers and scientists worldwide.

We believe that if we miss this opportunity we will all pay the price in wasted time, wasted money and the wasted lives of both humans and animals.

SUMMARY OBJECTIVES AND APPROACH

1. Awareness

We aim to measurably increase public, professional and political awareness, understanding and acceptance of One Medicine.

We will do this through:

- Public awareness marketing and communication
- Influencing key audiences and inspiring hearts and minds
- Publishing and disseminating research and wider discourse around One Medicine
- An engagement approach that creates desire, demonstrates the need for change and generates champions and advocates
- Generating support for One Medicine in general and the Humanimal Trust in particular, through giving, advocating, learning or educating

2. Collaboration

We aim to demonstrably increase collaboration between medical and veterinary professionals, to maximise value and minimise delays in progress.

We will do this through:

- Removing barriers to the sharing of experience and knowledge
- Facilitating collaboration through events, a digital hub and eventually, a physical centre for shared learning
- Encouraging the study of naturally occurring disease in both humans and animals and sharing the data between the professions to avoid wasted time, money and lives for both humans and animals

3. Education

We aim to inspire everyone to take the One Medicine message forward as a credible vision of hope for future generations of humans and animals.

We will do this through:

- Identifying aspiring researchers, scientists, doctors, vets and communicators and actively encouraging their interest in and understanding of One Medicine
- Working with secondary, further and higher education to influence relevant courses so that they encompass One Medicine
- Achieving a paradigm shift in credibility, respect and acceptance of One Medicine not only in the worlds of veterinary and human medicine but also in the wider academic and scientific communities

4. Research

We aim to improve and accelerate the growing understanding of the complex interactions between animal and human biological characteristics, the similarities between them and the opportunities arising from them.

We want to repaint the landscape in which medicine is researched and received; redefining the language of respectful interaction between species at the clinical coalface.

We will do this through:

- Funding research to provide the evidence needed to make One Medicine a reality together with the knowledge and skills to make it possible
- Influencing governments, funders and others to support research into One Medicine

Humanimal Trust is focusing activities in the following five areas:

- Musculoskeletal Disease
- Neurology & Neurosurgery
- Medical & Surgical Oncology
- Infection & Antibiotic Resistance
- Regenerative Medicine

5. Influence

As the evidence for One Medicine grows, we will continue to share knowledge with policy-makers and politicians to inform better legislation.

We will do this through:

- Active and resolute engagement with today's policy makers, politicians and the academic and research communities
- Seeking to identify those of the future and inspire them with our passion and belief in One Medicine
- Publishing and disseminating publications and briefings

FINANCIAL REVIEW

Income for the year ended 31st May 2021 amounted to £156,110 (£169,295 in 2019/20).

The charity had a net deficit of unrestricted income over expenditure for the year of (£74,013) (deficit of (£131,107) in 2019/20) and a net surplus of restricted income over expenditure of £7,285 (nil in 2019/20) resulting in total funds of £30,533 carried forward as at 31st May 2021.

Investment powers and policy

To date, funds have been held on current account at the charity's bank, have not been actively invested and no investment income has been earned. The trustees will monitor the cash balances of the charity and will make decisions as to the appropriateness of this policy going forward.

Reserves Policy and Going Concern

Reserves are required to bridge the gaps between the spending and the receipt of income, and to cover unforeseen circumstances. The charity will normally seek to hold sufficient unrestricted reserves to cover six months of operations, which will enable its work to continue uninterrupted.

Due to the impact of the Covid-19 pandemic, at 31st May 2021 the charity did not have sufficient funds to cover six months of outgoings. Since the year-end however, donations, legacy income and corporate sponsorship have enabled the charity to continue its operations. With further substantial legacy income confirmed at the present time, the trustees present the accounts on a going concern basis.

REFERENCE AND ADMINISTRATIVE DETAILS

Charity number: Registered in England and Wales, number 1156927

Registered in Scotland, number SC048960

Principal Office: Eashing Barns, Halfway Lane, Eashing, Surrey GU7 2QQ, United Kingdom.

Our advisors: Accountants:

Radford & Sergeant Limited, Building 3, Watchmoor Park, Camberley GU15 3YL.

Bankers:

CAF Bank, Kings Hill Avenue, West Malling, Kent, ME19 4JQ.

Trustees

The trustees serving during the year and since the year-end were as follows:

Prof. Roberto La Ragione (Chair since 11 Oct 2018)	Appointed for three years to August 2019 Re-appointed for three years to August 2022
Prof. Noel Fitzpatrick	Appointed indefinitely
Ms Dineke Abbing	Appointed for three years to May 2017 Re-appointed for three years to May 2020 Re-appointed for three years to May 2023
Mr. Mike Uglow	Appointed for three years to November 2018 (Chair from 14 th Sept 2016 to 11 Oct 2018) Re-appointed for three years to November 2021 Resigned October 2021
Dr. Ben Marshall	Appointed for three years to July 2019 Re-appointed for three years to July 2022
Ms Stephanie Borne	Appointed for three years to May 2023 Resigned December 2020

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing Document

Humanimal Trust is a Charitable Incorporated Organisation (CIO) governed by a Constitution dated 6th May 2014 and as last amended 28th May 2019, and is registered as a charity with the Charity Commission. Membership of the CIO is restricted to the serving trustees.

Appointment of trustees

As set out in the Constitution there must be a minimum of three trustees. Apart from the first charity trustees, every trustee must be appointed for a term of three years by a resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

Trustee induction and training

The charity trustees will make available to each new charity trustee, on or before his or her first appointment:

- (a) a copy of the current version of the Constitution; and
- (b) a copy of the CIO's latest Trustees' Annual Report and financial statements.

New trustees undergo an orientation meeting to brief them on: their legal obligations under charity and company law, the Charity Commission guidance on public benefit, and inform them of the content of the Constitution, the committee and decision-making processes, the business plan and recent financial performance of the charity.

Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role.

Organisation

The board of trustees, which can have up to twelve members, administers the charity and normally meets quarterly at a minimum. The board may from time to time establish sub-committees and three such committees had been active since July 2016: (1) for matters relating to medical and science review, (2) for matters relating to fundraising and marketing, and (3) for matters relating to finance and audit. In 2020 the latter two committees merged into one Income Generation, Finance and Audit committee (IGFA).

Related parties and co-operation with other organisations

None of the trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity and a university or research institution, sponsor, donor or commercialisation partner must be disclosed to the full board of trustees in the same way as any other contractual relationship with a related party.

Pay policy for senior staff

All trustees provide their time freely and no trustee received remuneration. However, trustees are entitled to receive reimbursement of expenses incurred on behalf of the charity.

Staff remuneration is set and reviewed by the trustees in accordance with resourcing strategy and financial status.

Risk management

The trustees have a risk management strategy which comprises:

- an annual review of the principal risks and uncertainties that the charity faces;
- the establishment of policies, systems and procedures to mitigate those risks identified in the annual review; and
- the implementation of procedures designed to minimise or manage any potential impact on the charity should those risks materialise.

Financial sustainability has been a continued principal area of risk for the charity. In light of the impact of the Covid-19 pandemic, a 'revival' strategy, associated budget and control measures were implemented in 2020 which continue to this date.

Trustees' responsibilities in relation to the financial statements

The charity trustees are responsible for preparing a trustees' annual report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity law requires the charity trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing the financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with charity law. They are also responsible for safeguarding the assets of the charity and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charitable and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

By order of the board of trustees

Professor Roberto La Ragione, Chair

Date: 17 March 2022

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE HUMANIMAL TRUST

I report on the financial statements of Humanimal Trust for the year ended 31 May 2021 on pages 23 to 29.

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the Charities Act) and that an independent examination is needed. It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act) and to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

1. which gives me reasonable cause to believe that in any material respect, the requirements:
 - to keep accounting records in accordance with section 130 of the Charities Act; and
 - to prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act

have not been met; or

2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

***Kim Swain MA (Oxon) FCA
Radford & Sergeant Limited
Chartered Accountants
Building 3
Watchmoor Park
Camberley
Surrey GU15 3YL***

Date: 17 March 2022

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE PERIOD FROM 1 JUNE 2020 TO 31 MAY 2021

	Note	Unrestricted Funds 2021 £	Restricted Funds 2021	Total Funds 2021 £	Total Funds 2020 £
Income from:					
Donations and legacies	3	101,651	50,000	151,651	162,889
Charitable activities	6	1,010		1,010	4,306
Other trading activities	7				2,100
Other income	8	3,449		3,449	
Total Income		106,110	50,000	156,110	169,295
Expenditure on:					
Raising funds	9	78,948		78,948	69,028
Charitable activities	9	101,175	42,715	143,890	231,374
Total Expenditure		180,123	42,715	222,838	300,402
Net income/(expenditure) and net movement in funds		(74,013)	7,285	(66,728)	(131,107)
Reconciliation of funds:					
Total funds brought forward		97,261		97,261	228,368
Total funds carried forward		23,248	7,285	30,533	97,261

BALANCE SHEET AS AT 31 MAY 2021

	Note	Total funds 2021 £	Total funds 2020 £
Fixed assets:			
Tangible fixed assets	11	1,504	2,946
Current assets:			
Stock	12	893	994
Debtors	13	9,972	14,577
Cash at bank and in hand		36,888	161,791
Total current assets		47,753	177,362
Liabilities:			
Creditors: Amounts falling due within one year	14	18,724	83,047
Net current assets		29,029	94,315
Total net assets		30,533	97,261
The funds of the charity:			
Restricted income funds		7,285	-
Unrestricted funds		23,248	97,261
Total charity funds		30,533	97,261

Approved by the board of trustees on 17 March 2022 and signed on its behalf by

Professor Roberto La Ragione, Chair

NOTES TO THE FINANCIAL STATEMENTS

1 Accounting Policies

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Humanimal Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) Preparation of the accounts on a going concern basis

The accounts are prepared on a Going Concern basis.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Tangible fixed assets

Tangible fixed assets are stated at their historic cost price less accumulated depreciation. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for use. The asset's residual values, useful lives and depreciation methods are reviewed if there

is an indication of significant change since the last reporting date. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment - 20% straight line, and Computer equipment - over 3 years.

e) Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Trust's work or for specific research projects being undertaken by the Trust. As at 31 May 2021 the Trust's funds consisted of £23,248 of unrestricted funds (2019/20: £97,261) and £7,285 of restricted funds (2019/20: nil).

f) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Expenditure is classified under the following activity headings:

- Expenditure on raising funds; includes the cost of goods sold, payment processing fees, plus fundraising specific materials, supplies and travel.
- Expenditure on charitable activities; includes website design and maintenance, fees of independent examiners, delivery of strategic objective activities.

Governance is included in expenditure on charitable activities. The Trust initially identifies the cost of its support functions. It then identifies those costs which relate to the governance function. Having identified its governance costs, the remaining support costs together with the governance costs are apportioned between the charitable activities undertaken in the year. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

g) Stock

Stock relates to merchandising items and is valued at the lower of cost and net realisable value, after allowance for obsolete and slow moving items.

h) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

i) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Cash in transit is included.

2 Legal status of the Trust

The Trust is a Charitable Incorporated Organisation and has no share capital.

3 Income from donations and legacies

The Trust benefits greatly from the involvement and enthusiastic support of its volunteers. In accordance with FRS 102 and the Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the accounts.

During the year to 31 May 2021 the Trust gratefully received £66,651 from general donations, mostly online, plus a generous legacy of £35,000.

	2021	2020
	£	£
Gifts (including Gift Aid reclaimable)	66,651	68,726
Legacies	35,000	94,163
	101,651	162,889

4 Restricted Income

The Trust received £50,000 of restricted income in the year ended 31st May 2021 (£nil in 2019/20). This donation is restricted for use towards the cost of the Humanimal Hub. This includes hosting and maintenance of the online platform, engagement and education to develop membership, and the expansion and development of relevant Hub content.

	2021	2020
	£	£
Balance brought forward	-	-
Restricted income received	50,000	-
Expenditure incurred	42,715	-
Balance carried forward	7,285	-

5 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

Throughout the year the Trust had the continued support from its Development Manager. A Science Officer was appointed in August 2020. Due to the financial impact of the pandemic the paid role of Supporter Relations Coordinator sadly ceased in March 2021. All other activities of the charity were carried out by volunteers, freelance contractors or consultants and there were no other remunerated members of staff.

The charity trustees were not paid nor received any other benefits from employment with the Trust. No charity trustee received payment for professional or other services supplied to the charity.

Support costs are directly allocated to activities where possible. The remuneration of the Development Manager and the Supporter Relations Coordinator is allocated 40% to raising funds and the balance to charitable activities. Remuneration of the Science Officer is allocated to charitable activities.

6 Charitable activities

The Trust generated income from merchandise sales during the year of £1,010 (£4,306 in 2019/20).

7 Other trading activities

There was no income from other trading activities in the year (£2,100 in 2019/20).

8 Other Income

The Trust received Government grants of £3,449 (£nil in 2019/20) through the Coronavirus Job Retention Scheme.

9 Expenditure

Principal expenditure included £78,948 to cover the cost of raising funds (£69,028 in 2019/20) and £143,890 towards the cost of delivery of the Trust's charitable objectives (£231,374 in 2019/20). The latter included £54,519 towards the ongoing development and maintenance of the Humanimal Hub (£36,502 in 2019/20).

Independent examiner's fees	2021 £	2020 £
Independent examination	2,400	2,400
Accounts preparation	1,080	1,080
	3,480	3,480

10 Corporate Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

11 Tangible fixed assets

	Office equipment £	Computer equipment £	Totals £
COST			
At 1 June 2020	1,632	3,708	5,340
At 31 May 2021	1,632	3,708	5,340
DEPRECIATION			
At 1 June 2020	601	1,793	2,394
Charge for year	326	1,116	1,442
At 31 May 2021	927	2,909	3,836
NET BOOK VALUE			
At 31 May 2021	705	799	1,504
At 31 May 2020	1,031	1,915	2,946

12 Stock

	2021	2020
	£	£
Fundraising merchandise	346	385
General merchandise	547	609
	893	994

13 Debtors

The Debtors balance of £9,972 as at 31 May 2021 largely relates to costs prepaid in regards the Humanimal Hub and database management.

Debtors	2021	2020
	£	£
Sundry debtors	1	1
Prepayments	9,971	14,576
	9,972	14,577

14 Creditors

The Creditors balance of £18,724 as at 31 May 2021 was made up of trade creditors and income tax, national insurance and pension contributions due in June 2021, along with accrued cost for services received but not yet billed and residual research grant funding committed to but not yet paid pending completion of the project.

Creditors	2021	2020
	£	£
Trade creditors	2,276	22,011
Taxes and NI	1,360	3,044
Other creditors	444	999
Accrued expenses	14,644	56,993
	18,724	83,047

15 Related Parties

There were no related party transactions during the year.